U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR DISEASE CONTROL NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH

+ + + + +

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

+ + + + +

SUBCOMMITTEE ON PROCEDURES REVIEW

+ + + + +

MONDAY JANUARY 9, 2012

+ + + + +

The Work Group convened in the Brussels Room of the Cincinnati Airport Marriott, 2395 Progress Drive, Hebron, Kentucky, at 9:00 a.m., Wanda I. Munn, Chair, presiding.

PRESENT:

WANDA I. MUNN, Chair RICHARD LEMEN, Member* PAUL L. ZIEMER, Member

ALSO PRESENT:

TED KATZ, Designated Federal Official BOB ANIGSTEIN, SC&A*
HANS BEHLING, SC&A*
ELIZABETH BRACKETT, ORAU Team*
STU HINNEFELD, DCAS
STEVE MARSCHKE, SC&A
JOHN MAURO, SC&A*
MICHAEL RAFKY, HHS*
SCOTT SIEBERT, ORAU Team*
MUTTY SHARFI, ORAU Team*
MATT SMITH, ORAU Team*
JOHN STIVER, SC&A
ELYSE THOMAS, ORAU Team*
BRANT ULSH, DCAS

*Participating via telephone

C-O-N-T-E-N-T-S

Call to order	6
Roll Call	6
Database Review and Comments Including Linking Status	11, 71
Steve Marschke	11
Discussion	13
Action Item - DCAS	15
Carryover Items - Closed OTIB 21-04, OTIB 51-01, OTIB 47- OTIB-19, et al db link	67 -02,
OTIB-0070 Status - Any Change Re	e Update 70
Mutty Sharfi	71, 87, 94 107, 109, 111
Discussion	73, 87, 95 107, 109, 112
Action Item - SC&A	120
PERs	120
PER-008	120
PER-018	123
PER-020	123
Action Item - DCAS	125

C-O-N-T-E-N-T-S (CONTINUED)

Carryover Items	125
TIB-10, Anigstein Report Review	125
Discussion 125,	128
Brant Ulsh	127
Action Item - DCAS/SC&A 129, 134,	135
Bob Anigstein	132
TIB-13, Status	135
Action Item - DCAS 147,	151
OTIB-52 Rev. 1 Response	151
Matt Smith 152, 157,	161
Discussion 152,	163
Action Item - SC&A	171
OTIB-6	176
Steve Marschke	177
Discussion	177
Report on Science Issues Work Group and Other Overarching Issues Status	180
Ted Katz	180
Discussion	182
Action Item - DCAS	210

C-O-N-T-E-N-T-S (CONTINUED)

Status of the Two-Pagers	215
Wanda Munn	215
Discussion	216
Action Item - Subcommittee Members and DCAS	226
Unassigned Queue	227
John Stiver	227
Discussion	229
PERs	238
John Stiver	238
Discussion	240
Administrative Matters	263
Next Meeting	263

1	P-R-O-C-E-E-D-I-N-G-S
2	9:00 a.m.
3	MR. KATZ: Wanda, it is your
4	agenda.
5	CHAIR MUNN: All right. Does
6	everybody have the agenda, including those on
7	the phone? It was only sent last week. So,
8	you haven't had it for a very long time, but,
9	hopefully, you have had a chance to take a
10	look at it.
11	Does anyone have any additions,
12	corrections, or deletions from what we have on
13	the agenda currently?
14	MR. KATZ: And, folks on the
15	phone, we have a couple of additions to the
16	agenda. One is
17	MR. MARSCHKE: OTIB-6
18	MR. KATZ: OTIB-6.
19	MR. MARSCHKE: Findings 3 and 4.
20	MR. KATZ: Findings 3 and 4.
21	Plus, at the end of the day, under
22	administrative details, we have discuss

1	whether there are new procedures to be
2	considered by SC&A and, also, discuss the path
3	forward for PER reviews. So that is what is
4	on the plate so far, folks on the phone.
5	DR. ULSH: Wanda, I don't have the
6	agenda open in front of me right at the
7	moment, but we are prepared to talk about
8	OTIB-70.
9	CHAIR MUNN: We are?
10	DR. ULSH: "We" meaning NIOSH.
11	CHAIR MUNN: Yes, and "we" meaning
12	the Committee.
13	DR. ULSH: OTIB-52, and I think we
14	already talked about OTIB-6.
15	CHAIR MUNN: OTIB-52, we will
16	include OTIB-6. We also had OTIB-10, Bob
17	Anigstein's report review, and you have a
18	couple of things to talk to us about under the
19	status of the PERs. Yes, that is what I have.
20	I believe we are okay.
21	The first item we have, as usual,
22	is our concern with the database review and

meeting where are. Αt our last September, we were hoping that there would be one or more productive meetings of the folks who were working on that database to try to of the issues resolve some that had discussed at that meeting and at previous meetings, and to see if we could get one step closer to where we need to be.

Steve, do you want to talk to us about that? Did you have an opportunity to meet with all the parties involved?

We didn't really MR. MARSCHKE: have any kind of a formal meeting between SC&A and NIOSH on this thing. What we have done is we have attempted to use the database. using the database, whenever once while Ι will come across some bugs or and I will send off an email to glitches, Brant.

A couple of them, I have one here on the screen -- basically trying to create -- one of the things that we talked about last

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

time was a PDF file and being able to create the PDF file --

CHAIR MUNN: Right.

MR. MARSCHKE: -- from the document. That has been implemented, but when I tried to use it, I was, you know, 90 percent successful. In one case, it didn't work. And so, I sent the email off, and I don't know, that is, I guess, being taken care of.

And then, just recently, when I tried to look at the findings of OTIB-10, I got an error message. The issue, again, you can see what came up in red. There was an issue loading the comment, finding details.

These are the types of things you would expect to find during the, I guess you would call it, the beta phase of software development. These are just normal, typical things, I think. These are probably going to continue for some time, as we get into the nitty details and start working with the software, and these things are going to creep

up, and we'll continue to -- but I mean, Wanda, you had probably the most significant thing was we still don't have a way to generate the summary table.

CHAIR MUNN: Right, which we were hoping for --

MR. MARSCHKE: Actually, we don't have any way to get any kind of summary information. It used to be SC&A's finding summary report, and that has gone away. So, right now, there is no way to get any kind of summary information out of the database. I mean, I think that probably should move to the top of the list of things to do.

CHAIR MUNN: I would very much like to see that moved to the top of the list, for more reasons than one. Not only is it the best tool that, in my opinion, we have had since we started this process, but also it is the ideal mode for reporting out to people outside of both the Subcommittee and outside of the Board itself as to the progress that we

1	are making here. Certainly, without it, there
2	is simply no few set of words, few set of data
3	points that can be put in front of someone to
4	say this is what we are doing; this is how far
5	we have gone. So, yes.
6	And we all agree that that needs
7	to move up to the top of the list for next
8	time. So I really would like to see this
9	happen.
10	DR. ULSH: Yes, to go back to our
11	last meeting, the highest-priority item coming
12	out of the last meeting was the ability to
13	generate the PDF
14	CHAIR MUNN: The PDF file.
15	DR. ULSH: summary findings.
16	CHAIR MUNN: Correct.
17	DR. ULSH: And that has been done.
18	CHAIR MUNN: Good. Hopefully.
19	DR. ULSH: Well, with occasional
20	bugs.
21	CHAIR MUNN: Yes.
22	DR. ULSH: But, by and large, it

1	has been done.
2	CHAIR MUNN: It is ready.
3	DR. ULSH: So we will continue to
4	work on the individual bugs as they come out,
5	but
6	CHAIR MUNN: Now the crucial
7	question is, is it ready enough for the
8	Subcommittee Chair to be able to get out of it
9	what she wants?
LO	(Laughter.)
L1	DR. ULSH: Well, let's leave that
L2	to be determined. But, for the next meeting,
L3	we will move this priority item up to generate
L4	the summary list. It used to be the SC&A
L5	summary list, for lack of a better term.
L6	CHAIR MUNN: Yes.
L7	MR. MARSCHKE: Well, there were
L8	two summaries. I mean, there was what we call
L9	the "Wanda summary list" or the summary table
20	from the Access database. And this SC&A
21	summary list or findings report that is here
22	was something that I think, NIOSH, you guys

1	put together when we migrated over to the SQL,
2	to this database.
3	And so, we really want to get the
4	so-called "Wanda summary table" or the summary
5	table that we had back in the Access database.
6	It gave a breakdown. Yes, it was more like
7	this table here, which had the date when the
8	findings were generated, and then it goes
9	MEMBER ZIEMER: We talked with the
10	IT guy about this last time, didn't we, I
11	thought?
12	MR. MARSCHKE: We talked with them
13	numerous times, Paul.
14	MEMBER ZIEMER: Was there another
15	column that had to be added? Or there was
16	something else that had to be searched. Was
17	it the date of the report or
18	MR. MARSCHKE: One of the things
19	we talked about
20	MEMBER ZIEMER: was missing
21	that didn't permit us to sort the way we
22	wanted on this.

MR. MARSCHKE: Oh, I don't know about on this, sorting on this, because there really wasn't much to sort on this.

One of the things that we have talked in the past about missing is a little descriptor, describer, as to what this date is. This is really the first package of --

CHAIR MUNN: This is the group.

MR. MARSCHKE: This is the group. Maybe this one here is the review of OTIB-52. Maybe this one is the review of PROC-70. And there should be а little bit descriptor associated with each one of these dates. I mean, we have talked about that going back to when we were on the Access database, and we determined at that time, because we were migrating over, that it wasn't But if we are on worth making the change. this one, we may want to add a column here saying, you know, a little descriptor as to what each one of these dates are.

MR. HINNEFELD: If I could have

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	one of those, I will take it. Brant is going
2	on travel tonight. So I will take it back to
3	Tom.
4	MEMBER ZIEMER: These were dates
5	of groups of findings.
6	(Simultaneous speakers.)
7	CHAIR MUNN: There were only three
8	groups of findings. The others were
9	individuals that came up from some generalized
10	Board discussion that directed them to our
11	attention.
12	MEMBER ZIEMER: Right. Like the
13	first one was 183 findings. That was
14	multiple.
15	CHAIR MUNN: Correct.
16	MR. MARSCHKE: Yes, the three in
17	there where you see a hundred findings
18	associated with them, those are multiple
19	reviews. The other ones are all individual
20	documents.
21	MR. STIVER: Those were the three
22	big sets.

1	CHAIR MUNN: That is correct.
2	MR. HINNEFELD: These are all
3	dates of SC&A deliverables.
4	MEMBER ZIEMER: Exactly. Those
5	are SC&A dates.
6	MR. STIVER: Rather than those
7	three with hundreds we are not quite sure
8	exactly what drove those dates on the other
9	MR. MARSCHKE: Those are dates of
LO	the report.
11	MR. HINNEFELD: Dates of the
L2	deliverable, dates of the report.
L3	MR. MARSCHKE: Dates of the
L4	report, dates of the deliverable.
L5	MEMBER ZIEMER: And the report
L6	was
L7	CHAIR MUNN: There were groups in
L8	that.
L9	MEMBER ZIEMER: a whole bunch
20	of, a certain set of procedures were reviewed
21	in that report. And that 183, or whatever the
22	number is

1	CHAIR MUNN: Correct.
2	MEMBER ZIEMER: is a
3	compilation of all the findings in multiple
4	reports.
5	CHAIR MUNN: There was one in
6	2005, one in 2006, one in 2007.
7	MEMBER ZIEMER: And they were
8	tasked in groups.
9	MR. HINNEFELD: Right.
10	CHAIR MUNN: The others were
11	individual assignments from
12	MR. MARSCHKE: I know the
13	construction worker was one of the individual
14	ones, and I think PROC-70 was an individual
15	one.
16	CHAIR MUNN: Yes.
17	MR. MARSCHKE: There was what
18	was it, 6000.
19	CHAIR MUNN: Yes, there are
20	several, all the others potentially.
21	MR. MARSCHKE: Yes, all the other
22	ones are individual reports. I think

WASHINGTON, D.C. 20005-3701

1	OTIB-54 before 44, I don't know even know
2	if that is on this list, but that was another
3	one.
4	MR. KATZ: Right.
5	CHAIR MUNN: And what you have up
6	on the screen right now, my system, if I click
7	on the SC&A finding reports, I get an error
8	message.
9	MR. MARSCHKE: Yes, yes, you get
10	an error message on that, right. That is not
11	working.
12	CHAIR MUNN: So there is just
13	nothing
14	MR. MARSCHKE: There is nothing.
15	CHAIR MUNN: other than what we
16	have up on the screen right now.
17	MR. MARSCHKE: Exactly. There is
18	no way to get any kind of automated summary
19	out of the way it stands right now.
20	MEMBER ZIEMER: Unless you had a
21	column identifying the SC&A finding date.
22	MR. MARSCHKE: And you could

1	search on it. But, then, you would have to
2	add them up by hand.
3	CHAIR MUNN: Or we could even say
4	group one, group two, group three.
5	MEMBER ZIEMER: Well, if any ones
6	that had this first date on it, if you
7	searched on that, you would get that whole
8	group of one
9	CHAIR MUNN: That's correct.
10	That's correct.
11	MEMBER ZIEMER: That's all I'm
12	saying.
13	MR. STIVER: That's true. Yes,
14	you could do it that way.
15	MEMBER ZIEMER: If each finding,
16	where it says "Total Findings" on that
17	document, if you had the date, the SC&A date
18	of those findings, you could search on it.
19	MR. STIVER: It would pull up that
20	group, wouldn't it?
21	MEMBER ZIEMER: Yes, I think it
22	would.

1	CHAIR MUNN: Well, we would hope
2	so, in any case.
3	I will make every effort, later
4	this week or early next, to see how successful
5	I am with getting the PDF files up. That will
6	be most helpful to the Work Groups as we
7	transfer
8	MR. MARSCHKE: Actually, Wanda, we
9	can run through an example, either during one
LO	of the breaks or if you want to do it when the
11	Subcommittee is in session, we can run through
L2	the steps of how to generate a PDF file, if
L3	you
L4	CHAIR MUNN: I wouldn't mind doing
L5	that right now.
L6	MR. MARSCHKE: Okay.
L7	CHAIR MUNN: Because there may be
L8	others from time to time who will need that,
L9	and certainly people outside those sitting in
20	this room will need it from time to time, if
21	they don't get it from there.
	f 1

Okay.

MR. MARSCHKE:

1	MR. STIVER: This is John Stiver.
2	I'm sorry to interrupt.
3	But before we move on to the PDFs,
4	I just wanted to say that maybe this is a
5	question for both Brant and Steve. Is there a
6	particular reason why generating this and
7	sorting by finding is particularly difficult?
8	Or is it just that it hasn't been addressed
9	fully as a priority item? It has been about a
10	year and a half since we were able to generate
11	that summary table.
12	DR. ULSH: Well, and over the past
13	year and a half, we have gone from having
14	pretty much nothing to where we are
15	MR. STIVER: Right. I know a lot
16	of progress has been made here.
17	DR. ULSH: Well, yes. As in
18	previous meetings where we have organized the
19	priorities, this has been near the top, but
20	the highest thing has been generating PDF.
21	CHAIR MUNN: The PDF.
22	DR. ULSH: So, this is now moved

up to the top.

MR. STIVER: I would just add that this is a tool that, to me, is very central. It is a very simple table, but it provides all that trending data right upfront, and it is very useful for Wanda, but it would also be useful for me in tracking our progress from SC&A's standpoint.

And I would just suggest that an interim measure. We can certainly put together the summary reports ourselves until such time as the automated system is available.

We have one of our junior engineers who is database-savvy, or several, who could spend a day or two pulling the information out by hand, generating the table.

I am going to essentially have that done on my side, and we can provide that to Wanda.

MR. MARSCHKE: Well, let's see. When we schedule the next meeting, and it probably will be in three or four months, I

1 would assume. MR. STIVER: See where we stand. 2 3 MR. MARSCHKE: See where we stand on the automated one. And if we can do it 4 5 with a click of a button, it is going to be a 6 lot easier than if we have to spend a day or 7 two to do it. Yes. Well, we will 8 STIVER: see where we are a month out from --9 But if we can't get 10 MR. MARSCHKE: it a month out or a couple of weeks out, if it 11 12 is not available, then we can have somebody, a 13 junior engineer, go through and make this, similar to a table like this before the next 14 15 meeting. 16 CHAIR MUNN: Ι would really appreciate that, John. Thank you very much 17 for the offer. We will keep our fingers 18 19 crossed and hope that it isn't necessary, that 20 we will be able to push a magic button and do

what we need to do by the time we meet again,

which I hope is not going to be more than

21

three months from now. I would like for us -
MR. KATZ: Yes, so let's just

check in two weeks before the meeting, and if

we need it, that will be great.

CHAIR MUNN: Excellent.

MR. MARSCHKE: Shall we move on?

The next kind of outstanding issue

The next kind of outstanding issue or problem with the database is -- again, we talked about this the last time -- this column that we call "Total Active Findings." That still does not seem to be working correctly.

I use OTIB-54 as my example of this because it is very illustrative. Basically, last time we talked we tried to discuss and determine what do we mean by active findings. And I think we settled on a definition of any finding except for those that are either closed or in progress is an active finding.

But you can see, basically, if you look at OTIB-54, you can see it has 26 total findings, and according to this database, it

NEAL R. GROSS

has 26 active findings. But if you click on the details of OTIB-54, you can go in here and you can see basically -- oh, I'm sorry, I screwed up the definition of active.

Anything that is closed or

anything that is closed or anything that is in abeyance -- well, that is not what we decided last time. We said, basically, in abeyance or closed were the ones kind of similar to what was the trip for the two-pagers. Anything that would generate a two-pager, all the findings had to be either in abeyance or closed. And so, we were kind of trying to use the same definition for here.

If you remember from the previous screen, it had 26 total and 26 active. Well, you can see from the detail screen, the first one is in abeyance. The second one is closed. The third one is closed. The fourth one is closed. So you get the idea.

CHAIR MUNN: Right.

MR. MARSCHKE: So that column is not working. I think that probably should be

NEAL R. GROSS

1	priority number two because that is a
2	convenient way, if that is working, that is a
3	convenient way to kind of like assign
4	priorities to the procedures, as to which ones
5	have the most active findings, and so which
6	ones should we tackle maybe next or get the
7	most bang for your buck.
8	CHAIR MUNN: Well, if we are
9	successful in getting our ability to get a
10	"Wanda report" out, a summary out, then that
11	will automatically take care of itself.
12	MR. MARSCHKE: That will help in
13	that area as well.
14	CHAIR MUNN: Right.
15	MR. KATZ: Well, no, but the
16	"Wanda report" will be inaccurate. So it is
17	just as important because the "Wanda report"
18	won't be correct, right?
19	MR. MARSCHKE: I don't know how
20	it depends upon how they do the calculation,
21	how they prepare the "Wanda report" and how
22	they prepare this.

DR. ULSH: It is all right. We can have two top priorities.

(Laughter.)

CHAIR MUNN: We can do that, yes.

Which is priority 1? Priority 1 and priority

1 plus.

MR. MARSCHKE: Now, coming back to Wanda's request to demonstrate, I mean, generating a PDF file is very simple at this point. The way it has been set up is that you generate a PDF file for each finding. It is finding-driven.

So, for example, if I wanted to get a PDF of OTIB-54, Finding No. 1, all you have to do is come over here and click on the PDF thing, and it basically comes up in a separate window. You can blow it up, and it shows all the history of Finding No. 1.

And then, you can come over here to the file and click on the file and just go to print. And again, it is going to come up here. It will print it to Document Writer or

1	you can down here to CDC PDF Writer, click on
2	that.
3	CHAIR MUNN: I'm sorry, I missed
4	that. Go down to where?
5	MR. MARSCHKE: Hang on for a
6	second.
7	Go back and go up to file here,
8	click on print, and then when it says up here
9	"Printer Type" up in the upper lefthand
10	corner, basically, you click on it, and it
11	basically says all the different types of
12	printers. And two of them are I don't know
13	what the difference is between CDC PDF Writer
14	in Session 7 and CDC PDF Writer down here.
15	But let's just pick one, and you just click on
16	that, and now it is going to generate a PDF
17	file. And you click on OK. And it should
18	come back. Okay, it comes back with a notice.
19	You click on OK.
20	MR. STIVER: Wait a second. I got
21	lost in that last little step there. It
22	didn't work out for me. Okay.

1	MR. MARSCHKE: And then, it asks
2	you where do you want to put it.
3	MR. STIVER: You used PDF Writer
4	in Session or the
5	MR. MARSCHKE: I used the Session
6	7.
7	CHAIR MUNN: You used Session 7?
8	MR. KATZ: Although when you are
9	hooked up to a printer, if you use in session,
LO	it will send it to your printer. That's it.
11	MR. MARSCHKE: Yes, right.
L2	Obviously, if you say PDF Writer, it is going
L3	to send it to a file, a PDF file, and you have
L4	to tell it where you want to put it in the
L5	PDF, in the file, where you want the file to
L6	be.
L7	CHAIR MUNN: Okay.
L8	MR. HINNEFELD: Can you just not
L9	"Save As" when the PDF first comes up? Can
20	you just not do the "Save As" and save it that
21	way? Do you have to run it through the PDF
22	printer? It comes up as a PDF

1	MR. STIVER: Yes, I think that is
2	kind of a redundant step.
3	MR. MARSCHKE: Well, let's try it.
4	Let's see. Save As. "This document does not
5	allow you to save any changes." Okay. That's
6	okay.
7	MR. HINNEFELD: It means that you
8	can save; you just can't edit it.
9	MR. MARSCHKE: Yes, you can do it
10	that way.
11	MR. STIVER: You know, it has a
12	little, if you look at it, if you just run
13	your mouse down to your bottom of the page, a
14	little bar will come up and it has the
15	different icons for either printing or saving.
16	So, you can just use that.
17	MR. MARSCHKE: Yes, you can use
18	that. You can click on this. So, there's
19	multiple ways that you can save it as a PDF
20	file.
21	So, this has been implemented.
22	It just so happened I was working

1	on OTIB-6. I was able to generate the PDF
2	file for Finding 4. I could not generate it
3	for Finding 3. I went and checked if I could
4	generate it for Finding 1. No problem.
5	Finding 2, no problem. But Finding 3, it just
6	refused to do it. So, I don't know what that
7	is all about. It is just going to get these
8	little hiccups.
9	MR. STIVER: Yes, some glitch that
10	needs to be worked through.
11	MR. MARSCHKE: So, I mean, it is
12	pretty simple, pretty straightforward.
13	CHAIR MUNN: Okay. Until I have
14	done this a couple of times, and until I have
15	actually gotten it into the hands of another
16	Work Group Chair, I will take at faith the
17	idea that I am doing something when I am doing
18	this.
19	All right. I have now saved,
20	hopefully, Rev. OPC-1.
21	Now I have a question for those
22	who have been working with this. In the past,

1	we have had one long continual batch of
2	procedures which were really easy to scroll
3	down. Now, on my computer, I have to change
4	pages. Was it necessary for us to paginate
5	this?
6	MR. MARSCHKE: Well, what do you
7	mean by changing pages?
8	CHAIR MUNN: In order for me to
9	get to OTIB-54, for example, I could not just
10	simply scroll down, looking at the document
11	number. I can only scroll down to RPG-44 and
12	then I have to click on page 2
13	MR. MARSCHKE: Right.
14	CHAIR MUNN: to go further
15	down.
16	MR. MARSCHKE: Yes. That is the
17	way, this database is set up that way.
18	CHAIR MUNN: Do we have a choice
19	or is it necessary?
20	MR. HINNEFELD: I don't know.
21	CHAIR MUNN: If it is necessary,
22	then that is one thing. If we have a choice,

1	it would be my choice to be able to scroll the
2	entire list. But I don't know what the
3	intricacies are.
4	MR. MARSCHKE: Right now, what you
5	can do, Wanda, is you can use the Search
6	CHAIR MUNN: So, I have to use the
7	Search screen?
8	MR. MARSCHKE: Use the Search
9	screen. Right now, the way the thing is set
10	up, you don't have a choice. You have to use
11	the Page Down. You can make your life easier
12	by using the Search screen. You can make your
13	life easier by basically doing sorts. You can
14	sort on the various document headings. You
15	can do filters to filter out. But, right now,
16	really, the way the thing is set up, you have,
17	I think it is 20 documents per page, and
18	there's no way to increase that number.
19	CHAIR MUNN: Okay. And the
20	numbers are not always sequential as they were
21	on the old
22	MR. MARSCHKE: Again, if you do

1	the sort on document number, then they should
2	be sequential.
3	CHAIR MUNN: Well, is that true
4	now of OTIB-54? No.
5	MR. MARSCHKE: If you get into the
6	OTIB area
7	CHAIR MUNN: I see OTIB-54, 66,
8	and 70 are four pages away from the first
9	batch of OTIBs.
10	MR. MARSCHKE: Yes, but I think
10	MR. MARSCHRE: 165, Dut I tillik
11	that is more because we have so many OTIBs.
12	But I think if you look at OTIB I mean, all
13	the OTIBs, I mean, if you look on this page,
14	it starts with OTIB-39, 43, 47, and it is
15	pretty much sequential until you get to
16	OTIB-70 and then you get into the PROCs.
17	CHAIR MUNN: Oh, no, not on my
18	page. What page are you? Oh, you are sorting
19	by filter.
20	MR. MARSCHKE: No, I didn't sort
21	by filter. I did a sort on the document
22	number.

1	CHAIR MUNN: Okay.
2	DR. ULSH: If you just click on
3	the document
4	CHAIR MUNN: All right. Very
5	good. I was just going from the bare menu.
6	MR. MARSCHKE: If you click on the
7	document no, no, the bare menu, it is not
8	quite sequential. It is kind of sequential in
9	the order that they were added to the
10	database.
11	MEMBER ZIEMER: So, that sorts by
12	document number or sorts by document title.
13	MR. MARSCHKE: Yes. And then, if
14	you wanted to really filter it out, I would
15	just go in here and filter by TIBs. I guess
16	you can't really filter by OTIBs, but you can
17	filter by
18	CHAIR MUNN: I will get
19	comfortable with the pagination. It is just a
20	personal preference to be able to scroll the
21	whole length of that.
22	All right. Thank you very much

1	for the work with the PDF file. I hope that
2	whatever glitches exist in there now will
3	magically disappear between now and the time I
4	start to get serious about getting these files
5	into the proper hands.
6	MR. MARSCHKE: Wanda
7	CHAIR MUNN: Yes?
8	MR. MARSCHKE: there is one
9	other thing about the database. And you have
10	it kind of here as a carryover item, about the
11	db link. I know you have that, you know, we
12	have the OTIB-21-04, OTIB-51-01. I think that
13	was the link to supplemental documents.
14	CHAIR MUNN: It was a link to
15	supplemental documents.
16	MR. MARSCHKE: And I don't know if
17	you want to wait until we get to the carryover
18	items or, if not, if we are talking about the
19	database, do you want to do it here?
20	CHAIR MUNN: I think while we are
21	in the database, let's talk about it because
22	links to the supplemental documents are

1	actually as important as being able to
2	transmit the PDF file for anyone outside this
3	room who is working on this item.
4	MR. MARSCHKE: I am just going to
5	go to OTIB-51, and 51-01, it says. I really,
6	to tell you the truth, Wanda, I have not
7	checked into this. I don't know if Elyse is
8	on the phone. Maybe she has really looked
9	into this. I haven't been keeping track on
10	this one.
11	CHAIR MUNN: She was on earlier.
12	I hope she is still there.
13	Are you with us, Elyse?
14	MS. THOMAS: Yes. Yes, I am still
15	on.
16	CHAIR MUNN: Great.
17	MR. MARSCHKE: And just looking at
18	OTIB it says down here that George Kerr,
19	for Finding OTIB-51-01, it says the last entry
20	was from George Kerr, and it has a file
21	attached to it, a PDF file attached to it.
22	And you click on it, and, sure enough, it

1	comes right up. You can look at it.
2	DR. ULSH: I think that was the
3	other high-priority item from the last one as
4	well.
5	MR. MARSCHKE: I believe you are
6	right.
7	CHAIR MUNN: I am sorry. Will you
8	go back and do that one more time?
9	MEMBER ZIEMER: You're doing 51?
10	CHAIR MUNN: I was looking at my
11	screen and not yours. I should have been
12	watching what you were doing.
13	MR. STIVER: Fifty-one-01.
14	MR. HINNEFELD: Oh, that's
15	interesting. If you close that PDF, it closes
16	the
17	MR. MARSCHKE: That is what I just
18	found out, too.
19	(Laughter.)
20	
	CHAIR MUNN: So, what did you do?
21	CHAIR MUNN: So, what did you do? MR. HINNEFELD: I clicked on the

1	opened up, and it took me out of the
2	application.
3	MR. MARSCHKE: It takes you right
4	out of the application.
5	MR. HINNEFELD: It took me back to
6	the tools screen.
7	MR. MARSCHKE: Maybe if we had a
8	preference, we may want to open the PDF in a
9	separate
10	MR. HINNEFELD: Open the PDF in a
11	separate window.
12	MR. MARSCHKE: In a separate
13	window, so that when you close it, it doesn't
14	close the application. But, as far as having
15	the ability to attach it, it seems to be
16	MR. STIVER: Yes, the attachment
17	seems to work. You can actually back out just
18	by using the back arrow.
19	MR. MARSCHKE: Yes.
20	MEMBER ZIEMER: There is no back
21	arrow on the PDF. There is no back arrow on
22	the PDF sheet.

1	MR. MARSCHKE: Yes, there is. Up
2	to the right up there.
3	MR. STIVER: It comes up on a
4	web tab.
5	MR. KATZ: Look at the top of the
6	page.
7	MR. HINNEFELD: Yes, that is where
8	Paul is looking and it is gray. It is not
9	activated. But that looks like a different
10	what happens if you minimize that?
11	MEMBER ZIEMER: That was this.
12	MR. HINNEFELD: Oh, that's that.
13	That's that. Okay. Yes, you printed a PDF
14	here.
15	MEMBER ZIEMER: Oh, I'm sorry.
16	MR. HINNEFELD: Expand this.
17	Expand this.
18	MEMBER ZIEMER: Okay. I'm doing
19	the wrong thing.
20	CHAIR MUNN: Now wait.
21	MR. HINNEFELD: Now scroll down.
22	MEMBER ZIEMER: Expand it there.

1	MR. HINNEFELD: Now scroll down.
2	MEMBER ZIEMER: Oh, now
3	MR. HINNEFELD: You're looking at
4	the details. Keep going down. No, keep going
5	down.
6	MEMBER ZIEMER: Right.
7	MR. HINNEFELD: Right there.
8	MR. MARSCHKE: There.
9	MEMBER ZIEMER: Oh, I see what you
10	are saying. Okay. Yes.
11	(Simultaneous speakers.)
12	MR. MARSCHKE: Now that one is
13	activated. So, you can back out of that.
14	MEMBER ZIEMER: Got you.
15	MR. HINNEFELD: So, that is what
16	George wrote. That's George's response.
17	MR. MARSCHKE: What George wrote
18	should probably be and, Elyse, you can
19	correct me if I am wrong but I believe
20	probably, if you go up and look
21	MEMBER ZIEMER: You don't want to
22	close this.

1	MR. HINNEFELD: No, if you "X" out
2	of that, it takes you out of the application.
3	MEMBER ZIEMER: Yes.
4	MR. HINNEFELD: You want to back
5	out.
6	MR. KATZ: You want to back out.
7	MEMBER ZIEMER: Yes.
8	MR. MARSCHKE: If you look at
9	basically this portion here where it says,
10	"Unspecified OCAS OD user", there is a whole
11	this goes on for a long time. I think this
12	is probably what is in the PDF file.
13	MS. THOMAS: Yes, that is true for
14	this one, for 51-01. And for some of the
15	others that were carryover items, the
16	attachment contains tabulated data that we
17	weren't able to put in the response because of
18	the limitations of the database.
19	But for 51-01, the only difference
20	between the previously-loaded response, okay,
21	that Steve was talking about, that you see the
22	long text there, and the attached PDF file or

1 the linked file, is just formatting. The 2 references that George had provided are a lot 3 easier to read in the link than they are in the response in the database. 4 Yes, the summary is 5 CHAIR MUNN: 6 too short. 7 MS. THOMAS: Yes. But, like I said, that is just the case for 51-01. 8 some of the others like 21-04, 47-02, and 19 9 10 -- I can't remember what the finding number is on No. 19, but we will see it -- those all had 11 12 tabulated data that was new. The Subcommittee 13 talked about it, but it wasn't able to be linked into the database until now. 14 15 So, I hope that helps. 16 CHAIR MUNN: A little. Elyse, do

CHAIR MUNN: A little. Elyse, do you foresee this problem with links to tabular data as being an insurmountable obstacle or is this just something that you are having to cope with behind the scenes right now? Are we going to be able to do eventually or not?

MS. THOMAS: Yes, we can do it

NEAL R. GROSS

17

18

19

20

21

22

1	now. NIOSH worked on that between the last
2	meeting and this meeting. And so, we are now
3	able to, by linking or attaching files, we can
4	look at tabulated data as part of the
5	response.
6	CHAIR MUNN: Good.
7	MR. HINNEFELD: Wanda, the problem
8	she referred to was, when you try to enter it
9	into the entry screen, when you try to enter
10	it
11	CHAIR MUNN: It won't go here,
12	yes.
13	MR. HINNEFELD: It is hard to get
14	the tabulation onto the entry screen.
15	CHAIR MUNN: Right, right, right.
16	MR. HINNEFELD: That is the
17	problem.
18	CHAIR MUNN: But the link it will
19	take.
20	MR. HINNEFELD: Oh, certainly.
21	MR. MARSCHKE: Wanda, this is the
22	way the data looked when we entered it

1	previously. See, you have a table, table 1,
2	and it just all kind of runs together.
3	CHAIR MUNN: I remember trying
4	to
5	MR. MARSCHKE: And you can't read
6	it. Now what they have done now is, when you
7	add the this is 47-02 I am looking at,
8	Elyse. And we go down here and you look at
9	it, and you click on the PDF file. Now,
10	basically, the tables are there.
11	CHAIR MUNN: Yes. Excellent. All
12	right. Then, my question was a non-question.
13	Thank you all. That's good.
14	MS. THOMAS: The only thing that
15	is a little bit confusing, although it is not
16	a big problem, I don't think, is it looks like
17	some of the findings were entered out of
18	order. But that is why I put the original
19	date on there and made a statement, something
20	to the effect that it couldn't be linked
21	previously and that kind of thing.
22	CHAIR MUNN: Dates are always

1	helpful. Chronology holds us up when all else
2	fails.
3	All right. Thank you very much,
4	Elyse, and thank you, Steve.
5	MR. STIVER: Elyse, this is John
6	Stiver.
7	Are the links limited to PDFs or
8	are there other file formats that can be
9	linked in?
10	MS. THOMAS: I will have to defer
11	to Brant on that one or Stu.
12	DR. ULSH: I think you can link
13	other file formats.
14	MR. STIVER: Okay.
15	MR. HINNEFELD: I would think you
16	would be able to link whatever you want. I
17	think it is just a link to another folder. It
18	just pulls up a file that you put in that
19	MR. STIVER: Right.
20	MR. HINNEFELD: I would think it
21	wouldn't matter, but I will check to make
22	sure. I don't know. I don't know.

1	CHAIR MUNN: Well, originally, we
2	had talked about whether or not the links were
3	going to be something that anyone could alter,
4	which is one of the reasons we were talking
5	about PDF files. They would be read-only
6	files for the purpose of transferring them,
7	when we were transferring them to someone
8	else.
9	MR. STIVER: True. That could be
10	a problem.
11	CHAIR MUNN: Yes. But, of course,
12	when we are in the position where the Work
13	Groups are going to pursue the issue, and they
14	will need to be making either additional files
15	or adding to the files that are there, I guess
16	one could make an argument either way.
17	MR. STIVER: Yes, that is kind of
18	what I was envisioning.
19	MEMBER ZIEMER: What other formats
20	were you thinking about?
21	MR. STIVER: Well, just like Excel
22	tables.

1	MEMBER ZIEMER: Well, but an Excel
2	table can be put into PDF form for this
3	purpose.
4	MR. STIVER: Sure. I understand
5	that, but if you wanted to transfer
6	MEMBER ZIEMER: And the same with
7	a JPEG or whatever.
8	MR. STIVER: Yes, I was just
9	thinking, though, if you wanted to transfer
10	it, say, to a Work Group, and then they would
11	see the PDF, but they wouldn't be able to
12	extract the data or manipulate it. Whereas,
13	if you sent them the link directly to the
14	Excel table, they would have that capability.
15	CHAIR MUNN: Yes, I guess the
16	thinking at the time was whatever we transfer
17	to them needs to be a part of the permanent
18	record, and it does not need to go away. If
19	they need to add to it or to revise it in any
20	way, they need to, in effect, duplicate that
21	material

ZIEMER:

Or

MEMBER

22

request the

1	original from whoever generated it.
2	MR. STIVER: Yes, they could
3	request the original.
4	MR. KATZ: Most of the stuff is
5	probably on this Site Research Database
6	anyway.
7	MR. MARSCHKE: Yes, most of the
8	time, I don't see that a big problem. I mean,
9	I think we are talking past each other a
10	little bit because we are talking about PDF
11	files which are being generated versus the PDF
12	files which are linked.
13	I am not even sure how this works.
14	When you generate a PDF file, for example, of
15	Finding OTIB-47-02, does that PDF file that
16	you generated include the attached PDF file or
17	does it just basically include the stuff which
18	in the database itself, the database proper?
19	So, you may not even, when you
20	generate your PDF file and I don't know how
21	that works. That is a question. But if it
22	does not include the PDF, what you would end

1	up having to do is send to the other Work
2	Group not only the PDF file that you generate
3	out of this database, but also the attachment
4	file.
5	MR. HINNEFELD: Why don't we find
6	out?
7	CHAIR MUNN: Well, yes, I can tell
8	you that it is my intent to transmit what is
9	here, and what happens in the Work Group is
10	their problem, not mine. But, as long as we
11	have gotten to this point where what we pick
12	up from the PDF file is going to be in a
13	correct, readable form and can be distributed
14	to the Members of the Work Group, then that is
15	key from our selfish perspective here.
16	So, let me give that a try and get
17	more familiar with the way we are set up now
18	and try to get comfortable with it.
19	Thank you all for the work you
20	have done on this. I know this is tedious for
21	all of us concerned.
22	DR. ULSH: I think there are a

number of these findings where the only reason 1 2 they weren't closed was we wanted to make sure 3 that this link was established. I don't know how you want to go through that today, whether 4 you want to wait and do that or do you want to 5 6 go through all of them? No, I do want to wait 7 CHAIR MUNN: to do it --8 DR. ULSH: Okay. 10

CHAIR MUNN: -- because, until I personally feel more comfortable manipulating this file, then you are going to spend more time trying to show me what to do than is worthwhile. This need not be an instruction session, and that is essentially what it would

According to the MR. MARSCHKE: test that we just performed with OTIB finding 47-02, the PDF file that you generate from the database does not include the PDF file that was attached to the database.

be, I'm afraid. So, let's wait on that.

MR. HINNEFELD: So, it would have

NEAL R. GROSS

9

11

12

13

14

15

16

17

18

19

20

21

22

1	to be provided in addition to the printout.
2	MR. MARSCHKE: Basically, all you
3	have in the PDF
4	MR. HINNEFELD: You have the name
5	of it there.
6	MR. MARSCHKE: Yes, you have the
7	name of it, but it doesn't actually pull the
8	data from it and merge the two PDF files
9	together. It does not actually do that.
10	So, what you would have to do,
11	then, is when you send it to your counterpart
12	at a Work Group, you would have to send two
13	files. You would have to send this file that
14	you just generated from the database. Then,
15	you would have to know, you would have to
16	send, also, this
17	CHAIR MUNN: Pull that up
18	individually and send it?
19	MR. MARSCHKE: Yes, exactly.
20	CHAIR MUNN: All right.
21	MR. MARSCHKE: I don't know where
22	they are stored. I don't know where to tell

1	you to go pick them up. There is probably a
2	directory somewhere on here where they can
3	basically or you can pull it up and save
4	it. When you open it, you could probably pull
5	it up and save it.
6	CHAIR MUNN: That is probably what
7	is going to have to happen
8	MR. MARSCHKE: Yes.
9	CHAIR MUNN: at least for the
10	time being.
11	MR. STIVER: How tricky of a
12	programming feat would it be to nest that
13	within the new PDF?
14	MR. HINNEFELD: I am making a note
15	to that.
16	MR. KATZ: We don't have any
17	computer whizzes here.
18	(Laughter.)
19	MR. MARSCHKE: I couldn't even
20	find a button on my computer to get on the
21	internet.
22	(Laughter.)

1	MR. STIVER: We had a similar
2	problem at a my former job and we were able to
3	solve it. I don't remember exactly how we
4	solved it. I didn't do it myself.
5	CHAIR MUNN: Well, the combination
6	of individual idiosyncracies and individual
7	even computer idiosyncracies, my system, for
8	example, has the title of the procedure I am
9	looking at in big, bold type over the top of
10	the information I am looking at.
11	MR. MARSCHKE: That is just a
12	click of the button. I don't know button to
13	tell you to click.
14	CHAIR MUNN: Which button it is?
15	MR. MARSCHKE: I said I don't know
16	which one it is, but I know that they told me
17	that before, and it is just a click of a
18	button to get that fixed.
19	CHAIR MUNN: Yes, I know. But, as
20	I said, my buttons are not known to me always.
21	So, we do the best we can.

Thank you.

Good.

22

1	Anything else anyone wants to
2	express any concerns about? Or any further
3	discussion we need to devote to the database
4	and where we are with it?
5	DR. ULSH: Well, we just sorry,
6	go ahead.
7	MEMBER ZIEMER: No, it looks good
8	to me.
9	DR. ULSH: We discussed
10	specifically finding OTIB-51-01. Is there a
11	status on that?
12	MEMBER ZIEMER: That is on the
13	agenda later, isn't it?
14	DR. ULSH: Oh, okay, never mind
15	then.
16	MEMBER ZIEMER: Fifty-one-01,
17	carryover item?
18	MR. MARSCHKE: That was, again,
19	for the link.
20	MR. KATZ: That was just the
21	linking. That was all that was left to do.
22	CHAIR MUNN: I think, yes, the

1	link was all that we had, yes.
2	MR. MARSCHKE: What was the status
3	of 51-01?
4	CHAIR MUNN: It says 51-01 is in
5	progress. "Lacking technical details and
6	clarity. Critical experiments. Facility is
7	mentioned in several places." On pages 7 and
8	11, it is stated "the main missed neutron dose
9	because of the energy threshold of the NTA
10	film. This 55 percent was determined in
11	1960." Reference is made to RPRT 33.
12	MR. MARSCHKE: Basically I
13	think we discussed this, we discussed 51-01
14	
	during the March 22nd, 2011 meeting. We can
15	during the March 22nd, 2011 meeting. We can pull up the transcript on that. And our
15 16	
	pull up the transcript on that. And our
16	pull up the transcript on that. And our conclusion was that the administrative problem
16 17	pull up the transcript on that. And our conclusion was that the administrative problem with the linking, upon correction of this
16 17 18	pull up the transcript on that. And our conclusion was that the administrative problem with the linking, upon correction of this problem, the issue can be closed.
16 17 18 19	pull up the transcript on that. And our conclusion was that the administrative problem with the linking, upon correction of this problem, the issue can be closed. CHAIR MUNN: Then, let's hope so

finding open was establishing this link which 1 2 we just looked at. So that it is linked now. 3 MS. THOMAS: This is Elyse again. think all of those carryover 4 5 essentially closed, items but were 6 remained on the agenda simply because of the 7 linking issue. OTIB-21-04, all of the others 8 except for 51-01, you know, there's 9 10 listed there, they are all closed database. 51-01 was the only one that was not 11 12 actually closed. In other words, the status 13 was not changed. But I agree with Steve it should 14 15 be the same as the others. In other words, it 16 should be closed. I think the technical discussions or approaches were agreed upon. 17 It was just a linking issue, and now that is 18 19 corrected. 20 So, just --MR. MARSCHKE: CHAIR MUNN: Shall we change it at 21 22 this moment or shall we wait until we get to

1	the proper spot?
2	MR. KATZ: Why not close them?
3	CHAIR MUNN: Dick, are you still
4	with us?
5	MEMBER LEMEN: Yes, I am.
6	CHAIR MUNN: Do you have any
7	objection to our closing this item now?
8	MEMBER LEMEN: No, I don't.
9	CHAIR MUNN: All right.
10	MEMBER LEMEN: I think it is a
11	good idea.
12	MEMBER ZIEMER: Where is the
13	attachment? Am I looking at the wrong one?
14	Are you finding the attachments?
15	CHAIR MUNN: Well, the very bottom
16	one. You have to go through about five, six,
17	and then at the very bottom you will find
18	George's.
19	MR. MARSCHKE: A big improvement
20	over the old database with this database is
21	that you can have multiple attachments to one
22	finding. The old database, if you remember,

1	we were limited to just a single attachment.
2	MR. STIVER: In theory, there is
3	no limit.
4	MR. MARSCHKE: In theory, there is
5	no limit.
6	DR. ULSH: There must be some
7	limit, but
8	(Laughter.)
9	MEMBER ZIEMER: No, I am at the
10	bottom of it.
11	MR. HINNEFELD: What is going on?
12	Paul doesn't have the last entry. And he
12 13	Paul doesn't have the last entry. And he also doesn't have 51-03.
13	also doesn't have 51-03.
13 14	also doesn't have 51-03. MEMBER ZIEMER: This is 51-01.
13 14 15	also doesn't have 51-03. MEMBER ZIEMER: This is 51-01. MR. HINNEFELD: No, see, he
13 14 15 16	also doesn't have 51-03. MEMBER ZIEMER: This is 51-01. MR. HINNEFELD: No, see, he doesn't have the last entry. But, then, you
13 14 15 16 17	also doesn't have 51-03. MEMBER ZIEMER: This is 51-01. MR. HINNEFELD: No, see, he doesn't have the last entry. But, then, you also have 51-04, and my next one is 51-03.
13 14 15 16 17	also doesn't have 51-03. MEMBER ZIEMER: This is 51-01. MR. HINNEFELD: No, see, he doesn't have the last entry. But, then, you also have 51-04, and my next one is 51-03. MEMBER ZIEMER: This is 51-01.
13 14 15 16 17 18 19	also doesn't have 51-03. MEMBER ZIEMER: This is 51-01. MR. HINNEFELD: No, see, he doesn't have the last entry. But, then, you also have 51-04, and my next one is 51-03. MEMBER ZIEMER: This is 51-01. OTIB-51-01.

1	MR. HINNEFELD: There is all that
2	stuff.
3	CHAIR MUNN: There is the long
4	one.
5	MR. HINNEFELD: Yes, all the long
6	one.
7	MEMBER ZIEMER: No attached file.
8	No attached. The third one, no attached.
9	CHAIR MUNN: The fourth one
LO	MEMBER ZIEMER: No attached file.
11	CHAIR MUNN: The fifth one
L2	MEMBER ZIEMER: I don't have a
L3	fifth one.
L4	CHAIR MUNN: And the sixth one is
L5	George's.
L6	MR. HINNEFELD: How did you get to
L7	where you are? How did you get to this
L8	application?
L9	MEMBER ZIEMER: I just expanded
20	it.
21	MR. HINNEFELD: Yes, but, I mean,
22	the entire database, how did you get here to

1	start it?
2	MEMBER ZIEMER: Let me go back.
3	MR. HINNEFELD: I'm wondering
4	because it seems like you have got an old one.
5	MR. MARSCHKE: That is what I was
6	wondering, too.
7	MEMBER ZIEMER: I sorted on TIBs.
8	MR. HINNEFELD: Okay, but just
9	close the thing. Just close out the database
10	altogether.
11	MEMBER ZIEMER: Oh, go out?
12	MR. HINNEFELD: Just close out the
13	database.
14	MEMBER ZIEMER: Close it out?
15	MR. HINNEFELD: Yes.
16	MEMBER ZIEMER: Okay, and then go
17	back?
18	MR. HINNEFELD: And now, how did
19	you get here?
20	MEMBER ZIEMER: Oh, well, you have
21	got to open it through the pull it up here
22	in order to use this. Then I went to the

1	TIBs. Then, I guess it was on page 3. I
2	expanded this.
3	MR. KATZ: I am going to
4	interrupt. I am going to close the record
5	just for now because this is all completely
6	process discussion. It is not really useful
7	for the transcript. So, we will reopen it
8	when we are back to work.
9	(Whereupon, the foregoing matter
10	went off the record at 9:55 a.m. and went back
11	on the record at 9:56 a.m.)
12	MR. KATZ: Back on the record.
13	MR. MARSCHKE: Are we back on the
14	record?
15	Now are we closing OTIB-51-01?
16	CHAIR MUNN: You bet. We have
17	heard no objection, and the statement seems to
18	be fairly straightforward. We have completed
19	the requirement of the linking, and that is
20	all that was necessary for that particular
21	finding. So, that one is now closed.
22	MR. STIVER: If I refresh, it

1	should come up as closed.
2	MR. MARSCHKE: No, not yet. Give
3	me a second.
4	(Laughter.)
5	CHAIR MUNN: Now does anyone else
6	have anything they need to say or ask about
7	the database before we move on to our next
8	item?
9	MR. KATZ: Just a question. I
10	don't have the agenda in front of me, but
11	didn't we have a few of these linking items?
12	CHAIR MUNN: Yes, we have got them
13	under carry forward, yes.
14	MR. KATZ: They could all be
15	closed, then, I guess, the same way. It is
16	the same problem, right?
17	MR. MARSCHKE: Elyse says they all
18	were closed except for 51-01.
19	MR. KATZ: Oh, okay.
20	DR. ULSH: I think they are
21	individual agenda items. As we walk through
22	them, that might very well be the resolution

1	then.
2	MR. KATZ: No, I am saying we
3	could just close them now.
4	MR. STIVER: I believe she said
5	they were closed technically, but they still
6	were open.
7	MR. KATZ: Right, right. So, just
8	as we have closed this formally now, we could
9	close the rest, the other two or three, or
10	whatever they are.
11	MS. THOMAS: Yes, the others are
12	closed.
13	MR. KATZ: Oh, they are?
14	MS. THOMAS: Yes.
15	CHAIR MUNN: We were only carrying
16	them on our agenda here as an agreement that
17	Elyse and I would track them to make sure that
18	the linking did occur.
19	MR. KATZ: Got it. Thank you.
20	CHAIR MUNN: That it is going to
21	occur.
22	MR. MARSCHKE: The link of the PDF

1	file has been implemented. Thus, the
2	Subcommittee has closed this finding.
3	CHAIR MUNN: Correct.
4	MEMBER LEMEN: I am confused about
5	the closing. Are you saying that OTIB-21-04,
6	OTIB-47-02, OTIB-19, all of those on the
7	agenda are closed?
8	CHAIR MUNN: Yes, they were closed
9	already. In prior meetings, we had closed
10	them because all of the actions were complete.
11	What was not complete was the link to the
12	supporting documents that would make it
13	possible for us to track what had happened and
14	what the final resolution was. The document
15	was out there, but it was not connected in any
16	way to the database.
17	MEMBER LEMEN: So, does that mean
18	on our agenda on carryover items that we still
19	have TIB-10 and
20	CHAIR MUNN: That's correct. We
21	are still looking at TIBs.
22	MEMBER LEMEN: That is all we have

1	on there.
2	CHAIR MUNN: Ten is an entirely
3	different thing.
4	MEMBER LEMEN: Then, that is the
5	only thing we have left on the agenda for the
6	carryover items, right?
7	CHAIR MUNN: We have TIB-10. We
8	have TIB-13, and we have
9	MEMBER LEMEN: Right. I'm sorry,
10	I missed that. Yes.
11	CHAIR MUNN: Yes, we have 52, and
12	we have added 6.
13	MEMBER LEMEN: But all the others
14	are closed out?
15	CHAIR MUNN: The ones that are
16	closed out are OTIB-21-04. Today we closed
17	out OTIB-51-01.
18	MEMBER LEMEN: Right.
19	CHAIR MUNN: We have already
20	closed out OTIB-47-02
21	MEMBER LEMEN: Right.
22	CHAIR MUNN: and OTIB-19.

1	MEMBER LEMEN: Right. Okay, I'm
2	with you now. Thank you.
3	CHAIR MUNN: Okay? Thank you.
4	Very good. Our next item is
5	OTIB-70, status, changes and update. It is, I
6	believe, NIOSH's response.
7	DR. ULSH: And I am going to call
8	on Elyse.
9	MS. THOMAS: Okay, and I will call
10	on Mutty.
11	(Laughter.)
12	MR. MARSCHKE: Before we move on,
13	I can't get the status on OTIB-51-01, I can't
14	get the status to change, speaking of beta
15	versions and bugs in the beta version.
16	I go in. You guys can test me
17	out, but I have done it twice now. I add a
18	response. Wait a minute.
19	MR. STIVER: Maybe it is in the
20	comment field.
21	MR. MARSCHKE: Maybe I am doing it
22	wrong. Added status. Maybe I am doing it

1	wrong. Okay. Never mind. Operator error.
2	CHAIR MUNN: Let's see if it
3	works.
4	MR. KATZ: Closed, yes.
5	Mutty, you can continue.
6	MR. SHARFI: Okay. Did you want
7	me to go through them one-by-one or?
8	CHAIR MUNN: For 70? Yes, I think
9	that is probably a good idea.
10	MR. SHARFI: The first finding I
11	believe deals with the 1 percent per day
12	source-term depletion rate as it compares to
13	the resuspension factor that is recommended.
14	Basically, the 1 percent per day
15	has been revised. This was already done
16	inside the Norton ER. I believe SC&A reviewed
17	that part. It has been changed to a .067
18	percent per day. This is based on other sites
19	that have actually done calculated source-term
	_
20	depletion rates, Blockson, Dow Madison,
21	General Atomics, Simond Saw, General Steel.
22	We have used that data to

1	recalculate a generic source-term depletion
2	rate. That is being now updated and OTIB-70
3	is currently being revised to include that new
4	value.
5	We should be pretty close, if you
6	use the SC&A approach to calculate our
7	resuspension factor. I think it gives you
8	pretty close to a value of 1E minus 6.
9	Do you any comments or shall I
10	just move on?
11	CHAIR MUNN: No, hold on a minute
12	because I have a question as to how your
13	report now goes into our database.
14	MR. HINNEFELD: Well, it sounds to
15	me as if we now need to enter essentially what
16	Mutty said
17	CHAIR MUNN: Yes.
18	MR. HINNEFELD: into the
19	database.
20	MR. STIVER: You have to add a
21	response.
22	MR. HINNEFELD: Then, you add a

WASHINGTON, D.C. 20005-3701

1	response.
2	CHAIR MUNN: Yes.
3	MR. HINNEFELD: And so, at that
4	point or now, I guess at that point, then,
5	SC&A may want to look and see, is this
6	satisfactory? What we actually write there,
7	is this a satisfactory closure to the finding?
8	And if they concur, then, theoretically, they
9	could provide recommendations and put this in
L0	abeyance until that document is revised.
11	MR. KATZ: Well, they may be able
L2	to respond to some of these in real time, I
L3	mean during our meeting here.
L4	MR. HINNEFELD: Well, I mean, I
L5	don't know if you guys want to
L6	MR. KATZ: Yes.
L7	MR. HINNEFELD: The discussion on
L8	that has occurred elsewhere.
L9	MR. KATZ: Right.
20	MR. HINNEFELD: It has occurred in
21	another Work Group meeting.
22	MR. STIVER: From what Mutty said.

1	he is basically concurring with our
2	recommendation.
3	MR. HINNEFELD: Yes, yes.
4	MR. STIVER: It is just a matter,
5	has it gone into the document yet?
6	MR. KATZ: That's what I am
7	saying.
8	MR. HINNEFELD: We have accepted
9	the fact of 1 percent a day isn't right, and
10	we have proposed a different value in whatever
11	site that was. I believe we have some
12	comments from that Work Group on that value.
13	MR. STIVER: Yes, this was
14	discussed in detail
15	CHAIR MUNN: I believe so, yes.
16	MR. STIVER: at the last
17	meeting.
18	MR. HINNEFELD: Yes. And so, we
19	can do whatever we want, I mean whatever the
20	Work Group is comfortable with, the
21	Subcommittee is comfortable with.
22	CHAIR MUNN: My question, does

1	SC&A concur with Mutty's report?
2	MR. STIVER: Yes.
3	CHAIR MUNN: Then, is our only
4	action that is necessary not to simply report
5	that here, that NIOSH indicates this change is
6	being made; SC&A accepts that? The item is
7	closed. Do we need to do anything other than
8	that? All we need to do is an entry here now,
9	right?
LO	MEMBER ZIEMER: Do we have copies
L1	of his words?
L2	MR. STIVER: We would need to
L3	actually verify that it is in the document as
L4	stated.
L5	MR. MARSCHKE: It would be not
L6	closed; it is in abeyance.
L7	MR. STIVER: So, I think it should
L8	be changed to in abeyance at this point.
L9	CHAIR MUNN: Okay, in abeyance.
20	In abeyance.
21	MR. STIVER: Until we can actually
22	verify that, yes, it has been.

1	CHAIR MUNN: That's fine.
2	MEMBER ZIEMER: Do we have a copy
3	of what he just gave us?
4	MR. MARSCHKE: I don't.
5	MR. STIVER: I do not have an
6	extra copy of that.
7	CHAIR MUNN: I am sure it is
8	possible for him to email that to you today.
9	MR. STIVER: Mutty, this is John
10	Stiver.
11	MR. MARSCHKE: I don't know that
12	he has got anything written.
13	MR. KATZ: It will be entered into
14	the database. I mean, that would be the way
15	to do this. So, it doesn't need a separate
16	email.
17	MS. THOMAS: This is Elyse.
18	I have those responses, and NIOSH
19	has looked at them. I thought I had entered
20	them into the database, and they are not in
21	there. If the Subcommittee or NIOSH would
22	like, and you can give me like 30 minutes, I

1	can get those entered. And then, when you go
2	through the OTIB-70 items, you will see the
3	responses as well. If that would make it
4	easier for the Subcommittee, I would just need
5	a little bit of time to get that done.
6	CHAIR MUNN: That would be most
7	helpful, Elyse, if you would.
8	MS. THOMAS: Okay.
9	MEMBER ZIEMER: Yes, I would like
10	to see the wording on that, if she has that.
11	But just informally, so instead of the 10 to
12	the minus 6, what is the new number? Is it
13	.67 times
14	MR. STIVER: It was to match the
15	depletion rate, the source term depletion rate
16	with resuspension factor.
17	MR. HINNEFELD: The value that we
18	are backing away from is not necessarily the
19	10 to the minus 6, although we may have done
20	that also. The value we are backing away from
21	is the 1 percent per day depletion
22	CHAIR MUNN: The 1 percent,

1	correct.
2	MEMBER ZIEMER: Oh, right. Okay.
3	Okay, yes.
4	DR. MAURO: The resuspension
5	factor did not change.
6	This is John Mauro. Maybe I could
7	help out.
8	When we discussed this, we all
9	agreed that there was a linkage between the
10	resuspension factor and the rate at which it
11	would decline. Under circumstances where the
12	site has been cleaned up already
13	MEMBER ZIEMER: Right.
14	DR. MAURO: the 10 to the minus
15	6 holds, and we are fine with that. Under
16	circumstances where the site has not been
17	cleaned up and you've got loose contamination,
18	the resuspension factor could be quite a bit
19	higher.
20	And it turns out that the rate of
21	removal is linked to that resuspension factor.
22	I recall Jim indicating that they have some

evidence that the rate of removal goes down substantially when the resuspension factor is very low, for obvious reasons. And the number that Jim cited when we discussed this -- and perhaps, Elyse, when you put this together -- this story could be told in sort of like a summary fashion.

I remember a number, instead of 1 percent per day, it might go down to .05 percent per day, on that order, like a twentyfold change in the rate at which it declines. But they are not independent. It was agreed during the discussion that the two are linked. So, that might help a little when we try to capture the sentiment here in the attachment that will go with this.

DR. BEHLING: John, this is Hans Behling. I just want to make a comment.

I tend to agree with you in a sense that there is a linkage between the resuspension factor and the depletion rate. However, it is not one-to-one.

I mean, just conceptually
speaking, think about the situation where you
had a facility that was hermetically sealed,
where there is no expulsion of resuspended
particles by way of a ventilation system,
where you would have, essentially, a
resuspension factor that remains around
essentially constant with zero depletion. Now
I am not saying that you don't remove some of
the resuspended material by virtue of a
ventilation system that may have HEPA filters
or something else. However, I don't think it
is a one-to-one relationship. To match the
resuspension factor to the depletion rate on a
one-to-one basis may not be correct.

DR. MAURO: And I agree. I believe that that sensibility was captured in Jim's proposed strategy for revising OTIB-70. I know when we discussed it, in principle, we all agreed, yes, you're right, I mean, it could be somewhat complex. But, apparently, Jim had some empirical data which showed the

1	rate of decline that he is prepared to work
2	into OTIB-70.
3	So, I mean, really, what we are
4	really saying here, I guess, is there is a
5	record in the transcript where this issue was
6	discussed. At the time of that discussion,
7	SC&A agreed in principle that that strategy
8	was a reasonable strategy to take. I guess it
9	would be a good idea to capture that sense in
10	an attachment to closing this issue, or at
11	least putting it in abeyance.
12	MR. STIVER: John, this is John
13	Stiver.
14	Essentially, that is what is
15	included in the comment by Steve, as of
16	December 30th, 2010. This discussion is there
17	in the database.
17	in the database. DR. MAURO: It is? Oh, okay.
18	DR. MAURO: It is? Oh, okay.
18 19	DR. MAURO: It is? Oh, okay. CHAIR MUNN: Yes, it is.

1 verged on categorization as an overarching 2 issue because it affected so many sites. 3 DR. MAURO: Yes. But you can't apply 4 CHAIR MUNN: 5 it broad-brush to all sites, obviously. 6 this was agreed to, and we've covered this one very thoroughly from a variety of sources. 7 should be, in my view, now closed. 8 We have what I consider to be full technical agreement 9 10 that, certainly, in most cases the definitions laid 11 that we have out going to are applicable and will be both claimant-favorable 12 13 and highly defensible from a technical point of view. 14 Wanda, this is John 15 MR. STIVER: 16 Stiver again. recall in going through the 17 Т transcript now, to account for what Hans is 18 19 bringing up, that each individual site would have to be looked at. 20 21 CHAIR MUNN: That's correct.

Yes.

MR. STIVER:

1	CHAIR MUNN: That's correct.
2	MEMBER ZIEMER: Right. It was
3	more of a methodology.
4	MR. STIVER: Yes, it was more it
5	would be a generalized methodology.
6	MEMBER ZIEMER: Right.
7	CHAIR MUNN: Yes.
8	MEMBER ZIEMER: So, what NIOSH was
9	saying today, basically they are agreeing with
10	what we have here then?
11	CHAIR MUNN: Yes.
12	MR. STIVER: Yes.
13	MEMBER ZIEMER: And it is agreeing
14	to an approach as opposed to a number.
15	MR. STIVER: Exactly.
16	CHAIR MUNN: Correct.
17	MR. STIVER: My only concern about
18	whether to close it or keep it in abeyance is
19	whether that language has actually gone into
20	TIB-70.
21	CHAIR MUNN: I understand.
22	MS. THOMAS: This is Elyse again.

1	Excuse me for interrupting.
2	But I went ahead and added the
3	NIOSH response for Finding 01, OTIB-70,
4	Finding 01. So, I think if you refresh your
5	screens, you might be able to see that. And I
6	will go on and do the others as you are
7	discussing it, but I think, if you refresh
8	your screen, you ought to see a new response
9	added there at the end of the string.
10	MR. KATZ: Thank you, Elyse.
11	CHAIR MUNN: Thank you, Elyse,
12	very much.
13	MR. STIVER: And there it is, by
14	Mutty, as of today. The time is a little off,
15	though, 12:00 a.m.
16	(Laughter.)
17	MEMBER ZIEMER: There it is.
18	Okay.
19	MR. STIVER: The very last line
20	is, the OTIB is currently being revised to
21	reflect this change. And so, I know we would
22	go into abeyance until we actually verify that

1	it is in the document.
2	MR. KATZ: Right.
3	MEMBER ZIEMER: So, the .00067 is
4	a default, if you don't have the actual data,
5	is that correct?
6	DR. BEHLING: That is correct.
7	MEMBER ZIEMER: Otherwise, you
8	would use the starting and ending point.
9	MR. STIVER: Right.
10	MEMBER ZIEMER: Yes. Okay.
11	DR. MAURO: We always prefer to
12	use actual scientific
13	MEMBER ZIEMER: Right.
14	CHAIR MUNN: All right. Are we
15	good?
16	MR. KATZ: So, Steve will put
17	abeyance?
18	CHAIR MUNN: Yes. It will show in
19	abeyance.
20	MR. KATZ: And, Mutty, I guess you
21	can move on. No?
22	MR. MARSCHKE: Well, again, are
	NEAL R. GROSS

1	you going to give Elyse a chance to enter
2	MR. KATZ: I think she is doing
3	that.
4	MS. THOMAS: Yes. If you would
5	refresh your screen again, you should be able
6	to discuss Finding 02.
7	MR. SHARFI: A lot of 02 is going
8	to be similar to 01. This is a lot of
9	discussion once again on the resuspension
10	factor and the source term depletion rates and
11	how they interact. The response is actually
12	identical, I think, to Finding 1.
13	This is, rather than talking about
14	the resuspension factor, we are talking about
15	resuspension rates and how they apply to the
15 16	resuspension rates and how they apply to the source term depletion rate.
16	source term depletion rate.
16 17	source term depletion rate. Based on this comment, we would
16 17 18	source term depletion rate. Based on this comment, we would still probably put this in abeyance if
16 17 18	source term depletion rate. Based on this comment, we would still probably put this in abeyance if everybody still agrees

1	that issue.
2	CHAIR MUNN: We agree. Let's abey
3	it.
4	MR. SHARFI: Finding 3 is going to
5	be the identical way. It is a direct comment
6	about the 1 percent per day. Finding 1 was
7	really more about the resuspension factor.
8	Finding 2 is more about the resuspension rate.
9	And Finding 3 is the direct statement on the
10	1 percent per day. One, 2, and 3 are kind of
11	all interrelated.
12	And so, the comments, the response
13	is still the same. The fact that the average
14	depletion rate of the four sites that is going
15	to be used is going to change the 1 percent
16	per day to the 0.00067 per day rate.
17	MR. STIVER: So, that one can go
18	into abeyance, as well.
19	CHAIR MUNN: Correct, 2 and 3 both
20	go into abeyance. We probably need to have
21	the comment that refers it back to Finding 1.
22	MR. SHARFI: Finding 4 is already

1	closed. Finding 5 deals with attachment B.
2	There is thorium intake rates or survey data
3	that is provided for generic sites. However,
4	this data has never been used, and we have no
5	intention of using it. So, this attachment is
6	actually going to be removed from the OTIB
7	during the revision.
8	CHAIR MUNN: And do we say that?
9	MEMBER ZIEMER: Which one is this?
10	CHAIR MUNN: Five.
11	MR. SHARFI: Five.
12	MS. THOMAS: Yes, if you refresh
13	your screen, you should be able to see the
14	response for 5.
15	MR. HINNEFELD: How about 3?
16	MS. THOMAS: Three, yes. I
17	entered 3, as well.
18	CHAIR MUNN: Both 2 and 3 have
19	gone into abeyance.
20	MR. SHARFI: Finding 6 will be the
21	same.
22	MR. MARSCHKE: Wanda, is it

1	changed to in abeyance?
2	CHAIR MUNN: Yes, on my screen 2
3	and 3 are changed to abeyance. I have not yet
4	seen the change on 5.
5	MR. MARSCHKE: Do you want 5
6	changed?
7	CHAIR MUNN: Yes.
8	MEMBER ZIEMER: It has been
9	entered. It is here.
10	MR. MARSCHKE: Yes, the response
11	is there.
12	MR. SHARFI: Five and 6 are
13	interrelated. They are both the same thing.
14	One is specific to one of the sites listed; 6
15	is specific to the Horizon site. But, once
16	again, the whole attachment is being deleted.
17	So, 6 will have the same NIOSH response.
18	That Attachment B is being deleted in the next
19	revision of the OTIB.
20	CHAIR MUNN: And No. 9?
21	MR. SHARFI: Nine is still part of
22	Attachment B. It is another site-specific

1	question. It has to do with the Linde data
2	that is inside Attachment B. Once again,
3	Attachment B will be deleted. So, 9 should
4	follow 5 and 6.
5	MR. MARSCHKE: Elsye, are you
6	entering the response to 6?
7	MEMBER ZIEMER: It is in.
8	MR. MARSCHKE: It is?
9	MS. THOMAS: I am trying. I am
10	getting an error message here. So, I am not
11	able to go on to 9 or 10. I was about one
12	step ahead of you and now I'm not.
13	(Laughter.)
14	MR. MARSCHKE: Yes, I wanted to
15	wait until you entered the response before I
16	closed Finding 6 or I put Finding 6 in
17	abeyance.
18	MS. THOMAS: Yes. See, my screen
19	says that Finding 6 in abeyance, and I am
20	wondering if that is why I am having trouble
21	saving it. But I am going to get out of 6 and
22	move on to 9 and 10, and see if I can enter

2	go back to 6.
3	MR. MARSCHKE: Elyse, sometimes
4	when you enter the finding, when you enter a
5	new comment for a finding and you put somebody
6	else's name, the database has a tendency to
7	change the status of the finding. So, you
8	might want to check that. Make sure that when
9	you enter your comments under 6 that, when you
10	click the Save
11	MS. THOMAS: Okay.
12	MR. MARSCHKE: it still saved
13	as in progress.
14	MS. THOMAS: Okay. I just tried
15	that. Let's see. That seemed to take. Okay.
16	Very good. Thank you.
17	You can look at 6, Finding 6, and
18	I will get 9 and 10 entered here.
19	MEMBER ZIEMER: Nine doesn't show
20	up.
21	MR. MARSCHKE: So, the status on 6
22	is now in abeyance.
	NEAL D. CDOCC

those before you discuss them, and then I will

1	MEMBER ZIEMER: Here it is, yes.
2	MR. MARSCHKE: Nine is already in
3	abeyance. Ten is the next one.
4	CHAIR MUNN: Yes, I think Elyse is
5	working on it right now.
6	MS. THOMAS: Yes, give me a
7	minute, please, on 10.
8	DR. MAURO: I would like to say it
9	is really great to see we are back in real-
10	time mode again. It has been a while.
11	(Laughter.)
12	Congratulations.
13	CHAIR MUNN: Yes, it is nice,
14	isn't it?
15	MR. KATZ: I agree, John.
16	MR. STIVER: It took some time,
17	but we got that.
18	CHAIR MUNN: It seems boring at
19	the moment, but it is great at the end of the
20	day.
21	
	DR. MAURO: Now all we need is

made during the day.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

CHAIR MUNN: Exactly. We're never satisfied. Everybody is an expert.

MS. THOMAS: Okay, 10 should be ready to go. Thank you.

CHAIR MUNN: Thank you.

MR. SHARFI: Number 10 is directly about the 1E minus 6 resuspension factor. This goes to what John was alluding to before about when it is appropriate and whether or not higher numbers can be used.

This generically for NIOSH is that four sites that have been cleaned up and you are applying a generic resuspension factor of It is claimant-1E to the minus 6. favorable, not only because we are applying it generically to all contamination, not just the removable. We have t.o remember resuspension factors are really more designed removal fraction, not the surface contamination. And generically, we apply this all, you know, to the

NEAL R. GROSS

1	contamination level. So, there is an inherent
2	factor that is built in because we are not
3	looking at just removable contamination.
4	However, the OTIB is not locking
5	anybody into the 1E minus 6. If there are
6	situations, as John alluded to, where a higher
7	resuspension factor is needed, the OTIB allows
8	for that. The default is still listed as 1E
9	minus 6.
10	MR. MARSCHKE: Is this a change?
11	I mean
12	MR. SHARFI: Not really.
13	MR. MARSCHKE: Basically, the
14	same?
15	MR. SHARFI: We are still in the
16	OTIB list of 1E to minus 6 as the default, but
17	noting that it is guidance; it is not a fixed
18	number that you have to use.
19	MR. KATZ: That is different from
20	before.
21	DR. MAURO: Is there language in
22	there that it is appropriate to use when the

site has gone through some D&D? I would just suggest that that type of language is important because that is really when it applies.

have many, many circumstances at AWE sites where the sites, you know, the 10 to the minus 6 was used in the past, when the site still had visible surface contamination. So, I mean, certainly, put as much qualifier in as you feel is appropriate, but I just want to caution that 10 to the minus 6 worked out just fine, for example, I believe it was on Linde after there was a D&D period. number of other sites we found it didn't work So, as long as there is cautionary out. language in there, Ι think the dose reconstructor will be okay.

MR. SHARFI: I will have to check,

John. I don't have it in front of me, the

revision, but I can check to see if there is

language that helps clarify that situation.

DR. ANIGSTEIN: This is Bob

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

Anigstein.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

I would like to interject comment just about a statement that was made a moment ago, about the resuspension factor removable contamination. applying to Historically, the literature on resuspension factors that I am familiar with describes resuspension in terms of total contamination. I am talking about if you could measure with survey meter or some other radiationdevice. measuring Whereas, removal contamination really depends on the technique you use with a wipe test.

That is not the way it is usually -- I mean, logically, you say, if it is not removable, it can't be resuspended. But I believe that the literature refers to total contamination.

DR. MAURO: I could help a little bit, too, there, Bob.

You are correct. When you folks use resuspension factors, as applied to

NEAL R. GROSS

surface contamination, your starting point for the surface contamination more times than not is based on this deposition velocity approach, where you know the dust loading in the air and you use that .0075 meters per second deposition.

So, when you do it that way, it is total. In other words, what you end up calculating is dpm per meter squared, and it is total.

However, as Bob correctly points out, there are occasions, though, when the activity, surface activity, in dpm per 100 centimeters squared, for example, is based on a swipes test. Then what you are looking at is the removable material.

And then, of course, there are times when it is based on a survey meter, and you back out. There are places where this is done where you say, okay, this is what you would measure, this is what was measured with a survey meter. And on that basis, you could

1	figure out what would be on the surface from
2	the survey meter. In all likelihood, that
3	would be the total.
4	So, unfortunately, I think we have
5	a bit of a mixed bag. But I would say that,
6	notwithstanding that the 10 to the minus 6
7	probably holds up pretty good, as a rule of
8	thumb, I know Reg Guide 1.86 and, Bob, you
9	could correct me assumes that 20 percent of
10	whatever the total is is the removable
11	fraction.
12	DR. ANIGSTEIN: No, they have
13	separate limits on total and removable. I
14	don't have it in front of me. They state them
15	separately.
16	DR. MAURO: Yes.
17	DR. ANIGSTEIN: They say so many
18	dpm total, so many dpm removable. And it may
19	be that it is 20 percent, but it is two
20	separate limitations. You will not exceed the
21	total and you will not exceed the removable.
22	CHAIR MUNN: We have discussed

1	this at length, and we have agreed to the
2	caveat that, although this is in many respects
3	an overarching issue, we must take into
4	consideration the situation that exists at
5	individual sites. So, I think we have put the
6	issue to bed. I believe everybody concerned
7	understands what the caveats are and what the
8	limits are within which we have to operate
9	when we do this.
10	DR. MAURO: Wanda, we accept your
11	admonition, and Bob and I will tone it down.
12	CHAIR MUNN: Thank you. You see,
13	we are running a little late, and we are past
14	time for a break.
15	MEMBER ZIEMER: I did have a
16	question, though. I notice in the previous
17	comment by Rosanna, which was dated in August,
18	she has a quote that says, "NIOSH recommends a
19	resuspension factor of 10 to the minus 6 per
20	meter is inappropriate." Is that a correct

MR. MARSCHKE: I would have to

NEAL R. GROSS

quote?

21

1	check that. What Rose did was, back in last
2	January, we had a meeting and we discussed
3	OTIB-70, but the database wasn't working. And
4	so, when the database became working, I asked
5	Rose to go through all the transcripts and
6	pull out the appropriate, if we talked about
7	something. And she pulled this out. I'm not
8	sure, it is kind of out of context.
9	MEMBER ZIEMER: It is out of
10	context because it stands contrary to what
11	they were recommending.
12	MR. MARSCHKE: If we take a break,
13	I would like to go to the January 2011
14	transcript and pull up page 263 and see what
15	it is exactly saying there.
16	MEMBER ZIEMER: And then, just a
17	comment here. I think Mutty's most recent
18	comment addresses the issues that Bob and John
19	have raised.
20	My understanding is that this
21	applies to clean sites, and even there, NIOSH

is assuming, even though we agree that, in

general, on a clean site there is not much 1 2 loose contamination; in a dirty site it is 3 maybe 10 to 20 percent removable. But, in any event, this says that 4 that NIOSH assuming all of 5 is the 6 contamination on the surface is potentially 7 removable, and that you apply the 10 to the minus 6 to that, even though, in practice, it 8 is almost 100 percent fixed. I think that 9 10 took into consideration all of these issues that were raised again this morning, because 11 we have had this discussion about five times 12 13 already in the past. Anyway, I was a little puzzled by 14 the previous remark that is in here that NIOSH 15 16 is not recommending that. MR. MARSCHKE: It is a little bit 17 out of context here, Paul, and we would have 18 19 to go back and look at the transcript. 20 We can go back and MR. STIVER: check that transcript. 21

MARSCHKE:

22

Yes, and find out

1	exactly what it means.
2	Wanda, if you want to take a
3	break, we can look at it during our break.
4	CHAIR MUNN: This is an
5	appropriate time for us to do so. Fifteen
6	minutes, please.
7	(Whereupon, the foregoing matter
8	went off the record at 10:33 a.m. and went
9	back on the record at 10:52 a.m.)
LO	MR. KATZ: Okay. We are
11	reconvening.
L2	Dick, are you back on the line?
L3	MEMBER LEMEN: Yes, this is Dick.
L4	MR. KATZ: Great. Okay. We are
L5	getting started again.
L6	CHAIR MUNN: I believe we have
L7	come to the conclusion that we are going to
L8	edit OTIB-70-10/36, not Mutty's, but the
L9	preceding one from August 5th. It is
20	misleading in its language and we are
21	refreshing that right now.

Thank you, Paul, for calling that

1	to our attention.
2	Thank you, Steve, for doing that.
3	MR. MARSCHKE: Okay. So, that has
4	been changed, Paul.
5	MEMBER ZIEMER: I just need to
6	refresh, then?
7	CHAIR MUNN: Refreshing is less
8	than a refreshing activity.
9	(Laughter.)
LO	MR. STIVER: Maybe we should give
11	it a new name.
L2	MEMBER ZIEMER: Yes, that is good.
L3	MR. MARSCHKE: What did the
L4	Subcommittee decide on the status? Have they
L5	decided on the status?
L6	CHAIR MUNN: Yes.
L7	MR. STIVER: Another aspect of the
L8	10 to the minus 6 being
L9	MEMBER ZIEMER: Right.
20	CHAIR MUNN: It is more of an in
21	abeyance.
22	MR. HINNEFELD: I almost hate to

1	bring this up. This is Stu.
2	It is not clear to me from the
3	most recent response from us, the one that
4	just went in
5	MEMBER ZIEMER: For which one?
6	MR. HINNEFELD: This is
7	MEMBER ZIEMER: Ten?
8	MR. HINNEFELD: 70-10. It has
9	got Mutty's name on it, 12-6-2011, NIOSH
10	response. It is not clear to me that we are
11	saying that we are going to edit OTIB-70. It
12	seems to say that Mutty, since you were the
13	one who was talking about this, are you saying
14	here in this response that the OTIB already
15	says that 10 to the minus 6 isn't chiseled in
16	concrete; it is just out there and it has to
17	be
18	MR. SHARFI: I committed to John
19	to verify whether it does leave the caveat in,
20	whether there is a caveat in there, and if
21	not, then I will add the caveat.

NEAL R. GROSS

MR. HINNEFELD: Okay. All right.

1	MR. SHARFI: I wasn't really
2	committing either way because I have to go
3	back and look at what is currently in the
4	hopper.
5	MR. HINNEFELD: Okay. All right.
6	CHAIR MUNN: Are we all on the
7	same page now?
8	MR. HINNEFELD: So, we are all on
9	the same page, except we don't know what the
LO	status is going to be, right?
L1	MR. KATZ: In abeyance.
L2	MEMBER ZIEMER: It is going to be
L3	in abeyance.
L4	CHAIR MUNN: It is in abeyance.
L5	MR. HINNEFELD: Okay. Steve is
L6	doing it now? Okay. All right.
L7	MEMBER ZIEMER: A quick question,
L8	you used plural "caveats" and then "a caveat".
L9	Is there more than one.
20	MR. STIVER: No, it is just a
21	caveat.
22	MEMBER ZIEMER: It has

1	inappropriate caveats then.
2	MR. STIVER: Single.
3	MEMBER ZIEMER: Yes.
4	CHAIR MUNN: So, where are we now?
5	MEMBER ZIEMER: So, this will be
6	in abeyance, is that right?
7	CHAIR MUNN: In abeyance, correct.
8	MR. MARSCHKE: Okay?
9	CHAIR MUNN: Correct.
10	Now next is where did we
11	leave
12	MR. KATZ: Mutty
13	MR. SHARFI: Yes?
14	MR. KATZ: Finding 10 is in
15	abeyance, and then we are ready to move on.
16	MR. SHARFI: Okay. Eleven deals
17	with the NUREG-1400 approach that was inside
18	the OTIB-70. It talks about source-term
19	analysis approach. There seemed to be some
20	question on whether or not it is applicable.
21	We have never really used this approach. It
22	was just something that was inside the OTIB.

1	So, we just agreed to remove it from the OTIB,
2	and that is currently being done in the
3	current revision.
4	MR. KATZ: Does SC&A concur with
5	that?
6	CHAIR MUNN: Well, it was their
7	finding.
8	MR. MARSCHKE: Basically, it seems
9	like they were taking we had problems with
10	NUREG-1400 and how they have committed to not
11	using NUREG-1400. I don't believe we have
12	any
13	DR. MAURO: We have never used the
14	approach, I think, on anything else.
15	MR. STIVER: Since it is being
16	removed, I don't see that we have any
17	MR. KATZ: Yes, I just wanted to
18	be explicitly
19	MR. STIVER: I was just reading
20	our previous response up here.
21	MR. KATZ: Right.
22	CHAIR MUNN: You may close it.

1	MR. MARSCHKE: Close it or in
2	abeyance? In abeyance.
3	MR. KATZ: In abeyance until the
4	new document is out.
5	CHAIR MUNN: I guess it does need
6	to be taken out.
7	MR. SHARFI: Ready for 12?
8	MR. KATZ: Sure, Mutty.
9	MR. SHARFI: Twelve has to do with
10	a reference to Battelle-TBD-6001. Yes,
11	Battelle-6001 has been cancelled, based on the
12	Battelle Working Group recommendations or
13	discussion that has gone through there. So,
14	all references to Battelle-6001 is being
15	I'm sorry, this is No. 13, not 12. Twelve
16	is already addressed. This is 13. Basically,
17	all references to Battelle-TBD-6001 are being
18	removed.
19	MR. STIVER: This is Stiver.
20	I am looking at Steve Marschke's
21	comment from Thursday, December 30th, 2010.
22	This was a comment by Bill Thurber that this

Even

2	though NIOSH decides to eliminate TBD-6001 and
3	the appendices, this is in relation to the
4	inhalation doses in TBD-6001 prior to 1948 and
5	extrapolating those backward in time.
6	So, I guess as long as the
7	residual period was after 1948, this would not
8	be an issue. So, that was kind of nested with
9	this whole discussion of removing TBD-6001.
10	John Mauro, do you have any more
11	in-depth understanding of how that transpired?
12	Are you out there, John?
13	(No response.)
14	CHAIR MUNN: We lost him.
15	MR. KATZ: Do we have anyone on
16	the line? Dick, are you on the line?
17	DR. BEHLING: This is Hans Behling
18	on the line. I'm not sure I fully understand
19	the question.
20	MR. KATZ: Okay.
21	MEMBER LEMEN: This is Dick. I'm
22	on the line.

could be also be a residual problem.

1	MR. KATZ: Okay. Great.
2	CHAIR MUNN: Do you want to try to
3	call John?
4	MR. STIVER: I am not sure whether
5	he will have that knowledge at this point.
6	I think that, why don't we just go
7	ahead and put it in abeyance? And then, we
8	will look at the changes that take place. I
9	think was more of a hypothetical comment that,
10	if in that time period had been considered,
11	that we might have a problem.
12	CHAIR MUNN: All right. So, it is
13	in abeyance.
14	Are you ready for 14, Mutty?
15	MR. SHARFI: Fourteen?
16	MS. THOMAS: Excuse me, Mutty, for
17	interrupting. This is Elyse.
18	And I was not able to add the
19	responses for Finding 14 or 15. I tried
20	repeatedly. So, they are short. Maybe Mutty
21	can read them to you, or whatever you would
22	like to do. I will try to get that addressed.

1	But, right now, those responses are not yet
2	entered.
3	CHAIR MUNN: Then, we will just
4	have to do it, hopefully, with what we have.
5	Do you want to start with 14, Mutty?
6	MR. SHARFI: Yes, 14 goes along
7	with 13. It is about Battelle-TBD-6001.
8	Since it is being removed, it is going to fall
9	in the same lines as 13, where we are removing
10	all references to the 6001 TBD.
11	It goes, once again, into that
12	prior-to-1948 situation, which now would be
13	handled on a site-by-site basis. The OTIB is
14	just not going to give generic guidance for
15	pre-'48. It will have to be looked at based
16	on its individual merits.
17	MR. STIVER: Mutty, this is
18	Stiver.
19	Is there going to be any change in
20	the language to indicate that expressly?
21	MR. SHARFI: At pre-'48, you would
22	have to look at the site-specific situation?

1	MR. STIVER: Correct.
2	MR. SHARFI: I don't think there
3	is any specific wording to that. I mean, a
4	guidance document doesn't give you guidance
5	I can't give you guidance on every small,
6	little issue that may come up. So, I don't
7	know what I would say.
8	MR. STIVER: In any case, this one
9	would be, as we have put in here in August, it
10	would be addressed in Finding 13.
11	DR. ULSH: The current status for
12	14 is in progress. I know that we have a
13	category called "addressed in finding".
14	MR. STIVER: Yes, so that is
15	DR. ULSH: Is that what you are
16	proposing?
17	MR. STIVER: I was proposing that
18	we change that to addressed in finding because
19	it is identical to 13.
20	CHAIR MUNN: We had gone back and
21	forth about that. I think that we did that
22	earlier, didn't we? Yes.

1 MR. HINNEFELD: It should be 2 changed. 3 CHAIR MUNN: From our January 4 meeting last year, we changed it from 5 progress" to "addressed in." It should have 6 been. MEMBER ZIEMER: Well, the original 7 finding had to do with an approach used in 8 TBD-6001 for inhalation, is that correct? 9 10 when 6001 went away, the Work Group that used to be the 6001 Work Group, which is I think 11 12 Henry Anderson's Work Group, now will handle, 13 I understand it, those facilities that would have fallen into the appendices. 14 Is that correct? 15 MR. KATZ: That is correct. Yes. 16 So, in each case, 17 MEMBER ZIEMER: 18 since there no longer will be a 19 approach to the inhalation, unless it is taken 20 from a different document, you would have to have an individual finding, I would think, for 21

22

a particular facility.

1	MR. STIVER: Right.
2	MEMBER ZIEMER: Because these are
3	going to go away as generic approaches, is
4	that correct, my understanding of that? Or,
5	Stu
6	MR. HINNEFELD: Well, 6001 is
7	going away as a generic.
8	MEMBER ZIEMER: As a generic.
9	MR. HINNEFELD: It was never
10	really used very generically anyway.
11	CHAIR MUNN: And from now on, it
12	will be an individual site.
13	MEMBER ZIEMER: So, one of the
14	sites now that has an inhalation situation,
15	would they draw on some other generic document
16	or would it be site-specific? Or it could be
17	either, I suppose?
18	MR. HINNEFELD: Well, the
19	approaches would be, the approaches for those
20	could be site-specific information or there
21	may be a use of, well, we know that there was
22	some sort of surrogate use. But it would be

1	to address a particular site.
2	MEMBER ZIEMER: Right. So, then,
3	there would be an SC&A review of that
4	document?
5	MR. HINNEFELD: Yes.
6	MR. STIVER: There would be some
7	further review.
8	MEMBER ZIEMER: Right, right.
9	So, I think the solution here is
10	that it goes away and you just
11	MR. STIVER: And, then, it becomes
12	a site-specific issue when something comes
13	up, and it is addressed within
14	MR. HINNEFELD: That is the way it
15	seems to me. I mean, I am not familiar with
16	you know, it says it refers to the 6001,
17	but you don't really know exactly.
18	MEMBER ZIEMER: Right. You are
19	not using it for anything.
20	MR. HINNEFELD: Yes.
21	CHAIR MUNN: So, that leaves us
22	where?

1	MEMBER ZIEMER: Well, it is not
2	going to be addressed in something else. That
3	is the point I am making. It says, I think
4	the last entry I have here for No is it
5	13?
6	MR. HINNEFELD: Fourteen.
7	MEMBER ZIEMER: Fourteen, the same
8	as item 13, change to "addressed in". It is
9	not going to be addressed in something, right?
10	MR. STIVER: Yes, they are
11	basically the same.
12	MR. SHARFI: It will be addressed
13	in 13.
14	MR. STIVER: Yes.
15	MEMBER ZIEMER: Oh, I see.
16	MR. STIVER: Thirteen is getting
17	rid of
18	MEMBER ZIEMER: I got you. I got
19	you.
20	MR. STIVER: It is 6001 is going
21	away.
22	MEMBER ZIEMER: I got you.

NEAL R. GROSS

1	MR. STIVER: It is just two
2	aspects of that same issue.
3	MR. KATZ: So, you can just close
4	this one because you have 13, which is in
5	abeyance, right?
6	MR. STIVER: Isn't that a separate
7	category "addressed in finding"?
8	MEMBER ZIEMER: What does
9	"addressed in" mean?
LO	MR. HINNEFELD: Basically, it is a
11	resolution of this other finding.
L2	MR. STIVER: A lot of these
L3	findings are really all related to the same
L4	basic
L5	MEMBER ZIEMER: Well, you say,
L6	"addressed in Finding 13."
L7	CHAIR MUNN: Correct.
L8	MEMBER ZIEMER: I got you.
L9	CHAIR MUNN: All right. Are we
20	finished with 14?
21	MR. KATZ: Yes.
22	CHAIR MUNN: All right. We will
	1

1	move on to 15.
2	MR. SHARFI: Fifteen is already in
3	abeyance.
4	CHAIR MUNN: It is, indeed. And
5	that is the bottom of my list, am I correct?
6	MR. KATZ: That is correct for 70.
7	CHAIR MUNN: We have, with Mutty's
8	assistance and Steve's perseverance, gotten
9	through 70.
10	MR. KATZ: That's good.
11	CHAIR MUNN: Is there anything
12	open on this? Eleven still shows in progress.
13	MR. KATZ: Eleven is in abeyance.
14	CHAIR MUNN: That is just an
15	artifact of where I am, I guess.
16	MR. KATZ: Yes.
17	CHAIR MUNN: There it goes.
18	And 14, my 14 is still showing in
19	progress.
20	MR. HINNEFELD: Steve is still
21	changing that.
22	MR. MARSCHKE: Yes, you have got

WASHINGTON, D.C. 20005-3701

1	to get a faster secretary.
2	(Laughter.)
3	CHAIR MUNN: All right.
4	MR. STIVER: We prefer accuracy to
5	speed.
6	(Laughter.)
7	MR. HINNEFELD: It should show up
8	as "addressed in finding" at this point.
9	CHAIR MUNN: Excellent.
10	MR. KATZ: So, TIB-70, you could
11	have a two-pager written. Everything is
12	either closed or in abeyance, is that correct?
13	Right?
14	CHAIR MUNN: It appears to be.
15	MR. KATZ: So, we can task SC&A
16	with a two-pager on this.
17	CHAIR MUNN: We can, indeed.
18	Now the next item on our agenda is
19	the PERs. We have three that were items of
20	concern.
21	The first one was 008, and the
22	last time we met Ted said he would take the

1	responsibility for seeing that our transcript
2	notations got over to Dr. Richardson after
3	did that happen?
4	MR. KATZ: No. You have to remind
5	me even what notations you mean. Or what was
6	the issue here?
7	MEMBER ZIEMER: It had to do with
8	the IREP model, whether there was I don't
9	know the
10	MR. STIVER: Yes, actually, this
11	is an issue that Hans had raised about the
12	time dependence in the Probability of
13	Causation. It is handled in IREP. Remember,
14	there were two different situations with that.
15	Actually, there were more than two.
16	If the onset was like 20 years
17	later or four years later, you are basically
18	in the same PoC. So, we agreed that this was
19	kind of an overarching science issue that
20	needed to be transferred to that Work Group.
21	MR. KATZ: And this is in the
22	transcript notations for transcript made

1	MR. STIVER: It would have been
2	the September 30th.
3	MR. KATZ: September?
4	CHAIR MUNN: March 22.
5	MR. KATZ: March 22?
6	CHAIR MUNN: March 22, pages 132
7	to 184.
8	MR. KATZ: One
9	CHAIR MUNN: One thirty-two to
10	184.
11	MR. KATZ: I may have sent those
12	to David, but I don't recall, because that
13	would have been so long ago. But I can
14	double-back and check that.
15	I mean, that fits with what that
16	Science Work Group has signed up to do, in a
17	sense, because all of their priorities to date
18	are risk-model-related work. So, it fits
19	within that sense. Now they have a long
20	laundry list, and when that will get addressed
21	is anybody's guess, given how long their

22

laundry list is.

1	But, anyway, I will follow up
2	after this meeting and check to see either
3	that I sent those transcript pages or send
4	them again. I will send them again, in any
5	event, actually, to David, so that he has
6	those in mind at least.
7	CHAIR MUNN: And the next item,
8	018, which was my commitment to do that. Even
9	though the Los Alamos Group knows what we are
10	sending to them, I was going to see it that it
11	got to them in written form and was, frankly,
12	hoping to see if I could do that in PDF. Now
13	that I can do it, I will proceed to do so, but
14	it has not yet been done.
15	And on PER-020, we had a question
16	with respect to the Blockson division. NIOSH
17	was going to take a look at the universe of
18	claims that we had to see whether there
19	actually would even be any claimants affected
20	by our items.
21	DR. ULSH: Wanda, I don't

MR. HINNEFELD:

22

What is the date

1	of that meeting? I think I asked Tom and I
2	got an answer. What was the date of the
3	meeting? This is from the September meeting?
4	MR. STIVER: Right.
5	MR. KATZ: Yes.
6	CHAIR MUNN: Correct.
7	MR. MARSCHKE: Basically, yes,
8	September. I have got a note saying Stu will
9	find out whether these issues affect anyone.
10	MR. STIVER: This is the issue of
11	Type M uranium
12	MEMBER ZIEMER: Which finding is
13	it?
14	CHAIR MUNN: Twenty.
15	MEMBER ZIEMER: Twenty
16	CHAIR MUNN: On 1 and 2 both.
17	MEMBER ZIEMER: One and 2 both.
18	CHAIR MUNN: We had those classes,
19	and there was one value for uranium,
20	converting data, inhalation and ingestion. We
21	were questioning whether it was necessary to
22	do that work, in light of the fact of the

1	probability that there were ever going to be
2	claimants that would even raise this question
3	was remote. We were just going to check to
4	make sure that that was true before we closed
5	it out.
6	We will carry that one over,
7	right?
8	MR. HINNEFELD: Yes, it is going
9	to take me a minute to find that.
10	CHAIR MUNN: So, all three of
11	these carryover.
12	MR. KATZ: Folks on the phone,
13	except when you are speaking, would you please
14	mute your phones? There is some static coming
15	back that is giving the transcriber a hard
16	time.
17	CHAIR MUNN: Now we will move on
18	to our other carryover items that we had, the
19	first one being TIB-10.
20	NIOSH was going to review Bob
21	Anigstein's report and have a position on that
22	for us.

1	MEMBER ZIEMER: TIB-10 is the
2	overestimating approach?
3	CHAIR MUNN: Yes, it is best
4	estimate, external dose reconstruction
5	for glove box
6	MEMBER ZIEMER: Oh, I have got the
7	wrong one.
8	DR. ULSH: This is OTIB-10 or
9	OCAS-TIB-10?
LO	MR. MARSCHKE: It is OCAS-TIB-10.
L1	DR. ULSH: Okay. I retract my
L2	answer then.
L3	MEMBER ZIEMER: OCAS-TIB-10.
L4	DR. ULSH: Okay. If you can't
L5	find it there, Paul, it might be it had been
L6	changed to DCAS.
L7	CHAIR MUNN: It is DCAS-TIB-10.
L8	DR. ULSH: Right. The story there
L9	is that it was originally issued as
20	OCAS-TIB-10. We changed our Division name and
21	we revised this document. It has been changed
22	to DCAS-TIB-10.

1	MEMBER ZIEMER: How are the DCAS
2	things sorted under here? I mean, I'm under
3	TIBs.
4	DR. ULSH: I don't know, but I
5	MEMBER ZIEMER: No DCASes.
6	CHAIR MUNN: Go back up. Just try
7	it up there under the Search box.
8	MR. MARSCHKE: Yes, if you do a
9	search on TIB-10, TIB-0010, it will the
LO	only problem is it showing these as all being
L1	open issues.
L2	DR. ULSH: This is one of those
L3	bugs that we talked about. Let me give you
L4	the status on this, and then I will tell you
L5	why the database appears the way it does.
L6	Basically, this is one where we
L7	have been going back and forth on this one for
L8	a long time. It is my summary that the
L9	substantive issues have been addressed, but
20	there were some examples that we provided in
21	response to some SC&A findings. While the

overarching or overlying issues have been

1	addressed, we are still not in concordance on
2	some of those examples that we provided.
3	So, I initiated a revision of this
4	document to take those examples out. That
5	revision has happened. Those have been
6	removed, those examples.
7	And so, I have findings written up
8	that I have not yet transferred to this
9	Working Group. The reason is we discovered a
10	bug in the database where some of these in
11	this situation where they originated in an
12	OCAS document were changed to a DCAS document,
13	the findings weren't ported over when we went
14	from Access to here.
15	So, I worked with Tom James, and I
16	think we have got that fixed, with the
17	exception of the status on the findings is not
18	up-to-date.
19	CHAIR MUNN: Okay.
20	DR. ULSH: So, I think the action
21	item here is for us, NIOSH, to go in and put
22	our updated finding into the database and

1	correct the status on this.
2	MR. MARSCHKE: Would you let me
3	know when you update the status on this?
4	DR. ULSH: Yes. Sure.
5	MR. MARSCHKE: Because some of
6	these, I think, have already been closed when
7	it was part of OCAS.
8	DR. ULSH: Right. Right.
9	MR. STIVER: Only one. I would
10	really recommend closing it.
11	DR. ULSH: Oh, yes, absolutely.
12	Don't trust the finding status on this
13	particular document because all Tom did was,
14	when he added the findings, he put a status of
15	all open. I think Elyse and I can go back and
16	fix the findings.
17	MR. MARSCHKE: Well, yes. I mean,
18	all you have got to do is go back to an older
19	version of the database and call off what the
20	findings were before
21	DR. ULSH: Right, right.
22	MR. MARSCHKE: when it was

1	still OCAS.
2	DR. ULSH: Yes.
3	MR. MARSCHKE: I don't know what
4	the status was when it was OCAS, but to kind
5	of make DCAS the same.
6	DR. ULSH: Yes, exactly.
7	CHAIR MUNN: Now I am trying to
8	recall if that is the sense of what I had
9	intended when I put this on the agenda.
LO	"Anigstein report review", I say, which makes
L1	me wonder if we had not had some other
L2	discussion about Bob's report. I would have
L3	to check the minutes.
L4	MR. STIVER: I think the only
L5	finding that was still open was Finding 8
L6	about the modeling using Attila, the glove
L7	box, the film badge, either on the chest or
L8	over
L9	DR. ULSH: I am not sure it was
20	just 8. My recollection is that there were a
21	couple of others, but I could be wrong on

that.

1	MR. STIVER: I am basing this off
2	of Bob's most recent response here.
3	DR. ULSH: Yes, Finding 8, I think
4	the original finding was the use of the Attila
5	software package is questioned. In response
6	to that, we added some material to the TIB
7	that was some MCNPX runs. And then, those
8	examples became a whole issue in and of
9	themselves that generated a lot of back-and-
LO	forth.
11	MR. MARSCHKE: I believe, yes, at
L2	one point we made some Bob, are you on the
L3	phone? we made some MCNP runs, and I think
L4	NIOSH requested
L5	DR. ANIGSTEIN: Yes, I am. I had
L6	my phone on mute.
L7	MR. MARSCHKE: You requested our
L8	input files, and I think that is kind of the
L9	report that is being referred to there. Have
20	you looked at Bob's MCNP input files and
21	determined whether or not you can duplicate
22	his results with those input files?

WASHINGTON, D.C. 20005-3701

1	DR. ULSH: Well, like I said, I
2	think if the MCNP examples that we provided
3	are taken out, which they have been, then I
4	think this issue becomes a moot issue. But
5	the next step is for me to put those findings
6	into the database, and you guys to respond to
7	them.
8	MR. MARSCHKE: Okay.
9	DR. ANIGSTEIN: This is Bob.
10	There are two things, without
11	belaboring which issue is which. One, we had
12	a problem with the use of Attila. That was
13	more of a procedural, technical issue.
14	But the substantive issue was we
15	disagree with the correction factors. I mean,
16	that doesn't go away. Whether you use MCNP or
17	Attila, that does not go away.
18	We found maybe something like I
19	am quoting from memory now but we came up
20	with something on the order of 3.3 and NIOSH
21	had something on the order of 2.1, 2.2,
22	something like that. So, we are about 50

percent higher in the correction factor. 1 2 And it is not because we use MCNP 3 instead of Attila. It is the way the Attila 4 was applied. It wasn't applied to a single They use Attila because 5 location. 6 convenient, more convenient than MCNP in 7 getting a lot of tally results in that mode. And then, they essentially did a 8 statistical sampling of those tallies. 9 10 objection was, when an individual comes up for a dose reconstruction, he has a cancer of a 11 12 certain organ, not a range of organs that you 13 can say, well, statistically, we evaluate all the organs. 14 in a nutshell, that 15 is the So, 16 basis of our objection or our findings. Right, and I have a 17 DR. ULSH: response from the document author. 18 19 haven't put it into the database yet. Ιt 20 addresses that issue. MR. MARSCHKE: So, basically, when 21

we get your response, Bob, you will respond to

1	it.
2	DR. ANIGSTEIN: Okay.
3	MR. MARSCHKE: And if we are still
4	unsatisfied with it, we will let them know.
5	DR. ULSH: We will have another
6	round.
7	MR. MARSCHKE: We will have
8	another round, yes.
9	CHAIR MUNN: All right. So, what
10	we need to have for next time is it is
11	still in NIOSH's court.
12	DR. ULSH: Right.
13	CHAIR MUNN: We might want to go
14	back and check. I was making an effort to get
15	back to our transcript. We had quite a
16	discussion on it.
17	MEMBER ZIEMER: On this item?
18	MR. STIVER: Especially on TIB-10,
19	in September TIB-10 was just briefly mentioned
20	and it was deferred until after these changes
21	had been reviewed. It is on page 150 in the

22

transcript.

1	CHAIR MUNN: Yes. "Greg had given
2	some draft responses, but NIOSH wasn't ready
3	to send it out. Brant said he would have it
4	for the next meeting."
5	DR. ULSH: Right. I have those
6	responses. We just did a revision to the TIB.
7	I just haven't loaded the responses into the
8	database yet.
9	CHAIR MUNN: Okay.
10	DR. ULSH: But I will get that in
11	by next meeting.
12	CHAIR MUNN: Very good. And then,
13	we will see what we can do with that.
14	TIB-13, the status.
15	MR. MARSCHKE: So, there are no
16	changes to I am not going to change,
17	because NIOSH has to clean up the status of
18	all the issues under TIB-10, I am not going to
19	try to do anything.
20	MEMBER ZIEMER: Nothing is changed
21	today.
22	CHAIR MUNN: No. No, we have gone

1	from TIB-10 for now.
2	MR. MARSCHKE: Okay.
3	CHAIR MUNN: We said we are done
4	with that at the moment here, and we have gone
5	on to TIB-13.
6	MEMBER ZIEMER: IS TIB-13 a DCAS
7	TIB now or is it an OTIB?
8	DR. ULSH: So, we are skipping
9	over the ones we covered earlier, the 21
10	and
11	CHAIR MUNN: We have already
12	covered those, I do believe.
13	DR. ULSH: All right. Yes.
14	CHAIR MUNN: We have agreed that
15	21-04, 51-01, 47-02, and OTIB-19 are all taken
16	care of because the data linkage is now
17	complete and they are workable. At least that
18	is what I think we agreed to earlier this
19	morning.
20	And now, we are searching for
21	TIB-13.
22	MR. MARSCHKE: There is no TIB-13.

1	MEMBER ZIEMER: Is this an OTIB?
2	MR. HINNEFELD: No, it is an OCAS
3	TIB.
4	CHAIR MUNN: It is an OCAS TIB.
5	MEMBER ZIEMER: It is OCAS?
6	MR. MARSCHKE: It is not OTIB; it
7	is just T-I-B.
8	MR. MARSCHKE: There it is. Don't
9	search for 0013; search for 13, TIB-13.
10	CHAIR MUNN: Refresh my memory.
11	Have we ever sorted out the business of how
12	many zeroes?
13	DR. ULSH: Yes, I thought we had.
14	CHAIR MUNN: I thought we talked
15	about it at great length last time.
16	DR. ULSH: It is a fix that we
17	made supposedly.
18	MR. MARSCHKE: Well, again, the
19	problem here, if you want to take a note, this
20	is another one of the beta version bugs.
21	There are two versions of OCAS, of this
22	TIB-13. There is an OCAS version, which is

1	013, and then there is a DCAS version, which
2	is 0013.
3	The OCAS version is specific to
4	Mallinckrodt. The DCAS version is more
5	generic. The OCAS version has the SC&A, it is
6	the version that SC&A commented on. It has
7	the SC&A comments and the comment history in
8	the database in the OCAS version. In the DCAS
9	version it does not. It has nothing.
10	DR. ANIGSTEIN: Excuse me.
11	I submitted comments on the DCAS
12	version.
13	MEMBER ZIEMER: Which one are we
14	looking at now?
15	MR. MARSCHKE: Who did you submit
16	them to, Bob?
17	DR. ANIGSTEIN: You.
18	CHAIR MUNN: I thought that we
19	were looking at Mallinckrodt.
20	MR. KATZ: And at the last
21	meeting, I thought we discussed this fact,
22	that this evolved from an OCAS version to a

1	DCAS more generic version. We discussed it at
2	the last meeting, I believe, because I think I
3	read that in the transcript.
4	CHAIR MUNN: We had a lot of
5	discussion about this.
6	DR. ANIGSTEIN: Basically, let me
7	clarify what I just said. I updated the
8	findings and responded to picking up the
9	findings from the earlier version and then
10	commented on to the extent to which the later
11	version addressed the original comments. So,
12	they are both taken into account in a single
13	it is not a separate review.
14	MR. MARSCHKE: Okay. That is what
15	we were trying to say, Bob. Basically, the
16	database doesn't have any comments on DCAS
17	TIB-13.
18	DR. ANIGSTEIN: Okay. Yes.
19	MR. MARSCHKE: Somehow we have to
20	import the OCAS-TIB-13 comments over into
21	DCAS-TIB-13. And I don't know if you want to
22	remove OCAS-TIB-13. Do we want to close out

1	those comments? I don't know procedurally how
2	you want to handle, I don't know how, yes, how
3	do we want to go forward on this.
4	MEMBER ZIEMER: I see only one
5	item open in
6	MR. MARSCHKE: There is only one
7	item open, which is
8	MEMBER ZIEMER: Right, Finding 4,
9	right.
LO	DR. ANIGSTEIN: It is issue 6 that
L1	was folded into issue 4.
L2	MR. MARSCHKE: Exactly.
L3	MR. KATZ: Right.
L4	MR. MARSCHKE: Yes.
L5	CHAIR MUNN: Essentially, they are
L6	all correction factors to be applied. And it
L7	was my understanding that NIOSH was going to
L8	take another look at the reviews that had
L9	already been made and make some suggestion as
20	to whether or not this was going to go to the
21	Science Issues group as an overarching issue

it was going to be a site-

or whether

1	applicable item. That was, I believe, my
2	understanding, the upshot of the discussion.
3	Am I thinking of something else?
4	MR. STIVER: No, Wanda, that is
5	what I have for the notes from the September
6	transcript, the idea of angular dependence
7	versus geometry
8	CHAIR MUNN: Right.
9	MR. STIVER: in the film
10	badges. That was to go with the overarching
11	category.
12	CHAIR MUNN: Whether it was going
13	to go to them or whether
14	MR. STIVER: I believe this was
15	going to be considered. I don't think a
16	decision had been made at that point.
17	CHAIR MUNN: No.
18	MR. MARSCHKE: My recollection is
19	that we discussed about it, and then I think
20	NIOSH I don't want to speak for you, but my
21	recollection is that you wanted to go back and
22	re-examine SC&A's comments. Before we took

1	the action to assign this over to the Science
2	Committee, you kind of wanted to take one last
3	look at the comments that were being made.
4	That is what we have in the database.
5	MEMBER ZIEMER: Yes, the September
6	meeting, it says that NIOSH is going to re-

MR. KATZ: Well, you may want to, on that last note about sending it over to the Science Committee, the Science Committee at this point has only committed to dealing with risk-model-related work. So, at the time that they met, I provided to everyone on the Science Committee risk both the model material, but also the dose reconstruction overarching issues. There are a slew of them, actually.

But the Science Committee did not bite on the dose reconstruction issues. So, it doesn't have an agenda for that at this point.

MEMBER ZIEMER: Well, keep in mind

NEAL R. GROSS

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

examine.

that that Committee is looking at what you might call longer-term issues, and they
might call longer-term issues, and they
prioritized and said these are the ones that
need the attention first.
MR. KATZ: Right.
MEMBER ZIEMER: So, it is not that
they are not interested in that, but
MR. KATZ: No, no, just to be
clear, what I am saying is I have in my notes
as to what they agreed to in the relative
near-term. And I have seven issues, and they
are all risk-model-related.
MEMBER ZIEMER: Right.
MR. KATZ: And I didn't even get a
prioritization for the dose reconstruction
overarching issues from that meeting. They
have only met once in a real substantive way,
except for the special meeting with the
Science Committee.
MEMBER ZIEMER: Yes, but one thing
on overarching issues, they can go into that

overarching category, and that doesn't mean

1	that that Work Group has to deal with them
2	because it has to do with, if there is a
3	generic OTIB, or whatever it is, that you
4	would put it all together. I don't think it
5	necessarily has to go through that Work Group.
6	It is just that we are not going to solve
7	this issue 20 times at a bunch of sites. It
8	can move to
9	MR. HINNEFELD: If I am not
10	mistaken, we talked about the overarching
11	issues rather than counting on the Science
12	group.
13	MEMBER ZIEMER: Yes.
14	MR. HINNEFELD: To say we are
15	going to build a dummy committee, a
16	subcommittee, on this application, and just
17	call it "overarching issues".
18	MEMBER ZIEMER: Yes, whether it is
19	resuspension factor or
20	MR. HINNEFELD: And then, all
21	these overarching issues get assigned into
22	that, so you can pull up, once any particular

1	group decides something is an overarching
2	issue, then you have in this a population of
3	overarching issues.
4	MEMBER ZIEMER: Right. And once
5	you guys develop an approach, then somebody
6	reviews it.
7	MR. HINNEFELD: Right.
8	CHAIR MUNN: But, on this specific
9	topic, on this one only, my question is, am I
10	incorrect that NIOSH was going to take a look
11	at, they were going to re-review the material
12	here and make a recommendation as to whether
13	or not this is an overarching issue or it is
14	site-applicable? That is what I had in my
15	mind at the time I wrote what I did on the
16	agenda. Am I incorrect in that?
17	MR. MARSCHKE: I believe you are
18	correct.
19	MEMBER ZIEMER: Before a final
20	decision is made
21	CHAIR MUNN: Correct.
22	MEMBER ZIEMER: as to whether

1	it is generic or not.
2	CHAIR MUNN: Yes. All right. So,
3	this is a carryover.
4	MEMBER ZIEMER: Was the DCAS-013 a
5	generic version of this? Is that what was
6	being said?
7	CHAIR MUNN: I don't think so.
8	MR. HINNEFELD: DCAS-013, yes, I
9	think that is right. OCAS-13 was
LO	Mallinckrodt-specific. DCAS-13 addressed the
L1	fact, well, these same geometries could exist
L2	other places besides Mallinckrodt. Why don't
L3	we write a more general
L4	MEMBER ZIEMER: Yes, so that
L5	becomes the overarching document.
L6	MR. HINNEFELD: Right.
L7	MEMBER ZIEMER: But you are going
L8	to determine whether you solve this
L9	immediately for Mallinckrodt or whether it
20	gets solved in the other document then. Well,
21	something like that.

MR. HINNEFELD: Yes.

1	MR. STIVER: It would have to
2	migrate to the DCAS document.
3	MEMBER ZIEMER: Well, unless it is
4	sufficiently Mallinckrodt-specific
5	MR. HINNEFELD: Yes, but I don't
6	think
7	MR. STIVER: It doesn't sound like
8	this would be. This is the kind of thing that
9	would be kind of overarching.
10	CHAIR MUNN: The ball is still in
11	the NIOSH court.
12	DR. ULSH: Yes.
13	CHAIR MUNN: And it is a
14	carryover.
15	DR. MAURO: This is John.
16	One other thing that just came out
17	of this conversation that I felt was something
18	I was not aware of is the segregation between
19	the science activities and what we would call
20	the overarching issues. The science
21	activities, I guess it is a higher-level
22	issue. There is another category that really

falls into more of a generic issue that lies, I guess, amongst us and NIOSH, but it is not part of the Science group. So, there are these two collections, so to speak, of generic issues that I did not make that distinction in my mind. Am I correct that there is that distinction?

CHAIR MUNN: It looks like that is the way it is going to be, John. I didn't make that distinction personally, either. In my mind, the issues that are before us are many and either fall into the kind of issues that we deal with here in this Subcommittee or they fall into a broader, general category. I don't know whether to call them overarching or not, but in my mind I have always thought of them as overarching issues. They are, also, in my mind all science issues.

But there has, clearly, in recent months been a distinction made between those.

And there was some discussion of that here in our September meeting.

NEAL R. GROSS

1	MR. STIVER: In my mind, I have
2	kind of an agreement with Wanda. I mean they
3	are really just two sides of the same coin
4	here. Although this idea of setting up an
5	overarching virtual Work Group, if you will,
6	to parse them out to various committees would
7	kind of indicate that you may have certain
8	situations where it is not really an
9	overarching science issue, but may apply to
10	several different types of facilities or
11	several facilities within a given type.
12	Like, say, AWEs may have certain
13	commonalities that need to be addressed in
14	kind of an overarching way, but it wouldn't
15	necessarily be a scientific issue that is kind
16	of programmatic-wide. It is kind of a sub-
17	element of
18	CHAIR MUNN: It is kind of what we
19	had in mind originally with 6001.
20	MEMBER ZIEMER: Well, keep in
21	mind, the science issue that they are looking

at seems like the CLL, the chronic lymphocytic

1	leukemia. That doesn't show up as an issue
2	in, let's say, the Rocky Flats Work Group.
3	MR. STIVER: Right, in any given
4	particular Work Group.
5	MEMBER ZIEMER: Right, and it is
6	sort of like programmatic overall.
7	And there are some other issues
8	like that. Whereas, the resuspension thing is
9	more of an application of the science
10	MR. STIVER: Yes.
11	MEMBER ZIEMER: that is already
12	there.
13	MR. STIVER: It is an application
14	that may span more than one
15	MEMBER ZIEMER: Yes. The IREP
16	model is a little different again. All the
17	Work Groups are saying, yes, the IREP model is
18	there. So, you are not getting findings that
19	well, you might. You have raised some
20	issues on the IREP model, but that is
21	partially an overarching science.
22	MR. STIVER: Yes, it really is,

1	and the other may be kind of subcategories of
2	that, but, yes, it can be addressed within the
3	purview of types of sciences as opposed to
4	programmatic-wide.
5	MEMBER ZIEMER: Right.
6	MR. KATZ: And clearly, this
7	Subcommittee deals with programwide dose
8	reconstruction matters. So, they don't need
9	to be all punted to another Science Work
10	Group, particularly when they are sort of
11	dose-reconstruction-specific. I think, just
12	as with OTIB-70, they can be addressed here.
13	CHAIR MUNN: The ball is in the
14	NIOSH court.
15	The next item that we have is
16	OTIB-52 Rev. 1 response.
17	DR. ULSH: And we are prepared on
18	that one, I believe. So, Elyse and Matt
19	Smith, do you want to discuss that one?
20	MR. SMITH: Sure. This is Matt.
21	For reference, I don't know if you
22	can bring it up in the room, but OTIB-52, Rev.

1	1, for the first item, which is -12, the page
2	of interest would be page 30 of 40.
3	CHAIR MUNN: Now hold on just a
4	moment.
5	MR. HINNEFELD: That is of the TIB
6	itself.
7	MEMBER ZIEMER: Oh, of the TIB
8	itself?
9	MR. SMITH: Yes, that is of the
10	TIB itself.
11	These items are issues that were
12	brought up previously and addressed in Rev. 1
13	of the TIB and are kind of based on a
14	discussion that took place way back in October
15	of 2008.
16	And just to add to the
17	documentation, I sent Elyse a copy of meeting
18	notes from Bob Morris, who is the OTIB-52
19	author, to Elyse. I don't know if that is
20	linkable yet or not.
21	MS. THOMAS: Yes, those did get
22	linked.

MR. SMITH: Okay.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

MS. THOMAS: You are looking at Finding 12. So, if the Subcommittee wants to look those up in the database, you can. Matt is starting with OTIB-52, Finding 12, and there are new responses that were uploaded, as well as a link to those meeting notes that he is referring to.

MEMBER ZIEMER: Right.

MR. SMITH: So, it is kind of three things being juggled here. Let me try to summarize on item 12.

The issue here was the use of the REMS database as opposed to the site-specific REX database at Hanford. There were several reasons the authors used the REMS data. Ιt the early years the only way to for separate out construction trade workers from all monitored workers. And then, even into the modern era, it just proved to be a very reliable way for them to do that separation of those involved in construction

NEAL R. GROSS

1	trades versus the all monitored workers.
2	So, as far as the pedigree
3	response to this, if you take a look at the
4	linked meeting notes that Bob Morris took in
5	2008, within that document he has got it
6	highlighted as item 3.
7	DR. ULSH: Just to briefly
8	interrupt, John, you had asked earlier whether
9	you could link different document types.
10	MR. STIVER: Yes, here you go.
11	DR. ULSH: Yes, this answers the
12	question, I think.
13	MR. SMITH: Let me pause. Is that
14	linking working there?
15	CHAIR MUNN: It is working.
16	Item 3.
17	MR. SMITH: That's great.
18	CHAIR MUNN: Good. Yes, it is
19	great.
20	MEMBER ZIEMER: What kind of
21	document is this?
22	CHAIR MUNN: It is a Word

1	document.
2	MEMBER ZIEMER: Oh, it came up and
3	I just didn't see it. There it is.
4	CHAIR MUNN: Item 3.
5	MR. KATZ: Just to be clear for
6	the record, for this one, since we are dealing
7	with Hanford, this is Dr. Ziemer, Paul and
8	Dick will have to deal with this.
9	CHAIR MUNN: They will.
10	MEMBER ZIEMER: Not a conflict.
11	MR. KATZ: Not conflicted, right.
12	MR. SMITH: Let me bring that up
13	as well. I am also conflicted with Hanford.
14	Sorry. Does that prohibit me from speaking
15	further?
16	MR. KATZ: Yes. So, who has done
17	the work on this, is the question.
18	MR. SMITH: The person who has
19	done the work on it is Bob Morris.
20	MR. KATZ: I see. Who is not
21	here. And you are just being his voice?
22	MR. SMITH: Well, I am listed as

1	the document owner. The author, though, of
2	the really the original and also Rev. 1 is Bob
3	Morris. And also, he directly collaborated on
4	the responses that we are talking about, even
5	the current responses.
6	MR. HINNEFELD: Well, the document
7	is construction workers.
8	MR. KATZ: Right. I understand.
9	MR. HINNEFELD: The document
10	relates to construction workers across the
11	conflict.
12	MR. KATZ: Right.
13	MR. HINNEFELD: And so, the
14	conflict doesn't apply to a generic thing like
14 15	conflict doesn't apply to a generic thing like this.
15	this.
15 16	this. MR. KATZ: No, I understand.
15 16 17	this. MR. KATZ: No, I understand. MR. HINNEFELD: This specific
15 16 17 18	this. MR. KATZ: No, I understand. MR. HINNEFELD: This specific issue we are talking about now is a finding
15 16 17 18	this. MR. KATZ: No, I understand. MR. HINNEFELD: This specific issue we are talking about now is a finding about something that was at Hanford.

are kind of in the clear.

MR. KATZ: Yes, I mean, I think he can present. It is not even his work he is presenting.

Go ahead.

MR. SMITH: Okay. In any event, you can see this item was discussed, again, back in 2008. The bottom line you can see on the final page of Bob's draft meeting notes, and that is the response that we have also listed currently, which is to add a statement.

I guess in this case it would be adding a statement to Rev. 1 that is on the street now that says, "Electronic access to the REX database was not available when this bulletin drafted. However, the data in REMS was derived from the data in REX and is judged to adequately represent the ratio of construction trade workers and all monitored worker doses."

So, that was the final outcome of the 2008 meeting. That particular language

NEAL R. GROSS

	doesn't look like it landed on page 30 of Rev.
2	1 of OTIB-52. There are several annotations
3	there that address response to this item, this
4	-12 item, but this particular language didn't
5	end up in the document. So, the response is
6	that this language would be added.
7	In terms of where would it be
8	added, if you are looking at page 30 of the
9	OTIB, probably about midway or actually almost
10	the second-to-last paragraph you will see
11	Annotation No. 9. That looks like that would
12	be the best place to add this language that I
13	just described.
14	MEMBER ZIEMER: Did SC&A already
15	see this response?
16	MR. MARSCHKE: No.
17	MR. STIVER: No, we haven't.
18	MR. MARSCHKE: No, we didn't the
19	response. It has been in the database, I
20	guess it has been in the database, but we
21	CHAIR MUNN: Will our action in
22	this case be SC&A will review this response

here?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

MR. MARSCHKE: Well, I think the if Ι recall the original comment was, comment -- and, basically, I was one who did the critique of 052 -- there was confusion as to what was actually used. When we initially brought up why was REX used as opposed to REMS, I think one of the initial responses we got was that REX was used. And based upon that, we said, okay. But that reflected in the document.

And now I think when NIOSH has gone back and said, well, no, REX wasn't used, we were confused and we wanted to get clarification. When we looked at Rev. 1, we made our report on Rev. 1, we said, well, basically, what is it; was REX used; what not REX used? Or was REMS used?

Now with this clarification that REMS was used and REMS is basically the same as REX, I don't have any problems with just making that clear in the document. If you

1	have this two sentences that they indicate
2	here, I would be happy with the NIOSH
3	response.
4	CHAIR MUNN: So, is the action
5	here that SC&A accepts NIOSH response?
6	MR. MARSCHKE: SC&A accepts NIOSH
7	response, that is what I am saying at this
8	point, yes.
9	MEMBER ZIEMER: And it would be in
10	abeyance until
11	MR. MARSCHKE: And it would be in
12	abeyance until these two sentences are
13	inserted into the document, with probably a
14	page change or something like that.
15	CHAIR MUNN: Dick, if you are
16	still on the line, are you in agreement?
17	MEMBER LEMEN: Yes.
18	CHAIR MUNN: Very good. It is in
19	abeyance.
20	MR. MARSCHKE: Just a procedure
21	thing for Ted, can I make this change in
22	Wanda's name or what should I do?

1	MR. KATZ: No, why don't you go
2	ahead and make it in
3	MR. MARSCHKE: Paul's name?
4	MR. KATZ: Paul's name. Thank
5	you. Just to keep in the paperwork in order.
6	Thank you.
7	CHAIR MUNN: Is that the last item
8	we have on OTIB-52?
9	MEMBER ZIEMER: What about the
LO	next, 13?
11	MR. STIVER: We have 13 I believe
L2	and 14 as well.
L3	MR. KATZ: Okay. Do you want to
L4	proceed with Finding 13?
L5	CHAIR MUNN: Please do.
L6	MR. SMITH: All right. Thirteen
L7	and 14 are linked, both in terms of when they
L8	were discussed earlier in 2008 and, also, in
L9	the response that ended up in the revision of
20	the OTIB itself.
21	So, in the OTIB-52 document, the
22	Rev. 1 document, let me send you all the way

1	back to page 9 of 40. The section of interest
2	is Section 4. And then, also for reference
3	is, again, the 2008 meeting notes, and the
4	item listed as item No. 2 is addressing, as
5	you can see there in the title, it is
6	addressing Findings 13 and 14.
7	The language that was added to the
8	OTIB you can see right in basically the center
9	of Section 4. It ends with Annotation No. 2.
10	And the issue here was the
11	treatment among the different sites, and then,
12	also, there was a file on issue regarding the
13	factor, I guess you would call it the
14	threshold factor is the best way to describe
15	it.
16	So, for item No. 13, the response,
17	the current response dated 12/7, the methods
18	were always the same when a certain site was
19	evaluated. I will just go ahead and read the
20	response from 12/7.
21	"Regardless of comparison method,

the outcome would be favorable to construction

workers because the correction trade is typically applied to doses in a site-specific coworker model which is based on data for all monitored workers. When construction trade are from workers removed the comparison construction population, the ratio favors trades if the construction trade doses are, in act, elevated."

In addition, regarding the 20 percent threshold criteria, that threshold criteria falls inside the margin of uncertainty for dosimetry, which roughly in the film era is 30 percent. And also, for dosimetry programs, the modern era that would be covered by DOELAP, you typically see a 30 percent criteria that you need to conform to to pass DOELAP.

MR. STIVER: Yes, this is John Stiver.

We are having a similar problem or a similar issue we are dealing with at Fernald, very close to this. That is the

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

issue of do you lump construction trade
workers with all workers for the comparison?
And clearly, when you do that, you are
diluting out the effect. In our case, in the
all monitored workers category when you give
the ratio of construction trade workers to all
monitored workers, I think we ended up with
about, NIOSH came up with an adjustment factor
of about two or so. But when you pull them
out of that denominator, you would see that
the effects of course, it was dependent on
various years it could have been up to a
factor of four or more.

And so, this is something that is still being debated in the Fernald Work Group.

We have put together a White Paper on that, which we are going to prepare.

But I am not familiar with how this was handled in OTIB-52. I know Steve did the review of that.

So, maybe, Steve, you can speak to that situation.

NEAL R. GROSS

1	MR. MARSCHKE: Well, sometimes it
2	was compared to, the construction workers were
3	compared to all monitored workers and
4	sometimes they were compared to non-
5	construction work monitored workers. So,
6	there is a little bit difference in the ratio.
7	So, when you come up to what is an acceptable
8	ratio, you get a slightly different value.
9	When we did talk about it last
10	time, I mean we did discuss, again, like the
11	20 percent, where did the 20 percent come? If
12	this is like a cutoff for acceptability, what
13	is the basis for it?
14	Now I think in what Matt had just
15	said, he has presented what the basis for it a
16	little bit is, which I think, to my
17	recollection, that is kind of new information,
18	that it is based on the accuracy of the
19	readings.
20	And I think that is really what we

is the basis for the cutoff?

were asking for, what is the cutoff and what

21

22

And you are

1	saying that between the two methods, you know,
2	construction workers to all monitored workers
3	or construction workers to non-construction
4	monitored workers, the difference is going to
5	be less than 20 percent. And that is an
6	acceptable difference based upon the accuracy
7	of the readings. That is really the
8	information that I think we were looking for.
9	MR. SMITH: Okay. And kind of
10	back to the big picture, that paragraph in the
11	middle of Section 4 you can see is basically
12	verbatim from the meeting notes from 2008.
13	You can see the language there listed under
14	item 2 in those meeting notes, as well as a
15	summary of the discussion regarding that
16	language.
17	MR. MARSCHKE: I do have a concern
18	about I know that there was a meeting, there
19	was a number of meetings on OTIB-52.
20	MR. SMITH: Right.
21	MR. MARSCHKE: And you keep
22	referring back to the 2008 meeting. I am not

1	sure that there weren't a number of meetings
2	after the 2008 meeting. So, I am not 100
3	percent sure that that is the definitive
4	meeting and should be referred to as the
5	definitive meeting.
6	Because I think and I have to
7	go back and I am desperately looking for my
8	report, and I can't find where I have it on my
9	flash drive. But I think we continued to talk
10	about some of these findings after the 2008
11	meeting.
12	MR. SMITH: The main reason I am
13	using this summary or these minutes is that I
14	can see you know, at that time I was not
15	document owner, but, historically, looking
16	back, I can see, like we are speaking of this
17	item, exactly where the language in Rev. 1
18	that is now on the street came from.
19	MR. MARSCHKE: Well, that was one
20	of my problems when I looked at Rev. 1, was

that the language came out of a meeting.

MR. SMITH:

Okay.

21

1	MR. MARSCHKE: And then, we
2	continued to discuss the issues after that
3	particular meeting.
4	DR. ULSH: It sounds like you
5	might want to take some time and review this
6	response before we make any kind of a status
7	change. Is that
8	MR. STIVER: I would recommend
9	keeping this in progress because there are
10	still some issues about how that ratio is
11	determined. So, yes.
12	MR. MARSCHKE: I think what we
13	should do maybe, I see now that Matt's
14	responses are in the database. To be honest
15	with you, they have been in there for a while.
16	I wasn't aware that they were in the
17	database, and I should have looked at these
18	before the meeting. I would have liked to
19	have looked at these before the meeting and
20	prepared SC&A's position on these responses.
21	So, I think what I would like to
22	do on OTIB-52, if it is okay with the

1	Subcommittee, is I would like SC&A to take an
2	action item to go through and review the
3	latest replies from NIOSH and see where we
4	agree and if we disagree on some of the
5	issues.
6	MR. KATZ: Can I ask a process
7	question? I mean, I know often we get notices
8	from you, Brant, saying we have just responded
9	to "X". Did that not happen with this?
10	DR. ULSH: I don't know. I would
11	have to go back and look at my email.
12	MR. KATZ: Okay.
13	MR. STIVER: I was not notified.
14	MR. KATZ: Going forward, anyway,
15	we need to make certain that we get
16	notifications out when someone makes an
17	addition
18	MR. MARSCHKE: Yes. I know we did
19	it on
20	MR. KATZ: responses or
21	reviews, either way.
22	MR. MARSCHKE: Right.

1	MR. KATZ: Because, I mean, then,
2	you don't need to be tasked; you know when you
3	get notification that there is a response.
4	MR. MARSCHKE: That is what we did
5	on OTIB-6.
6	MR. KATZ: Right. No, I
7	understand.
8	MR. MARSCHKE: And so, yes, this
9	one must have just
10	DR. ULSH: Yes, it is always my
11	intention, when we load something into the
12	database, to let you guys know.
13	MR. KATZ: Right.
14	DR. ULSH: I would have to go back
15	and look at my emails.
16	MR. KATZ: Yes, we don't need to.
17	It is water under the bridge. I just mean,
18	going forward, let's
19	MR. STIVER: Yes, certainly,
20	everybody needs to stay abreast of the changes
21	made.
22	MR. KATZ: Notifications, yes.

1	CHAIR MUNN: That process has
2	worked for us in the past, but, obviously, it
3	is not impossible to simply be overlooked.
4	Our action item for the next
5	meeting will be an issue for SC&A on the
6	current status of OTIB-52. Specifically, item
7	13 or broader than that?
8	MR. MARSCHKE: I would say it is
9	broader than that, Wanda.
10	CHAIR MUNN: All right.
11	MR. MARSCHKE: All the ones
12	CHAIR MUNN: We will just say 52.
13	DR. ULSH: We talked about Finding
14	12, 13, and 14. I thought 12 we agreed to
15	change to in abeyance or
16	MR. MARSCHKE: Right. So,
17	basically, it is 13 and 14.
18	MEMBER ZIEMER: I have one
19	question on 13. It might apply to 14 also,
20	I'm not sure. But I noticed we have the
21	current response, Matt Smith's response,
22	right, December 16th? The previous comment is

1	2008, a NIOSH response, 2008, that SC&A
2	should review, and so on. Then, there is this
3	big gap here and then this new response from
4	Matt Smith. Are there some missing things
5	here? It says that SC&A is going to respond
6	in September 2008. I don't see that.
7	MR. MARSCHKE: What happened was
8	yes, Paul what happened was NIOSH issued
9	Revision 1 to OTIB-52, and we did a review of
10	Revision 1 to OTIB-52 and issued a document.
11	Like I say, I was desperately trying to find
12	that document on my 0: drive, or not on my 0:
13	drive, but on my flash drive. And I haven't
14	been able to locate it yet.
15	So, I guess you could say there
16	are a few steps missing in this history, one
17	step being that Revision 1 has been issued.
18	Another step being that SC&A has issued a
19	document reviewing Revision 1.
20	So, what we probably should do is
21	take our critiques or whatever critiques that

we had from the document and put them into the

1	database.
2	MEMBER ZIEMER: Yes. I think
3	something to transition between these two
4	would help.
5	MR. MARSCHKE: I just don't know
6	whether, I don't know if I can make it in
7	chronological order. It may be out of
8	chronological order.
9	MEMBER ZIEMER: Right.
10	MR. MARSCHKE: But I will make
11	sure
12	MEMBER ZIEMER: I think what you
13	do is you review this and fill in those gaps
14	maybe.
15	MR. MARSCHKE: Make sure that it
16	gets in there.
17	CHAIR MUNN: Notation of a link,
18	if nothing else.
19	MEMBER ZIEMER: Yes.
20	CHAIR MUNN: A date and a link,
21	now that we have links.
22	MR. KATZ: Very good.

1	CHAIR MUNN: All right. We have
2	one more item, but it is after 12:00, and I
3	don't believe OTIB-6 is going to take us that
4	long. I suggest that we break for lunch and
5	that we be back at 1:30. Is that amenable
6	with all?
7	MR. KATZ: How about 1:15, an
8	hour?
9	CHAIR MUNN: 1:15 will be fine.
10	MEMBER LEMEN: I will try to be
11	back with you.
12	CHAIR MUNN: Thank you, Dick.
13	MR. KATZ: Thank you, Dick.
14	MEMBER LEMEN: All right.
15	MR. KATZ: Thank you, everyone
16	else on the line. We will speak to you again
17	at 1:15.
18	(Whereupon, the foregoing matter
19	went off the record at 12:11 p.m. and resumed
20	at 1:17 p.m.)
21	

WASHINGTON, D.C. 20005-3701

1	A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N
2	1:17 p.m.
3	MR. KATZ: Okay. We are back
4	online. This is the Procedures Subcommittee
5	of the Advisory Board on Radiation and Worker
6	Health.
7	Let me check online and see if we
8	have a Board Member or more back on the line.
9	Dick, are you with us?
10	MEMBER LEMEN: I am. Can you hear
11	me?
12	MR. KATZ: Yes, perfectly.
13	Welcome back.
14	And let me check and see if Mike
15	Gibson has joined us at this point.
16	(No response.)
17	Okay. No Mike.
18	CHAIR MUNN: We are picking up the
19	last item that we have on our carryover items,
20	which is OTIB-6. I think I sent you all a
21	note over the weekend reminding you that you
22	had received information from SC&A on their

1	response to OTIB-6 and that we would cover it
2	at this time.
3	Steve, are you up on this one?
4	MR. MARSCHKE: Yes. As you see on
5	the screen, what we have is the two pieces of
6	information that have developed on OTIB-6,
7	Finding No. 3, since last time we met.
8	Essentially, what it says is that
9	NIOSH has issued Revision 4 to OTIB-6, and
10	SC&A has reviewed Revision 4 to OTIB-6 and
11	found that NIOSH has effectively incorporated
12	the agreed-upon resolutions to Finding 3. And
13	we recommend that Finding 3 be closed at this
14	point.
15	CHAIR MUNN: Any objection to
16	closing Finding 3?
17	MEMBER ZIEMER: Is this 0006?
18	Yes.
19	CHAIR MUNN: Yes.
20	MEMBER ZIEMER: Finding 3, 4, and
21	5, are they the same? I am looking at the
22	thing you sent out, which is the overview. Or

1	did you send that out?
2	CHAIR MUNN: No.
3	MR. MARSCHKE: There is only
4	Finding 3 and 4.
5	MEMBER ZIEMER: Oh, I'm sorry.
6	Okay. There was a summary thing
7	CHAIR MUNN: Yes, yes, there was a
8	summary thing, yes.
9	MEMBER ZIEMER: that came from
LO	SC&A. I opened the wrong thing here. I need
11	to be in the database then?
L2	CHAIR MUNN: I think you need to
L3	be, yes, the database is probably the best
L4	thing.
L5	MR. MARSCHKE: I mean, Brant sent
L6	an email, I guess it was probably before
L7	Christmas, indicating that Revision 4 had been
L8	issued. We took and ran with that, and we
L9	sent out an email right around Christmastime,
20	I think it was
21	CHAIR MUNN: Yes.
22	MR. MARSCHKE: indicating that

1	we agreed with NIOSH on these two issues. And
2	subsequently, I have updated the database to
3	reflect that SC&A does agree.
4	CHAIR MUNN: Yes, 3 and 4 were the
5	only two outstanding findings that we had on
6	OTIB-6.
7	MR. MARSCHKE: That is correct.
8	And they were both in abeyance. So, I mean,
9	what it was was that everybody had come to
10	agreement what the resolution should be. It
11	was just a matter of updating OTIB-6 and
12	incorporating those agreements and changes.
13	CHAIR MUNN: Making sure the
14	procedure was itself done, and they have done
15	that. SC&A has reviewed the revisions and
16	agrees that the contents have been covered for
17	the new revisions.
18	Closed.
19	MEMBER ZIEMER: Closed.
20	CHAIR MUNN: Agreed, Dick?
21	(No response.)
22	I take that to be assent.

1	And 4 is essentially the same as
2	12, correct?
3	So, should now be off our list.
4	MR. KATZ: Closed.
5	CHAIR MUNN: And because I was so
6	happy that they were closed, I left them off
7	the original agenda. My apologies.
8	The next item that we have is a
9	report on the Sciences Issues Work Group and
10	overarching issues status. We have touched on
11	that briefly this morning, but I don't know
12	whether everyone is aware of the items that we
13	discussed that the Science Issues Work Group
14	agreed to take and the statuses of the other
15	overarching issues.
16	Do you want to give us a brief
17	rundown, Ted?
18	MR. KATZ: Sure. So, the Science
19	Subcommittee met back in, I believe, October
20	and made a priority list, as Paul mentioned
21	earlier. It had seven items of priority that
22	all fall under risk model issues. As I said

earlier, none of them really relates to the dose reconstruction overarching issues.

The first priority is dose and dose rate effectiveness factor. SENES has written major paper this, а on and Dr. Richardson is reviewing that paper with a proposal that he would write а sort summary, a manageable summary, and whatever might related thoughts there be to summary in terms of the Board's views that he would produce for the Work Group to consider.

So, that is on his plate. He hasn't delivered that summary yet. I don't know what the status of that is, but it was a big chunk of work that he was going to have to comprehend to get to that point. So, I am not surprised I haven't seen it yet.

The other items in the priority list were RBE, relative biological effectiveness. Other factors sort of like other workplace exposure factors, and so on, was three. Age-at-exposure analysis for

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	incorporation of nuclear worker epistudies.
2	The IREP models is five. Grouping of rare
3	miscellaneous cancers was six on their list of
4	priorities. And seven was discussion of in-
5	house data and what could be made of that
6	analytically going forward, I guess, for epi-
7	models, and what have you.
8	So, those seven items are their
9	priorities at this point. Anything more you
10	want to know about it?
11	CHAIR MUNN: I am wondering how to
12	approach the issues that we were discussing
13	this morning, such as placement of badges, the
14	kind of, as you said, operational activities
15	that affect not necessarily every site, but a
16	great many, and are science issues in
17	themselves, but not in the same sense that
18	these are.
19	Perhaps we should have a
20	discussion with Dr. Richardson and get views
21	of his Work Group on issues of that type.

I

KATZ:

MR.

22

that

is

think

1	certainly one thing you could do. You and
2	Paul are both on that Work Group as well, and
3	so is Dick. So, you certainly can have that
4	discussion next time that Work Group meets,
5	about these DR overarching issues.
6	MEMBER ZIEMER: I think the
7	overarching ones tend to show up in other
8	contexts where they get sort of identified by
9	a particular Work Group or by NIOSH or by SC&A
10	that says this is a reoccurring thing; it
11	occurred here, here, and here.
12	CHAIR MUNN: Yes, it keeps showing
13	up.
14	MEMBER ZIEMER: It becomes
15	overarching, and then NIOSH usually has picked
16	that up. They will say, for example, well, we
17	are developing a White Paper or a position on
18	this. And then, that leads to a review.
19	But my question is, are there any
20	such issues that have been identified that are
21	already sort of in the pipeline?
22	CHAIR MUNN: In the pipeline

1	where?
2	MEMBER ZIEMER: Are most of those
3	overarching ones like resuspension factors?
4	That is being addressed. Construction
5	workers, that was a generic thing and
6	addressed.
7	MR. STIVER: That is a generic.
8	MEMBER ZIEMER: But what else is
9	on that
10	MR. KATZ: I will tell you what
11	was on that list: oral/nasal breathing.
12	MEMBER ZIEMER: And that is in
13	process, right?
14	MR. KATZ: That is in process, I
15	think.
16	Workplace ingestion, doses from
17	hot particles, NTOA rehashed, non-standard
18	external exposures, thoriated welding rods,
19	interpretation of unworn badges, material
20	tracking, and internal dose from the Super S
21	Pu.
22	MEMBER ZIEMER: Super S has been

1	addressed, I think. I mean, that was an
2	overarching one that has been addressed.
3	MR. KATZ: Okay. Well, I mean,
4	back in August it wasn't done, because this
5	came from Jim's list originally, which he
6	presented in August.
7	CHAIR MUNN: And you see this,
8	what we were just discussing earlier, the
9	issue of badge geometry is one of those things
10	that shows up on multiple sites.
11	MR. STIVER: The list that Ted
12	just put forth are science issues, but they
13	may have limited applicability. The things we
14	are looking at here, like say with the film
15	badge placement and modeling, it is almost
16	more of a mechanistic approach. How do you
17	address this problem? It is almost like a
18	method that is common to a lot of different
19	sites that have these types of
20	MEMBER ZIEMER: Well, that is for
21	overarching issues.
22	MR. STIVER: Yes, yes. I know,

but it is almost like there is a subtle distinction between like, say, hot particles being an issue in itself. But, then, it is like we have these methods that we have developed. Sometimes they have kind of sprung up in different disparate Work Groups, but they are all looking at the same kind of issues. It is more like, now that we have it, what types of approaches are we going to take and agree upon to incorporate that into the DR framework?

Another one would be these DWEs, the daily weighted exposures, and how those are addressed, the uncertainty factors and how that is applied in dose reconstruction at Fernald and Weldon Spring and some other sites as well.

The approaches that have been taken are quite different in some cases. And so, there is some communication among the different Work Groups to determine how best to arrive at a final conclusion on that.

NEAL R. GROSS

CHAIR MUNN: Whether the ones that have been used in the past are, in fact, okay, which I think in many cases they probably are.

MR. STIVER: For example, Fernald and the DWEs, up with a we came methodology. It is kind of an overarching It wasn't, probably because we just didn't have the mechanism in place to kick that up to this overarching category and then disseminate that among the different Groups, Weldon is kind of operating in their little universe. It has kind of suffered from what we were doing. They came up with a slightly different approach.

And so, it was kind of a matter of how do you kind of integrate all this together. I think this idea of having this virtual Work Group where you can kind of put all these different things in and then sort them out, and then disseminate them to the different Work Groups that have that common interest, I think it is great. It is just a

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	matter of how do you go about building the
2	tool to do that.
3	CHAIR MUNN: It sounds cumbersome
4	to me.
5	MEMBER ZIEMER: Well, part of this
6	grew out of what you guys did originally when
7	you said, you know, we have certain findings;
8	we want to see how consistent we are and how
9	we address the findings, "we", SC&A.
10	MR. STIVER: Oh, yes, as it is
11	internalized, yes.
12	MEMBER ZIEMER: Because you would
13	have different people working these things. I
14	think NIOSH has done some of this where they
15	have asked themselves, are we consistent in
16	how we are responding to a finding at this
17	site that is basically the same finding as
18	another site?
19	MR. MARSCHKE: That is what NIOSH
20	had us do. A couple of years ago, we went
21	back and looked at a whole series of
22	procedures. Most of them were these coworker

1	dose procedures.
2	MEMBER ZIEMER: Right, to see
3	how
4	MR. MARSCHKE: To see how
5	consistent they were.
6	CHAIR MUNN: Yes.
7	MR. MARSCHKE: So, there is a
8	document out there somewhere that has
9	enshrined that analysis. I don't know whether
10	or not
11	MEMBER ZIEMER: Some of these grew
12	out of that, I think. I suppose the question
13	is, are there some others now that there are
14	some additional issues that either you have
15	seen in your reviews or NIOSH has seen in
16	their procedures?
17	MR. KATZ: I think this all boils
18	down, though, when you talk about
19	dissemination, I mean really dissemination
20	between the Work Groups, or whatever, I don't
21	think that is the way that things should be

driven. Really, at the end of the day, what

have these issues identified, whether it is in one Work Group or it has come up in two Work Groups, or what have you. And it is seen that it has broad applicability. At the end of the day, I think it all gets boiled down with DCAS producing a procedure related to that first, right?

MEMBER ZIEMER: Once it is identified.

MR. STIVER: Sure. Once it is identified, then it comes back --

And then, it MR. KATZ: here. If there needs to be involvement of other groups, it can, but this is sort of the central repository for dealing with generic procedures that cut across sites, and so on. So, it seems to me it is all of these. At the end of the day, if there is agreement that there is an issue there that needs to be the working out needs to be, worked out, ultimately, a DCAS procedure for handling that consistently.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	MR. STIVER: I guess we just all
2	need to be cognizant of how these things come
3	up and elevate them.
4	MR. KATZ: And I am just trying to
5	distinguish between that and this sort of idea
6	of a virtual Work Group. There is not really
7	a virtual Work Group you need. You just
8	need
9	MR. STIVER: Maybe that is the
10	wrong word.
11	MR. KATZ: Yes.
12	MR. STIVER: It is sort of
13	MR. KATZ: No, no, you didn't coin
14	it. I am just saying it is really that
15	concept of the Board sort of minding it.
16	Really, the Board doesn't need to mind it
17	until DCAS creates a sort of original
18	approach.
19	MR. HINNEFELD: To my way of
20	thinking, I think I am in the virtual Work
21	Group.
22	(Laughter.)

1	So, I am guilty of that.
2	But, to my way of thinking,
3	though, it is a way to essentially keep them
4	concisely in a record, in a place where we
5	have got them all down, as opposed to a list
6	on Jim's computer.
7	And then, also, to me, they seem
8	to come up in DR reviews fairly often.
9	CHAIR MUNN: Yes, they do.
10	MR. HINNEFELD: You know, that is
11	where they pop up.
12	CHAIR MUNN: Yes.
13	MR. HINNEFELD: And so, catching
14	them there and getting them someplace, and
15	probably they would come, I would guess
16	logically, to this group, but after DCAS
17	opines on how we are going to deal with that.
18	MR. KATZ: Yes.
19	MR. HINNEFELD: And so, it takes
20	the discussion out of a specific DR discussion
21	in acting
22	MR. KATZ: Right.

MR. HINNEFELD: and gets it
into this broader discussion. And then, once
you have a resolution, then you have a broad
resolution and, ultimately, a finalized
procedure that is then utilized when that
situation comes up.
MR KATZ: Ves I agree So I

MR. KATZ: Yes, I agree. So, I think it is sort of a DCAS to-do list. And then, I mean, where DCAS wants to air things while you are developing the solution, where you want to air them here, this is probably the natural default repository for airing them. But, of course, some of these you might work out because a Work Group is heavily engaged in that, and you may work it out with that Work Group as opposed to this one, this Subcommittee.

MR. HINNEFELD: Right.

MR. MARSCHKE: I believe it wasn't a virtual Work Group; it was a virtual document in the database where we were going to put all these different issues into a

NEAL R. GROSS

1	virtual document.
2	CHAIR MUNN: We discussed that.
3	MR. MARSCHKE: We discussed that.
4	CHAIR MUNN: Yes.
5	MR. MARSCHKE: And I don't think
6	we wanted to do that.
7	CHAIR MUNN: No.
8	MR. MARSCHKE: I don't know.
9	CHAIR MUNN: As I said, it seemed
10	cumbersome at the time.
11	MR. MARSCHKE: It seemed
12	cumbersome, but it may be the best way to do
13	it.
14	CHAIR MUNN: It may be
15	MR. HINNEFELD: Well, my thought
16	was this: now this is a little offbase,
17	although I think we may have identified I
18	don't know if you identified anything or not
19	from this Subcommittee. But in dose
20	reconstruction, if you have a finding that is
21	overarching, you say, well, we are going to

transfer that to the overarching issues. And

then, it would show up as a finding in this system under the virtual Overarching Issues Work Group. Then, you have a place to track the conversation of the issue the way we track the conversation of these issues. That was my thought.

You see, what strikes me about this is, in terms of re-creation of the record of the discussion, we are in a little bit of a dicey situation in most of the Work Groups because it is kept on notes and matrices that are published. And trying to make sure everybody is working from the same one and that changes are made to the correct, most recent master is really hard to do.

MR. KATZ: Yes.

MR. HINNEFELD: This takes care of that. Now that is why we try to make our records electronic at our place, so that your record is maintained by your system, and this is the record.

And so, instead of having these

NEAL R. GROSS

1	matrices being sent around and shipped around
2	and confused, this provides the mechanism for
3	doing that and establishes a record. That was
4	the advantage of the virtual Work Group, was
5	to do that.
6	MR. KATZ: Yes. So, in effect, it
7	is not necessarily an SC&A finding, but it is
8	finding, whether it is from a Work Group or a
9	Subcommittee, the Dose Reconstruction
10	Subcommittee, or whatever. It is a finding
11	that, then, needs to get resolved.
12	So, we need to load those up?
13	MR. HINNEFELD: I would propose we
14	do that.
15	MR. KATZ: Yes.
16	MR. HINNEFELD: I think that is on
17	our priority list somewhere, but I am sure it
18	wasn't a top priority on top.
19	MR. STIVER: So, I guess the
20	starting point would be to take Jim's list and
21	then populate this virtual grouping with that.
22	Then, as new ones arise

1	MEMBER ZIEMER: Well, some of
2	them, there are already procedures.
3	MR. STIVER: Yes. Yes, they would
4	already be in there.
5	CHAIR MUNN: Yes.
6	MEMBER ZIEMER: So, they are in
7	there.
8	MR. STIVER: As new ones come
9	up
LO	MEMBER ZIEMER: Yes.
11	MR. STIVER: then at least that
L2	would provide us with a central repository.
L3	DR. ULSH: So, I am looking at the
L4	first page in the Board review system. There
L5	is a filter, a Work Group filter. If you
L6	click on that it is a dropdown there is
L7	all the different site-specific Working
L8	Groups. I think what we are talking about,
L9	then, is Work Group on Overarching Issues, or
20	something like that, that would appear in this
21	dropdown list, that we could transfer findings
	1

to when we deemed it was appropriate, right?

1	MR. HINNEFELD: That is what I en
2	visioned.
3	MR. KATZ: Yes. And my only
4	question is I don't know why this Procedures
5	Subcommittee wouldn't be the Work why
6	wouldn't it be the default, instead of having
7	a virtual Work Group?
8	MEMBER ZIEMER: It is a place to
9	put the things in the document
LO	MR. KATZ: Yes.
11	MEMBER ZIEMER: but we could be
L2	the owners.
L3	DR. ULSH: Because there is a time
L4	period before the issue is identified, and
L5	then, at some later point in time, NIOSH picks
L6	it up and issues a procedure. But, in the
L7	interim, we need to make sure that we have a
L8	place to put them, so they don't fall off the
L9	radar.
20	MR. KATZ: I know, but why not put
21	them under Procedures, is what I am saying.
22	Because these are findings, we have findings,

1	and we have this Subcommittee. Why not put
2	them here?
3	MR. HINNEFELD: Well, all the
4	findings currently are tagged to specific
5	documents.
6	MR. KATZ: I know, this is
7	different.
8	MR. HINNEFELD: Well, I mean, the
9	structure of the application is such that you
10	have a document and you have these findings
11	under that document.
12	CHAIR MUNN: So, we need a title
13	for the pulldown that will indicate for us
14	that this is a corral that we are holding
15	things in to assure all involved that they
16	will be addressed in the appropriate manner,
17	things we don't want to lose, regardless of
18	where they came from. And we may need to give
19	a little thought to exactly what our
20	terminology needs to be because we don't want
21	to be misleading on this.

if we are going to gather

But

1	things, we have need of a place to gather
2	them. And certainly, our database that we
3	have worked so assiduously on seems to be the
4	logical place. I still believe it could be
5	cumbersome, but it seems to be the most
6	logical place to do it.
7	And Ted's position that Procedures
8	is the de facto spot to look at them is well-
9	taken.
10	MEMBER ZIEMER: So, let me ask a
11	question of Stu. Could NIOSH think, or DCAS,
12	could you conceivably have almost virtual
13	documents that don't actually exist, except
14	maybe in title?
15	For example, let's suppose that an
16	overarching issue was how do you evaluate hot
17	particles on Asians.
18	(Laughter.)
19	I don't know. Or, you know, it is
20	some issue where we say that it could apply to
21	many sites. Could you have a collection of

documents that don't actually exist, but are

2	MR. STIVER: It is basically
3	topics.
4	MEMBER ZIEMER: They are topical,
5	you know, "proposed procedure on" that we
6	could dump a finding in, if it related to that
7	topic under this virtual thing that you are
8	talking about.
9	MR. HINNEFELD: Yes.
10	MEMBER ZIEMER: In other words, a
11	document hasn't been developed, but we know it
12	has to be, and we already have some findings
13	to go in it, originally start to populate the
14	document that doesn't exist with some
15	findings
16	MR. HINNEFELD: Yes.
17	MEMBER ZIEMER: that the
18	document is going to have to address?
19	MR. HINNEFELD: That seems
20	eminently doable to me.
21	MEMBER ZIEMER: I mean, you might
22	need to think about what that would look like.
	NEAL R. GROSS

identified by title --

1	Defining on something that doesn't exist is
2	kind of weird, but
3	MR. HINNEFELD: We may have a
4	position where we I was just trying to
5	think about how this could work. Because the
6	structure right now, you know, it is hinged on
7	there is a document, there is a technical
8	document, and then there is a list of
9	findings. That is the way the structure is
10	now.
11	So, in order to now start
12	collecting overarching issues, which maybe we
13	don't know what kind of a document they go
14	with, we have to do one of two things. You
15	invent a document for that specific issue
16	MEMBER ZIEMER: Right.
17	MR. HINNEFELD: and say such-
18	and-such, and then it has one finding under
19	it.
20	MEMBER ZIEMER: But, I mean,
21	suppose there was no document on
22	MR. HINNEFELD: Yes.

suspension
ld you do
then, the
nere might
angular
e than one
going in,
that the
e is an
e, as you
t, just a
ent some
it "FD",
ot?
just "PD",

1	potential document.
2	MR. KATZ: Potential, right,
3	whatever.
4	MR. HINNEFELD: Yes, exactly. And
5	you put it in there, and then you would write
6	the one finding.
7	MR. KATZ: Right.
8	MR. HINNEFELD: You maybe have to
9	do it every time. Every time you have an
LO	overarching issue, write "Potential Document"
11	such-and-such, give it a title, write the one
L2	finding. And so, you have got all these
L3	documents in one finding.
L4	I mean, to me, that is the way to
L5	start.
L6	MR. KATZ: Yes.
L7	MR. HINNEFELD: You may decide
L8	later on that there is some other way to do
L9	it. Chances are you can modify it.
20	MR. KATZ: And actually, I mean,
21	in some of these topics, you actually have a
22	lot of discussion already which you could put

1	in that system. You could put the links in
2	there
3	MR. HINNEFELD: Yes.
4	MR. KATZ: for the discussion.
5	MR. HINNEFELD: Yes.
6	MR. KATZ: Because some of these
7	are well-discussed
8	MR. HINNEFELD: Yes.
9	MR. KATZ: although they are
10	not solved.
11	MR. MARSCHKE: What you do have
12	the capability in the database right now is
13	you could do a filter on anything that has
14	been transferred or anything that is
15	"addressed in."
16	MR. KATZ: Right.
17	MR. HINNEFELD: All the
18	transferred ones you can pull up.
19	MR. MARSCHKE: You can pull up and
20	you kind of walk through these. I was looking
21	for one that basically transferred to an
22	overarching issues, but I can't seem to find

1	an example of that.
2	MEMBER ZIEMER: TBD-6000, we have
3	the resuspension factor finding that got
4	transferred.
5	MR. MARSCHKE: Everything in
6	TBD-6000 was transferred out of this group
7	into your group.
8	MEMBER ZIEMER: No, but some of
9	the TBD findings got transferred to
10	overarching
11	MR. MARSCHKE: Right.
12	MEMBER ZIEMER: if you want to
13	pull one up.
14	MR. MARSCHKE: But we haven't been
15	tracking them. They were just transferred to
16	your group. In this database tracking
17	MEMBER ZIEMER: Well, where does
18	our group transfer them to?
19	MR. MARSCHKE: That's
20	MR. HINNEFELD: Well, no other
21	group is keeping their work on the system.
22	So, your transfer would not be reflected.

1	MEMBER ZIEMER: But, in principle,
2	where would it go?
3	MR. HINNEFELD: Well, in
4	principle, you would have
5	MEMBER ZIEMER: In principle, that
6	one you would pull out and say that is going
7	to go this other group instead TBD-6000
8	because it is overarching.
9	MR. HINNEFELD: Yes.
LO	MEMBER ZIEMER: The finding on
L1	MR. HINNEFELD: Yes, yes. Yes, I
L2	understand.
L3	MEMBER ZIEMER: That is all I am
L4	saying.
L5	MR. HINNEFELD: Yes.
L6	MEMBER ZIEMER: Right now, it is
L7	in the Work Group, but if you had this other
L8	mechanism, you would pull it out. So, these
L9	five are going to the Work Group and this one
20	is overarching; it is going over here.
21	MR. HINNEFELD: Yes.
22	CHAIR MUNN: Well, for the time

1	being, can we just simply add to our list of
2	Work Groups one more thing that says,
3	"Procedures Subcommittee Potential Document
4	Topic?" Just have a heading for that and put
5	our "PD"
6	MR. HINNEFELD: Can we keep the
7	term "overarching issue"? I mean, we have
8	called these overarching issues for so long.
9	MEMBER ZIEMER: Yes.
10	MR. HINNEFELD: Can we just keep
11	the term "overarching issue?"
12	MR. KATZ: You can code it
13	whatever is easiest.
14	CHAIR MUNN: Potential overarching
15	topic.
16	MR. HINNEFELD: And then, we will
17	have to design with our TST guys, you know,
18	sit down with them and give them the answers
19	on what kind of analogs to use for each of the
20	things that are proceeding from the database.
21	And then, we will just design a set of rules
22	for that. Then, I think we can do most of the

1	design.
2	Steve, we might get you on the
3	phone, if you want.
4	MR. MARSCHKE: Okay.
5	MR. HINNEFELD: And we will see
6	what we can do with the TST guys. And then,
7	we will try to load Jim's overarching issues
8	and whatever other ones we identify. We will
9	include the TBD-6000 overarching issues.
10	CHAIR MUNN: All right. Would it
11	be helpful for us to consider having our
12	telephone call sometime between now and our
13	next meeting to brainstorm a little bit what
14	some of the beginning topics are going to be,
15	a very short phone call, an hour or so?
16	MR. HINNEFELD: About which of the
17	overarching issues you want to take up first?
18	CHAIR MUNN: Right. Well, no,
19	ideas about what needs to go on the list to
20	begin with. Or would you prefer to build the
21	first scaffold yourselves?
22	MR. HINNEFELD: I would propose

4	that we about a build the first work assumed as
1	that we should build the first part ourselves.
2	CHAIR MUNN: Very good.
3	MR. HINNEFELD: Because we have
4	got Jim's list.
5	CHAIR MUNN: Yes.
6	MR. HINNEFELD: We know Paul said
7	the TBD-6000 Work Group has transferred a
8	number of the ones that were transferred from
9	here to them.
10	MEMBER ZIEMER: But there are only
11	some that are on that list.
12	MR. HINNEFELD: Okay. Then, we
13	can comb through DR reports, you know,
14	reviews, as we can, and look for overarching
15	issue kind of solutions, comments on the
15 16	issue kind of solutions, comments on the matrices.
16	matrices.
16 17	matrices. CHAIR MUNN: We have already
16 17 18	matrices. CHAIR MUNN: We have already discussed badge geometry here.
16 17 18	matrices. CHAIR MUNN: We have already discussed badge geometry here. MR. HINNEFELD: We can try to move

NEAL R. GROSS

1	John a ring to see that your list includes
2	what SC&A thinks have been identified as
3	overarching issues.
4	MR. STIVER: Coordinating this
5	with the Dose Reconstruction Subcommittee
6	would be very important, too, because part of
7	those are going, you know, discussions and
8	some may already be captured.
9	MR. KATZ: Yes. So, you can
10	check, but
11	CHAIR MUNN: I am thinking of how
12	many matrices you are going to go through.
13	Good luck with that.
14	(Laughter.)
15	But very good. At least we will
16	have a kickoff next time. We don't anticipate
17	a lot of good meat to begin with.
18	DR. ULSH: Well, just to make sure
19	that I have got these things appropriately
20	prioritized, I have got in my notes right now,
21	anyway, that the highest priority is the
22	"Wanda summary list"

1	CHAIR MUNN: Yes.
2	DR. ULSH: And also high priority
3	is fix the Total Active Findings column. I
4	don't think that will be difficult.
5	I mean, the summary list will be
6	significant.
7	CHAIR MUNN: Yes.
8	DR. ULSH: But the other one
9	shouldn't be. If we can get those done, then
10	next on the list would be the overarching
11	issues capacity or
12	CHAIR MUNN: I believe so.
13	Comment, Steve?
14	MR. MARSCHKE: Just a point. I
15	noticed, happened to notice that, when we
16	updated OTIB-6, the Active Findings column
17	basically was updated. When we updated
18	OTIB-70, it was not updated.
19	So, I was kind of thinking that
20	you made a phone call and turned somebody on,
21	but it looked like the OTIB-6 updates, if you
22	look at OTIB-6 here now, if I can find it

1	quickly, OTIB-6 is now showing me we have
2	total findings four, active findings none.
3	So, that is reflects what is going on.
4	But if we go back and look at
5	you remember we closed out 70.
6	MR. KATZ: Right.
7	MR. MARSCHKE: If we go back and
8	look at 70, and you go back and here's
9	OTIB-70, it still has all the findings as
10	being active. So, I don't know what it is
11	doing.
12	MR. KATZ: But that is a good
13	example, actually, to provide to the computer
14	folks because that will help them figure out
15	what is going on.
16	MR. STIVER: It is some good
17	diagnostic information they can use.
18	MR. KATZ: Yes, right. Because
19	they have the date when we changed it, and now
20	they know exactly what should have happened.
21	MEMBER ZIEMER: Has it been
22	refreshed? Did one get refreshed and the

1	other didn't?
2	MR. MARSCHKE: Well, we changed 6
3	after we changed OTIB-70.
4	MR. KATZ: Yes. Hypothesis 1.
5	(Laughter.)
6	CHAIR MUNN: Oh, well.
7	MR. MARSCHKE: I mean, I was
8	thinking we did 6 after lunch and 70 before
9	lunch. And I was thinking maybe, if Brant had
10	contacted them, maybe they got right on the
11	ball and did something.
12	DR. ULSH: Sadly, no.
13	(Laughter.)
14	That's not what happened.
15	CHAIR MUNN: But it is baffling
16	because one wonders whether there was some
17	mechanism of which we were unaware that was
18	different in the way those
19	MR. MARSCHKE: They were updated.
20	CHAIR MUNN: changes were made.
21	MR. KATZ: That is for the
22	computer folks to puzzle through. There is no

1	point in us trying to ponder the thing.
2	MEMBER ZIEMER: Because, remember,
3	my thing pulled up some old information. Who
4	knows where that came from.
5	CHAIR MUNN: Well, we will let
6	them work on that, and everybody knows what
7	they are going to do with that, which is a lot
8	of work, but, hopefully, it will turn out to
9	be not as difficult as expected.
10	We are going to move on to status
11	of the two-pagers. We are moving very slowly,
12	but we are moving.
13	I am assuming that all of you
14	received the markups that Dr. Ziemer provided
15	for us last week. Well, he provided them to
16	me before that. But I have not added my
17	markups to those.
18	But you have a good starting
19	point. Do you have any concerns about any of
20	those that he has identified?
21	I actually rewrote the four PROCs
22	that you saw, mostly rewrote them, not

1	entirely. But I had intended those to be
2	pretty much as final as possible because I
3	hadn't had any feedback from anybody about any
4	of them.
5	I don't know whether, Paul, have
6	you had an opportunity to read the ones that I
7	redid or not?
8	MEMBER ZIEMER: I read the first
9	one, but I realized I needed to put it side-
10	by-side with the others, and I hadn't done
11	that. So, basically, the answer is, no, I
12	didn't really go through them.
13	CHAIR MUNN: Has anyone had an
14	opportunity to go through any of them?
15	MEMBER ZIEMER: Are these
16	different ones?
17	CHAIR MUNN: Those four are the
18	first four on the full list that was sent out
19	by Ted. He sent the whole list of
20	MEMBER ZIEMER: OTIB-0006. Yes,
21	what I was saying, that I didn't put yours
22	side-by-side with mine to see whether we were

1	thinking in the same terms or not.
2	CHAIR MUNN: Well, I didn't see
3	that you had those four PROCs on your list.
4	MEMBER ZIEMER: Yes, they're
5	there.
6	MR. MARSCHKE: No, it is PROCs,
7	not OTIBs, Paul.
8	MEMBER ZIEMER: Oh, well, I took
9	Ted's and I thought I did every one. I did
10	30-some different ones.
11	CHAIR MUNN: I think I only got
12	about 20.
13	MEMBER ZIEMER: Here's PROC-0006
14	that I did.
15	CHAIR MUNN: Oh, you did?
16	MEMBER ZIEMER: That is 0060 or 6?
17	CHAIR MUNN: No, it is 0006. And
18	then, there's 0060. There's No. 6 and there's
19	No. 60. There's 31.
20	MEMBER ZIEMER: Well, I thought I
21	did every one that Ted had sent. Yes, here's
22	0006. So, that's OTIB. Yours is PROC. Well,

1	I don't know. How did I miss that? I don't
2	know.
3	CHAIR MUNN: I don't know, but
4	maybe we need to have some phone calls or some
5	email exchanges about this.
6	Does anyone have anything to say
7	about anything that they see with respect to
8	these two pagers so far?
9	Dick, have you had an opportunity
LO	to look at any of these? Dick, are you still
11	with us?
L2	(No response.)
L3	He said he might not be able to
L4	stay the whole time.
L5	Here's what I propose, since I
L6	don't think anyone has had an opportunity to
L7	really do anything with these: I am going to
L8	continue doing what I have done so far.
L9	But the first thing I am going to
20	do is spend some time with what Paul has
21	already done and make any discussions with him
22	about my concerns and what changes I feel

might be made to shorten -- my primary concern is shortening them for the most part.

But these were pretty brief to begin with. My primary concern with what is there is the continued use of acronyms and several other things I would like to take out. But we can avoid that; that is easy enough. But it is what I have tried to do with the four that I have done.

And that will give you an opportunity to read the four that I did to see if you have any grief with it, Paul.

And we will try to seek especially Dr. Lemen, who has been active with us when we went through this. We will make sure that he is in the loop with what we are doing here.

Hopefully, we will be able to bring a proposal to you at our next meeting that incorporates all of the two-pagers that have already been drafted, which will eliminate the things that we have agreed we are going to eliminate and try to smooth them

1	out a little.
2	MEMBER LEMEN: Hello, this is
3	Dick. Can you hear me?
4	CHAIR MUNN: Oh, yes, Dick. Now
5	we can hear you.
6	MEMBER LEMEN: I had to hang up
7	and call back because I couldn't get the
8	stupid thing off of mute.
9	CHAIR MUNN: Oh, I'm sorry about
10	that.
11	MEMBER LEMEN: So, anyhow, my
12	comments, if you still want them, are that I
13	would like to have a little bit more time on
14	those two-pagers. I have started on them, but
15	I haven't finished all of them.
16	But I think we have made some good
17	progress, and I really appreciated Paul's
18	comments. I thought that his comments on them
19	helped me a lot.
20	CHAIR MUNN: Yes, they are
21	helpful. There's no question about it. As I
22	said, the only additions that I am likely to

1	make, from what I have seen of Paul's work so
2	far, is just to eliminate some of the acronyms
3	and one or two of the other simplifying things
4	that we have agreed on.
5	I appreciate that, Dick. Did you
6	hear me say that it is our hope that we can
7	incorporate you into the loop that Paul and I
8	have been working on here to move these
9	forward a little? Are you going to be able to
10	do that?
11	MEMBER LEMEN: So, yes, I will.
12	MR. KATZ: Dick, just trying to be
13	concrete, how much time do you need to get
14	through them yourself, do you think?
15	MEMBER LEMEN: Well, I would like
16	a couple more weeks at least.
17	CHAIR MUNN: That is generally my
18	thought. I am going to try to get my thoughts
19	on Paul's work out within that period of time,
20	and I will get them to both you and Paul. If
21	you have any additional or feel that we are
22	being too sparse or too broad in cases, just

1	please feel free to let me know.
2	MR. KATZ: So, let me just say I
3	think, if the three of you want to conclude
4	that work, you don't have to wait until next
5	Subcommittee meeting to get these done and
6	posted. You can just, once you have concluded
7	and the three of you are happy with the
8	product
9	MEMBER ZIEMER: I was going to
10	suggest that if Dick Lemen and I give our
11	comments to Wanda, I am happy if she just
12	makes the final editorial decision, and then
13	that is the copy we will post.
14	And just for comment, a lot of
15	mine are trying to eliminate acronyms
16	CHAIR MUNN: Yes.
17	MEMBER ZIEMER: and then, also,
18	to use different terms. I am just looking at
19	one right now, for example, where we say
20	"computer methodology," just call it "computer
21	calculations."
22	CHAIR MUNN: Or even "computer

1	methods."
2	MEMBER ZIEMER: Or "computer
3	methods."
4	CHAIR MUNN: Yes.
5	MEMBER ZIEMER: And where it says
6	"the prostate gland could be modeled by the
7	testes," I don't know if people know what
8	"modeled" means.
9	CHAIR MUNN: No, no.
10	MEMBER ZIEMER: You know, are you
11	modeling?
12	CHAIR MUNN: Yes. No, we have
13	discussed
14	MEMBER ZIEMER: Wanda, I see I
15	spelled "represented by" here wrong,
16	"represented-ed."
17	CHAIR MUNN: Yes. Those are the
18	kinds of things.
19	MEMBER ZIEMER: But get some
20	simpler words, a few cases where I eliminated
21	dangling participles in some of these
22	CHAIR MUNN: Yes, yes.

NEAL R. GROSS

1	MEMBER ZIEMER: which tend to
2	be used over and over by scientific writers.
3	CHAIR MUNN: Yes, they do, and
4	they also have a tendency to use the same
5	terminology sentence after sentence after
6	sentence.
7	As just a passing point of
8	interest, and as a point of record of how
9	difficult some of these things are, one of the
10	summaries of the PROCs that I sent you had to
11	do with, its title even included the word
12	"ambient."
13	MEMBER ZIEMER: Right.
14	CHAIR MUNN: Well, "ambient" is a
15	word that means something to every single
16	person here. But my thought was there are a
17	great many people for whom the word "ambient"
18	may not be clear.
19	I am concerned about the fact that
20	in the draft that had been sent they used,
21	said in parentheses, "environmental." And I
22	thought, well, "ambient" is not actually

1	environmental. It is something different than
2	that.
3	So, I whipped up through my
4	electronic thesaurus. And would you believe
5	that there is no synonym given for "ambient?"
6	MEMBER ZIEMER: Well, I think that
7	is one that I had spent some time on, too.
8	The ones particularly where it is in the
9	title, you can't change that.
LO	CHAIR MUNN: Yes. No, you can't.
11	MEMBER ZIEMER: But you can
L2	explain it.
L3	CHAIR MUNN: Yes.
L4	MEMBER ZIEMER: And there were a
L5	couple of them that the explanations that were
L6	in there were very complex.
L7	CHAIR MUNN: Yes.
L8	MEMBER ZIEMER: Partially,
L9	sentences just had to be broken into little
20	pieces.
21	CHAIR MUNN: Very good. There
22	isn't any other way you can get around that.

1	MEMBER ZIEMER: And so, it can be
2	done. I am satisfied to have you make the
3	final decision this.
4	CHAIR MUNN: Well, I came to the
5	conclusion in that particular case that
6	probably "environmental" conveys as much of
7	the context that was intended in that case as
8	any other word could be. So, I left it as
9	well.
10	MEMBER LEMEN: I would concur with
11	Paul. I will make my comments and just send
12	them to Paul and Wanda. And I agree to let
13	Wanda make the final decision on it.
14	MR. KATZ: Okay. And so, Wanda,
15	if you will, just at the end of that process,
16	if you will send me the finals, I will get
17	them to DCAS to get posted.
18	CHAIR MUNN: Very good. All
19	right. That is what we will do.
20	The only other item that I have
21	left on the agenda oh, no, there are two.
22	We had asked for some time to make a couple of

comments about PER use.

MR. STIVER: Actually, there are a couple of different things we might look at. Given the fact that we are probably about 85 percent complete on addressing the findings of the original 500, it kind of brings up the issue, well, where do we go from here?

And I contacted Brant in search for an updated listing of the current active documents as well as prospective documents.

The last version we had was from January of 2009.

Steve went through and just looked at the TIBs and looked at the revisions and whether they appeared to be substantive changes that might warrant potential follow-on reviews, and I believe came up with about 11 of them that were possible candidates.

And so, that is something we want to look into. We are charged with monitoring these to determine when a substantive change comes along that may warrant this type of

NEAL R. GROSS

1 review, that we bring it to the attention of 2 the group. 3 Another thing is that, because we don't have the glitch fixed in the Board 4 5 review system, we are identifying completely 6 closed-out findings to put together a list of 7 OTIBs that may require two-pagers. At this point, we have to go through it basically by 8 hand and sort through those. We can certainly 9 10 do that, but I think that is another thing that is kind of on the back burner. 11 I mean, I see this, going forward, 12 13 going to be looking more at PER are development and tracking and all the issues 14 15 that go along with that, as well as wrapping 16 them up with these two-pagers. So, that is kind of where we stand on the OTIBs. 17 18 As far as the PERs, Kathy 19 Behling --20 before MR. KATZ: So, qo forward with that, though, the procedures that 21

that

are

identified

you

have

22

possible

1	candidates, are you going to send a document
2	to the Subcommittee, so that they can see?
3	MR. STIVER: Yes, at this point,
4	it is kind of we are waiting for Brant to give
5	us an updated version of that. Some of these
6	documents on here that we had reviewed are no
7	longer there or are not on this list. So,
8	they have been retired.
9	MR. KATZ: Okay.
10	MR. STIVER: So, we would like to
11	get the complete list before we put together
12	any kind of definitive subgrouping on that.
13	MR. KATZ: Okay.
14	MR. STIVER: But that is the
15	ultimate goal.
16	CHAIR MUNN: That would be
17	helpful.
18	MR. MARSCHKE: This is what this
19	document looks like that we put together. You
20	can see some of them are missing a web number.
21	What we did, as John said, we pulled this
22	information off of a NIOSH-approved document

list which was dated January 2009. So, it is dated.

OTIB-3 was not on the list. You will see some that don't have any numbers in here, and it is not on the list. And the reason there are no numbers is because that particular OTIB was not in the document from 2009.

And then, over here you can see basically SC&A -- first, we have a column whether or not we reviewed the document, when we reviewed it, and what revision we would use. Then, the final column we have got is, is it a candidate for re-review or initial review, if we hadn't already reviewed it?

And for re-review, what I did, basically, was if there was a full revision number between what we reviewed and what is currently, then I said, yes, that is a candidate. If there was basically Rev. 0 here and we reviewed Rev. 0, then it is no candidate for review.

NEAL R. GROSS

1	Some places there was a page
2	change.
3	MR. KATZ: Okay, but just to go
4	back to your first sort of criterion, a full
5	rev. change, but in some cases you will find
6	that, yes, there is a full rev. change, but it
7	is all followup responses that have been
8	derived from this work, and you don't need to
9	review it because it is all followup from
10	MR. MARSCHKE: That is why this is
11	just an initial cut.
12	MR. KATZ: Yes.
13	MR. MARSCHKE: This is just a
14	first cut.
15	MEMBER ZIEMER: Some of them, we
16	are awaiting confirmation that the change is
17	in the document, right?
18	MR. KATZ: Right.
19	CHAIR MUNN: Correct.
20	MEMBER ZIEMER: And that would
21	verify that.
22	MR KATZ: Yes

1	MR. MARSCHKE: We would already do
2	that. If it was just the changes that we had
3	already requested, that should already be done
4	as part of the closeout of those findings.
5	So, that is what we did.
6	And the other thing was document
7	OTIB-9, which basically was revised, we had
8	not reviewed it. I did not make it as a
9	candidate because it is a site-specific OTIB.
10	And so, I felt that that was more appropriate
11	for anything that was site-specific would
12	be more appropriate for a Work Group than it
13	would be for this group.
14	MR. KATZ: Right.
15	MR. MARSCHKE: So, we can forward
16	you this.
17	MR. KATZ: Well, it is not ready
18	yet. So, you don't need to
19	MR. MARSCHKE: But this is kind of
20	like the approach that we are taking.
21	MR. STIVER: This is just to make
22	you aware of what we are planning here. I

1	assume that within about a week or two we will
2	have that. Brant indicated, when he gets back
3	from Savannah River, he can go ahead and put
4	together an updated document.
5	MR. KATZ: That sounds good.
6	MR. STIVER: Yes.
7	CHAIR MUNN: Good. All right.
8	That will be very helpful information to have.
9	MR. HINNEFELD: You are talking
10	about the list of documents that are out
11	there, right?
12	MR. MARSCHKE: Yes.
13	MR. HINNEFELD: Did Brant say
14	anything about the utility of the existing
15	applications? Because we were trying to set
16	it up, so when a new document got published,
17	it would appear in the application under the
18	to-be-assigned queue. What's that called?
19	MR. MARSCHKE: Unassigned.
20	MR. HINNEFELD: Unassigned queue.
21	MR. MARSCHKE: Unassigned queue.
22	MR. HINNEFELD: Yes.

1	CHAIR MUNN: I don't hear anything
2	about that.
3	MR. HINNEFELD: Well, no. No.
4	This is Brant and me talking to each other,
5	okay?
6	CHAIR MUNN: Okay.
7	MR. HINNEFELD: I don't think you
8	would have heard that.
9	CHAIR MUNN: I wouldn't have.
10	MR. HINNEFELD: And I am not sure
11	now if you look there now, you will see a
12	long list of procedures or documents, and the
13	reason they are in this is because the last
14	time we met all the documents, the application
15	grab that the application knew about
16	were under these documents that are Board
17	reviewed.
18	We have split them up. I did this
19	partially for the numbers I presented at the
20	last Board meeting. We split them up into
21	unassigned and under Board review, but the
22	only way we could do that easily and without

1	actually looking at each one was to put any
2	document that had zero findings in the
3	unassigned queue.
4	So, if there were any documents
5	that SC&A reviewed but had zero findings on
6	them it seems like there were one or two
7	they would be in this list incorrect
8	because the Board has actually reviewed those.
9	CHAIR MUNN: Yes.
10	MR. HINNEFELD: And then, all the
11	documents with findings are in the documents
12	under Board review list, when you pull that
13	list up.
14	My intention was that when a new
15	document gets published, when a document is
16	final and published, we have a specific place
17	on our K: drive where that gets put. I want
18	that document, then, to load into the
19	unassigned queue in this application.
20	So, at anytime SC&A users can be
21	able to look at the entire population of
22	procedures that have not been reviewed and

1	decide, or the Board, the Work Group, are
2	there things here that warrant review?
3	So, today, if you look at that, if
4	there is anything in there that you think that
5	warrants review, that might be a place to
6	start in terms of looking for additional
7	things for review.
8	I don't know that it is 100
9	percent up-to-date. I believe it is up-to-
10	date within a couple of months, but I don't
11	know that it is 100 percent up-to-date. So, I
12	will check with Brant and Tom and see if that
13	is.
14	Because that would be my view, is
15	whenever we publish something, it pops up in
16	here in the assigned queue, or in the
17	unassigned queue, and it doesn't mean it has
18	to be assigned. It just means it is
19	available.
20	MR. KATZ: Right, but that is
21	good.
22	So, you got that, Steve?

1	MR. MARSCHKE: I got that, yes.
2	When we made this list, I wasn't aware that
3	this "unassigned to" had been populated. I
4	think back in September it wasn't populated.
5	MR. HINNEFELD: It wasn't then.
6	We populated this before the December Board
7	meeting.
8	MR. MARSCHKE: So, now that it is
9	populated, we may be able to get rid of that
10	matrix that I was doing or maybe I can just
11	MR. STIVER: You can certainly can
12	compare whatever Brant puts together.
13	MR. MARSCHKE: Yes.
14	MR. STIVER: If there is anything
15	new that has come out in a few-month interim,
16	or there may be a few others in here that
17	have zero findings as well, but it certainly
18	gets us a real leg up on getting started.
19	CHAIR MUNN: Yes, that should be
20	very helpful. Good.
21	Now I have been both dreading and
22	expecting today that we were going to have to

1	face this, what else is out there. It is good
2	to know that it is working.
3	MR. STIVER: And that kind of
4	segues nicely into the PERs.
5	CHAIR MUNN: Into the PERs.
6	MR. STIVER: Because in looking
7	through this unassigned queue, I discovered
8	that all of the
9	MEMBER LEMEN: This is Dick.
10	Before you get started
11	MR. KATZ: Sure, go ahead, Dick.
12	MEMBER LEMEN: I have to cut off
13	now. I told Wanda I might have to cut off
14	early, and I do.
15	So, Wanda or Ted, could you send
16	me the date for the next meeting? And I will
17	make sure I can get it on my calendar.
18	CHAIR MUNN: We will make sure to
19	do that soon.
20	MR. KATZ: Yes.
21	MEMBER LEMEN: And if there is
22	anything that comes up that you need my vote

1	on it before the end of this meeting, just
2	send me a note and I will try to make my mind
3	up on it.
4	MR. KATZ: Okay.
5	CHAIR MUNN: We have no votes
6	scheduled.
0	scheduled.
7	MEMBER LEMEN: Okay.
8	CHAIR MUNN: We will be in touch
9	with respect to the two-pagers.
10	MEMBER LEMEN: Okay. Happy new
11	year all, and I am sorry I can't stay the next
12	half-hour with you.
13	CHAIR MUNN: The same to you.
14	MR. KATZ: Thanks, Dick.
15	CHAIR MUNN: Bye-bye.
16	MEMBER LEMEN: Bye.
17	MR. KATZ: Bye-bye.
18	Sorry. Go ahead.
19	MR. STIVER: Yes, the other issue
20	of what is out there are these PERs. Remember
21	back before the St. Louis meeting Kathy
22	Behling had put together this nice, little

1	summary that had a few different tables, table
2	one being the PERs that had already been
3	assigned, I believe of which there are 14.
4	Eleven of those have been started, and they
5	are in various stages of completion. Three
6	have not been started yet.
7	And there was also an additional
8	18 that she identified that had not yet been
9	assigned. She went through a couple of days
10	ago and updated that list and discovered there
11	were two more PERs which she added to this
12	list.
13	And looking last night, looking at
14	this unassigned order of these documents, I
15	found that essentially all of them are in that
16	unassigned queue. So, the system you put
17	together seems to be working.
18	However, there are two that
19	MR. HINNEFELD: Aren't there
20	probably?
21	MR. STIVER: that we didn't
22	have findings.

1	MR. HINNEFELD: Are they there?
2	MR. STIVER: They showed up in
3	there, too.
4	MR. HINNEFELD: Oh.
5	MR. STIVER: At least the
6	algorithm is working correctly.
7	CHAIR MUNN: That's wonderful.
8	MR. HINNEFELD: At least it was
9	up-to-date when those two were
10	CHAIR MUNN: Yes.
11	MR. STIVER: So, Kathy, we
12	probably could have saved her a day's work by
13	having her look at this.
14	CHAIR MUNN: That is marvelous to
15	hear that they are so current.
16	MR. STIVER: Yes. And so, we have
17	gone through and kind of summarized where we
18	were on the 14. Eleven of them are in stages
19	of development. Seven of them are awaiting
20	action by NIOSH. And then, beyond that, they
21	will have to go to the Board for discussion.
22	But, of these other 20 that are

remaining, Kathy, if you have seen them, and take a look at the list there, this is the table two. She has them grouped, first, by the number of claimants. There is a kind of binary assignment by classification, if you will. One is the number of potentially affected claimants, and the other is the difficulty of the science that was involved in developing the change. Of course, this is reflected in the cost estimate for reviewing these things.

So, before we go on further than that, I want to go to this next -- there's four different subtests that we look at in doing these PER reviews. The last one is really, again, that set of representative dose reconstructions that have been done under the revised procedure and really doing the evaluation representation, were the agreed-upon changes actually followed in any dose reconstructions.

As I understand it, there's only

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	the PER 12 cases assigned or 10 cases. They
2	hit various aspects of the selection process.
3	As of September, those cases have not yet
4	been posted. And I was wondering if that was
5	on the way to being posted?
6	MR. HINNEFELD: Meaning the
7	identity of the 10?
8	MR. STIVER: Just basically taking
9	the administrative case files and putting them
10	out there.
11	MR. KATZ: We talked about this at
12	the Dose Reconstruction Subcommittee meeting.
13	I mean, because I had assumed you had already
14	gotten started on that at that point, and you
15	folks made the comment that they had been
16	posted.
17	We talked at that meeting about
18	I mean, if there is something you need to get
19	from Brant to go forward, you need to, but you
20	were going to do that based on
21	MR. STIVER: Yes, I just wanted to
22	make a reminder that we have not yet they

1	are still not out there.
2	MR. KATZ: Okay. So, you just
3	need to get on the line with Brant and get
4	that solved, whatever that is.
5	MR. STIVER: Yes.
6	MR. KATZ: It doesn't need to
7	await any action by any Subcommittee or Work
8	Group.
9	MR. STIVER: Okay.
10	MR. KATZ: I don't understand why
11	it has taken all this time to pick up the
12	cases and work them.
13	CHAIR MUNN: An easy connection,
14	yes. We don't need to be an obstacle here
15	MR. STIVER: Absolutely not.
16	CHAIR MUNN: moving forward.
17	MR. STIVER: But the other issue I
18	have been thinking about is and we haven't
19	really thought about this too much; maybe
20	this is more of an issue to bring up in the
21	Dose Reconstruction Subcommittee, but how to
22	go about evaluating these cases. In my mind,

it seems that you are really looking at kind of a focused metric here. You are taking a look at how was the case done before the procedure was changed and looking at that.

So, you are really just looking not at the broad spectrum of everything that would go into a full dose reconstruction, but really what is the outcome of this particular change in procedure. So, I see them as more focused reviews that could be expedited in comparison with a full dose reconstruction.

of that, I think Because should be tracked separately, either within the Board review system or within a matrix and the Subcommittee. Keep them separate from those other cases and really track them differently.

I was a little concerned about the database that we have here. But, after seeing the improvements that have been made, I think we can link PDFs and transfer findings, and I think it is a very good tool.

NEAL R. GROSS

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

1	I am not sure if David Richardson,
2	becoming the new Chair of that Committee, is
3	even aware of what is needed at this point. I
4	know, as Mark has been kind of been pulled
5	more and more into his Chemical Review Board
6	work, he has been less and less involved. And
7	so, I think that is something that maybe SC&A
8	or this group could get together with David
9	and kind of brief him on where we stand on
10	this and what the issues are, and how we feel
11	that should be handled.
12	MR. KATZ: Let me explain
13	something because you may have missed it
14	because John has been in here for this whole
15	evolution, John Mauro.
16	DR. MAURO: I am here and I am
17	listening.
18	MR. KATZ: Okay.
19	DR. MAURO: Keep going, Ted.
20	MR. KATZ: John Stiver hasn't been
	II
21	here for all of it.

1	Subcommittee, all they do is select the cases.
2	That is their whole involvement in this.
3	They are not involved in the review of the
4	cases after. The cases come back, actually,
5	to this Subcommittee for consideration about
6	the implementation questions. So, really,
7	they have a very small, limited, and sort of
8	mechanical role of doing the selection of the
9	cases once this Subcommittee assigns a PER to
10	have its cases reviewed.
11	MR. STIVER: Okay. Although
12	during the DR Subcommittee meetings we go
13	through those findings.
14	MR. KATZ: But not for PERs. That
15	is what I am saying. The Dose Reconstruction
16	Subcommittee is not going to be evaluating the
17	cases that are PER reviews.
18	MR. STIVER: Okay. Well, see,
19	this is the thing I am not really 100 percent
20	sure on.
21	MR. KATZ: Yes.
22	MR. STIVER: And so, that is the

WASHINGTON, D.C. 20005-3701

kind of feedback I am interested in getting. 1 2 CHAIR MUNN: Yes. 3 MR. KATZ: Yes. This is John. 4 DR. MAURO: 5 the things I Ted, yes, one of 6 didn't do is get into this level of detail on 7 this particular matter with John. MR. KATZ: 8 Sure. You're right. 9 DR. MAURO: 10 think, John, you came to the same place I did, but we didn't really have a chance to talk 11 12 about it. I think these cases and each PER, 13 not only the PER, the one, two, three steps, the first three steps that we completed be 14 15 tracked of the Procedures part as 16 Subcommittee, but also the findings related to, once we do do a review of the cases 17 associated and track them here. 18 19 But the very important point that you just brought out is all we do is track 20 that aspect of that DR that pertains to the 21

PER issue at play. And so, you're right, it

would be a focused review.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

Because, very often, a lot of these redone cases under a PER may very well reflect many different adjustments made to the dose reconstruction. My understanding from the last time we talked about it is this Subcommittee would only track those issues that are related to the PER itself.

MR. STIVER: Yes, that is exactly how I see it unfolding as well.

DR. MAURO: Yes. Okay.

What Ι have MR. KATZ: been assuming all along is at the end of that process where you have reviewed the 10 cases, for example, of PER-12, you will have reviewed those 10 cases. At the end of that review that you do, as opposed to the way you do DR reviews where you report out each DR case and you have a couple of Board Members with you and that whole process, you will have reviewed 10 cases and you will produce one report that will basically explain here's what you found

NEAL R. GROSS

about implementation. Yes, I mean, there will 1 be, of course, details 2 that may be relevance in individual cases, but it will be 3 4 a report on the whole. 5 And that is exactly MR. STIVER: 6 how I envision the whole thing taking place. 7 MR. KATZ: Yes. Well, what we can 8 MARSCHKE: do is, for example, if you look at PER-12, 9 right now we have one finding 10 in PER-12. 11 After you do your case review, we may have a 12 half dozen more findings. We can just go in 13 and add those findings to this PER and basically use this database. The way it is 14 15 set up now, I think it should be relatively 16 easy to use this to do that. MR. KATZ: Yes. 17 So, in a sense, 18 MR. MARSCHKE: 19 this Subcommittee is the one that is going to 20 be looking at it. We are already familiar with the database. So, it should 21

naturally.

1	MR. STIVER: We need to keep in
2	mind here that there is a subtle difference.
3	I mean, if a finding was uncovered during the
4	review of the procedure, it doesn't
5	necessarily reflect how well that procedure
6	was implemented. They are really going to be
7	kind of separate.
8	MR. MARSCHKE: It is going to be a
9	finding. Now you will have, instead of having
10	one finding, you will have several findings,
11	but they will still be
12	MR. STIVER: We need to make sure
13	that everybody understands that there is a
14	differential between those. Maybe there
15	should be
16	MR. KATZ: Code them as
17	implementation findings or whatever, but
18	MR. STIVER: They just need to be
19	tracked.
20	MEMBER ZIEMER: Well, for example,
21	take high-fired plutonium as an issue, and
22	there was a finding that drove that. Now when

1	NIOSH goes back and does the PER process, Stu,
2	on a given dose reconstruction, do they simply
3	take the previous one and recalculate with the
4	new solubility value in the system? Or is the
5	dose fully reconstructed from start to finish?
6	Do you know what I am asking?
7	MR. HINNEFELD: Yes. The dose is
8	completely recalculated with current
9	techniques. For instance, if a case had been
10	done with TIB-2 that is not a good example.
11	MEMBER ZIEMER: Okay. Yes, some
12	other thing that changed. But these guys are
13	only going to see, did they plug in the high-
14	fired plutonium
15	MR. HINNEFELD: That's right.
16	MEMBER ZIEMER: solubility,
17	right?
18	MR. STIVER: Already I can see a
19	problem here.
20	MEMBER ZIEMER: Well, that is why
21	I am asking the question.
22	MR. STIVER: Yes.

1	MEMBER ZIEMER: Because they may
2	have a different workbook or something that
3	they are using
4	MR. STIVER: Yes.
5	MEMBER ZIEMER: for the other
6	parts of it.
7	MR. STIVER: Yes.
8	MEMBER ZIEMER: But you have
9	already addressed that in a different way?
10	MR. STIVER: Yes. These cases
11	have already been through our review cycle in
12	a reasonable period of time.
13	MEMBER ZIEMER: Right. But when
14	they redo it, they may be doing it differently
15	than it was the first time around.
16	MR. STIVER: So, that may confound
17	our ability to do this in a very expedited
18	MEMBER ZIEMER: I mean, what would
19	you look at say it was high-fired plutonium
20	because the changing critical item there is
21	that solubility factor?
22	MR. STIVER: Well, you could look

1	at that particular component. Say it was done
2	under maybe IREP, or whatever
3	MEMBER ZIEMER: Right.
4	MR. STIVER: that subcategory
5	of
6	MEMBER ZIEMER: Here's what the
7	old IREP gave and
8	MR. STIVER: Yes, we just look at
9	that and we look at the new method of how that
10	was done, just compare the two.
11	MEMBER ZIEMER: And the thing you
12	won't know is whether or not, whatever the
13	bottom line was, the change in the PoC was due
14	entirely to that factor
15	MR. STIVER: Rarely would you have
16	that luxury of being able to just
17	MEMBER ZIEMER: Because there are
18	some other things that might have changed that
19	you aren't going to be looking at.
20	MR. KATZ: But it doesn't matter
21	really because that is not the bulk of the
22	review.

1	MEMBER ZIEMER: What are they
2	trying to report? What is it you are trying
3	to achieve here?
4	MR. STIVER: We are going to be
5	able to see, what are the methods and the
6	corrective actions that have been implemented
7	or recommended and put into the document?
8	Were they actually implemented in the tail-end
9	of the dose reconstruction process.
10	MR. KATZ: Right.
11	MR. STIVER: And that is really
12	what we are concerned with. So, if we can
13	identify how that aspect with high-fired
14	plutonium, the task was done, and just compare
15	it to the new way.
16	MR. KATZ: Right.
17	MR. STIVER: And then, we have got
18	the differential. We have got that increment.
19	Then, we can identify that.
20	MEMBER ZIEMER: But what are you
21	going to report on the 10 cases, for example,
22	that they were all done correctly on that

1	item?
2	MR. STIVER: If we find findings
3	that they weren't done correctly, then we
4	would certainly list those.
5	MEMBER ZIEMER: Right.
6	MR. STIVER: But it would be, yes,
7	in this particular case I think there were
8	five different exposure pathways or aspects of
9	the scenario that could have given rise to a
LO	high-fired plutonium intake. So, we look at
11	each of those and how well they were actually
L2	implemented in the process.
L3	CHAIR MUNN: You reviewed the work
L4	and it was done
L5	MR. STIVER: We are not going to
L6	go into every aspect of whether a dosimeter is
L7	.015 or .013 rem for whatever reason.
L8	MEMBER ZIEMER: No.
L9	MR. STIVER: That is not really
20	we are not going to look at the total universe
21	of potential findings, only those that are
	1

pertinent to the change in procedure.

1	MEMBER ZIEMER: But, then, you
2	would take all the cases, the 10 cases, 20
3	cases, whatever it is, and then you would say,
4	for example, 19 of these seem to be done
5	correctly, but this other one doesn't
6	MR. STIVER: Yes, it would be one
7	overarching report that would look at kind of
8	the entire package of those cases. We
9	wouldn't look at each one separately.
10	MEMBER ZIEMER: This may be a case
11	where you sort of have to develop the
12	methodology. I mean, we did this in some of
13	the other stuff.
14	MR. STIVER: Yes.
15	(Simultaneous speakers.)
16	MEMBER ZIEMER: When you get into
17	it, you say
18	MR. STIVER: We also have to go
19	through and this is going to be a nice test
20	case. This is how we are going to work out
21	all the kinks. Think of it as the beta
22	version, I guess. Things are going to come up

1	that we didn't anticipate, and we will have to
2	come up with
3	CHAIR MUNN: Yet another work-in-
4	progress.
5	MEMBER ZIEMER: Yes.
6	MR. STIVER: Yes, another work-in-
7	progress.
8	DR. MAURO: And this is John.
9	What is good is that this PER-12,
10	which is the high-fired plutonium, I believe,
11	is poised to be done. I think we were hoping
12	to have all those 10 cases in folders. But
13	that is going to be a very nice pilot. We
14	will do it, and we will put our report
15	together. And it will take form, and everyone
16	will have a chance to say, okay, yes, this is
17	the way we would like to see the product.
18	So, the reality is, until you
19	actually do one and see how it unfolds and
20	this is a good one because it is somewhat
21	complicated. It will reveal to everyone and
22	the Subcommittee what the product is and how

1	useful it is to the process.
2	My sense is that this is in a
3	funny sort of way where we are all headed to.
4	In the end, the whole mission of the Board is
5	SECs and DRs. And here's the end result of
6	the DR review process. All of the Site
7	Profile Reviews, all the SEC petition reviews,
8	and all the procedure reviews, eventually, the
9	reason we are doing most of this is to see, is
10	there a process in place where the corrections
11	are made when they need to be made? This is
12	sort of like the end of the line.
13	So, I think this is going to be
14	important. This outcome of the review of the
15	PERs is going to be like the final step in the
16	review process that triggered the need to make
17	these changes in the procedures and the degree
18	to which they were, in fact, implemented.
19	CHAIR MUNN: I think you're right,
20	John.
21	MR. STIVER: That is a good
22	summary, John.

CHAIR MUNN: Good.
MR. STIVER: It ties it all
together.
CHAIR MUNN: Thank you for the
information, both on the struggles you have
been going through and where we are.
MR. STIVER: I guess at the tail-
end of that we would want to produce a two-
pager when we are completely finished up. I
saw there is already in that list of the two-
pagers there is a couple of PERs in there that
require no followup action.
CHAIR MUNN: Yes. We have done
one, two.
MR. STIVER: There were two of
them.
CHAIR MUNN: Yes, I think we have
done two that we have already gone through the
process.
All right.
MR. KATZ: Very good.
CHAIR MUNN: The only

1	administrative item that I have is our next
2	meeting. Does anyone else have any other
3	administrative items that we need to address?
4	DR. MAURO: This is John.
5	I had to step away for about 20
6	minutes. I know that Ted mentioned a two-
7	pager for OTIB-70.
8	MR. KATZ: Yes.
9	DR. MAURO: Did you folks talk
10	about any other two-pagers? Did I miss any?
11	Did you discuss the possibility of having
12	another round of two-pagers?
13	CHAIR MUNN: Oh, we took care of
14	all of them and cleaned them all up, John.
15	(Laughter.)
16	DR. MAURO: Okay. Thank you very
17	much.
18	MR. KATZ: No, no, John, Wanda is
19	teasing you.
20	DR. MAURO: Oh, she's teasing me?
21	MR. KATZ: But you can't see her
22	to tell that, although you could assume it

1	always.
2	(Laughter.)
3	CHAIR MUNN: How unusual.
4	MR. KATZ: But that is the only
5	new assignment of a two-pager so far that we
6	have discussed.
7	MR. STIVER: Yes, we talked about
8	that while you were out.
9	DR. MAURO: Yes.
10	MR. STIVER: It was how could we
11	identify those, either by just brute force
12	going through and looking at all the ones that
13	have closed-down findings. And I guess we
14	will have to do that until such time as the
15	review system can correctly handle tallying
16	the closed findings.
17	So, I think at this point we don't
18	know how many other potential candidates are
19	out there for two-pagers.
20	CHAIR MUNN: But I think we have
21	our plate full in any case, John.
22	DR. MAURO: Okay.

1	MR. KATZ: Are we looking at
2	dates?
3	CHAIR MUNN: We are looking at
4	dates. And as usual, the key factor is how
5	long will it take us to get many of the things
6	done that we want to get done. I hate to put
7	us too far out there, but I don't know about
8	other people's calendars. Obviously, February
9	is out of the question. That's too soon.
10	(Laughter.)
11	And my March calendar is starting
12	to look pretty cluttered. But I could do the
13	no, not the week before Oakland.
14	MR. KATZ: No, we won't get enough
15	work done to have a meeting before we have
16	to be looking at April I think, well into
17	April, before we would have productive work.
18	CHAIR MUNN: Okay. So, you don't
19	think the third week in March is even
20	feasible?
21	MR. KATZ: I don't think it is
22	sensible in terms of how much gets done.

1	CHAIR MUNN: What about the first
2	week in April? Is the first week in April
3	possible?
4	MR. HINNEFELD: I don't see
5	anything that would preclude it on our side
6	right now.
7	MR. KATZ: Who has a good sense
8	for what is on people's plates and timing?
9	MR. MARSCHKE: Again, I think most
10	of the balls are in NIOSH's court because we
11	have made our findings and we don't have
12	anything under active review at this point.
13	MR. KATZ: Well, you have some
14	things, responses you are going to review that
15	we have talked about today.
16	MR. MARSCHKE: Right.
17	MR. KATZ: But not any new
18	material.
19	MR. MARSCHKE: No. Right.
20	MEMBER ZIEMER: Well, they should
21	be getting some TBD-6000 stuff this week, I
22	think.

1	MR. KATZ: Well, yes.
2	MEMBER ZIEMER: I mean, it was due
3	out last week from NIOSH, a White Paper.
4	MR. MARSCHKE: But that has been
5	transferred out of this Subcommittee.
6	MEMBER ZIEMER: Oh, you are just
7	talking about this Subcommittee? No, but I
8	thought you said SC&A
9	MR. MARSCHKE: Well, SC&A for this
10	Subcommittee.
11	MR. KATZ: What sort of timeframe
12	are we thinking about with respect to the dose
13	reconstruction review for PER-12? How many
14	months is that effort? Ten cases.
15	MR. STIVER: Ten cases.
16	MR. KATZ: And it is a narrow
17	dimension that you are looking at.
18	MR. STIVER: It is a narrow
19	dimension. I could say probably by mid- to
20	late April we should be able to have
21	something. That is my best sense for it.
22	CHAIR MUNN: So, if we aimed for

1	Tuesday, the 3rd, would that be feasible?
2	MR. KATZ: John was just saying
3	mid- to late April would be for the PER-12
4	cases.
5	So, Stu, what are your thoughts
6	about it since you have deliverables?
7	MR. HINNEFELD: That should be a
8	straightforward issue. You just want them
9	written somewhere on the O: drive?
10	MR. STIVER: Just to post the
11	administrative files.
12	MR. KATZ: No, I am not talking
13	about the PER-12. I am just talking about in
14	terms of deliverables for the Subcommittee for
15	the next meeting.
16	MR. HINNEFELD: Mid-April is what,
17	three months away? Let's just make a point of
18	having some things ready.
19	MR. KATZ: Okay.
20	CHAIR MUNN: Mid-week?
21	MR. STIVER: Mid-week works for
22	me.

1	MR. KATZ: Mid-week of what week?
2	CHAIR MUNN: The 11th.
3	MR. KATZ: Sorry. Okay, the 11th?
4	CHAIR MUNN: Would April 11 be
5	feasible?
6	MR. KATZ: It is open on my
7	calendar right now.
8	CHAIR MUNN: April 11th?
9	MR. KATZ: Okay.
LO	CHAIR MUNN: 9:00 a.m.
11	Okay. Good.
L2	Is there anything else that we
	Is there anything else that we need to have on our plate that we have not yet
L2 L3 L4	
L3 L4	need to have on our plate that we have not yet
L3 L4 L5	need to have on our plate that we have not yet covered?
L3 L4 L5 L6	need to have on our plate that we have not yet covered? (No response.)
L3	need to have on our plate that we have not yet covered? (No response.) If not, then we are adjourned.
L3 L4 L5 L6	need to have on our plate that we have not yet covered? (No response.) If not, then we are adjourned. Thank you all very much. I do appreciate your
13 14 15 16 17	need to have on our plate that we have not yet covered? (No response.) If not, then we are adjourned. Thank you all very much. I do appreciate your effort more than I can say, and you will be
13 14 15 16 17 18	need to have on our plate that we have not yet covered? (No response.) If not, then we are adjourned. Thank you all very much. I do appreciate your effort more than I can say, and you will be hearing from us with a bunch of two-pagers.

1 mee

meeting was adjourned.)